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ABSTRACT
JUSTIN T. BROWN: STRUCTURAL BASIS FOR LIGAND-BINDING AND 
ACTIVATION OF D1-LIKE DOPAMINE RECEPTORS
(Under the direction of Richard B. Mailman, Ph.D.)
The D1-like dopamine receptors have been implicated in the etiology of several 
neurological and psychiatric disorders. Recent advances in neurobiology have 
demonstrated the potential utility of D1-like dopamine receptor agonists as therapeutic 
compounds.  Despite immense promise, there are no D1 centrally available agonists 
currently available as therapeutic compounds. Moreover, there are no selective ligands 
that can distinguish between the two D1-like receptors (D1 and D5). One of the major 
obstacles to the discovery of such agents is limited information about the structural basis 
for ligand-binding and activation of the D1-like receptors. There are few such studies that 
have been done with the D1 receptor, and virtually none with the D5 receptor. This 
dissertation was aimed at gaining a greater understanding of the structural mechanisms 
necessary for ligand-binding, receptor activation, and receptor internalization. Rationally-
selected point mutations of the D1-like receptors were made, and detailed analysis of 
binding and function made for a series of structurally and functionally diverse test 
compounds.  Work in this dissertation provides the first experimental evidence that T3.37 
plays an important role in binding and activation of D1-like receptors.  Studies of a TM6 
phenylalanine at residue at position 6.51 revealed that this residue plays a key role in 
coupling ligand binding to receptor activation.  Studies of another aromatic residue 
iii
located in TM6, W6.48, provided evidence that this amino acid serves as an important 
switch residue for creating an active receptor conformational state. Furthermore, this 
work revealed what may be the largest structural differences ever seen between the D1 
and D5 receptor subtypes.  Results from this dissertation provide important insight into 
the structural mechanisms that govern ligand-binding and receptor activation, and may 
aid in the design of clinically relevant D1 agonists.
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CHAPTER 1. INTRODUCTION
DOPAMINE RECEPTORS: BIOLOGY AND PHARMACOLOGY
History of dopamine systems
Until the late 1950’s dopamine was considered to function solely as an 
intermediate in the synthesis of epinephrine and norepinephrine. Arvid Carlsson 
discovered an important role for dopamine in 1957 (Carlsson et al., 1957), and 
subsequent work that demonstrated localization of dopamine in the basal ganglia led 
Carlsson to suggest that dopamine depletion was responsible for parkinsonism (Carlsson 
et al., 1958). Biochemical studies of dopamine receptors began in the 1970’s (Iversen, 
1975), with a direct biochemical mechanism linking dopamine to the stimulation of 
cAMP production first being demonstrated in the laboratory of Paul Greengard in 1971 
(Kebabian and Greengard, 1971). Greengard’s laboratory showed that dopamine could 
dose-dependently stimulate the accumulation of cAMP, and an ensuing study 
demonstrated that this response could be inhibited by antipsychotic drugs (Clement-
Cormier et al., 1974). In the mid-to-late 1970’s, experiments utilizing new antipsychotic 
agents (i.e. butyrophenones and substituted benzamides) resulted in discrepancies 
between the experimental data that was obtained and the hypotheses held by most 
investigators (Kebabian, 1977). These new antipsychotic drugs bound receptors with low 
affinity and exhibited little potency in inhibiting dopamine stimulated adenylate cyclase 
(Garau et al., 1978; Trabucchi et al., 1975). These observations, along with parallel 
studies characterizing dopamine receptor localization, led to the notion of the existence of 
2two distinct subtypes of dopamine receptors, D1 and D2. (Garau et al., 1978; Kebabian 
and Calne, 1979). The D1 receptor, the original receptor reported by Greengard’s group, 
linked to the stimulation of adenylate cyclase and bound thioxanthines and phenothiazine 
antipsychotics with high affinity, but had lower affinity for the butyrophenone and 
benzamide classes (Garau et al., 1978). The D2 receptor exhibited high affinity for the 
butyrophenones and benzamides, but was not linked to the stimulation of adenylate 
cyclase. 
Dopamine neurotransmission
Dopamine is the predominant neurotransmitter in the mammalian brain, where it 
contributes to the regulation of motor and limbic processes. Dopamine systems in the 
brain originate from cells bodies in three brain regions: the substantia nigra, the ventral 
tegmentum, and the hypothalamus. 
Nigrostriatal
pathway
Mesocortical
pathway
Mesolimbic
pathway
Tuberoinfundibular
Pathway
Figure 1.1. Schematic of brain dopamine pathways.
There are four major dopaminergic systems in the brain (Figure 1.1): (i) The 
nigrostriatal pathway projects from the substantia nigra to the dorsal striatum and is the 
3pathway that degenerates in Parkinson’s disease. (ii) The mesolimbic and (iii) 
mesocortical pathways include those neurons that project from the ventral tegmental area 
(VTA) to regions of the limbic system (e.g. nucleus accumbens and amygdala) and 
prefrontal cortex. The mesocortical system is thought to be involved in motivation and 
emotional response, while the mesolimbic system is associated with feelings of reward 
and desire. Finally, the (iv) tuberoinfundibular pathway comprises those neurons that 
extend from the hypothalamus to the median eminence and is responsible for controlling 
prolactin levels (Cooper et al., 1996). 
Dopamine biosynthesis and metabolism
Like all catecholamines in the nervous system, dopamine synthesis originates 
from the amino acid precursor tyrosine. L-tyrosine is converted to L-
dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase, representing the 
rate-limiting step in dopamine biosynthesis. Subsequent removal of the carboxyl group 
by L-aromatic amino acid decarboxylase converts L-DOPA to dopamine. Tyrosine 
hydroxylase is susceptible to endogenous mechanisms of- as well as pharmacological-
regulation. Dopamine is converted to dihydroxyphenylacetic acid (DOPAC) by 
intraneuronal monoamine oxidase (MAO) following reuptake by the nerve terminal. 
Dopamine that is not taken up by the dopamine transporter is degraded by the 
extracellular enzyme catechol-O-methyltransferase to homovanillic acid (HVA), the 
major brain metabolite in primates and humans.
Classification of dopamine receptors
G protein-coupled receptors (GPCRs) are commonly divided into five or six 
distinct classes based on sequence homology: Class A (rhodopsin-like), Class B (secretin 
4family), Class C (metabotropic glutamate/pheromone), Class D (fungal mating 
pheromone receptors), Class E (cyclic AMP receptors), and Class F 
(frizzled/smoothened). Dopamine receptors, members of the rhodopsin-like subfamily of 
GPCRs, are comprised of five distinct dopamine receptor genes divided into two classes, 
D1-like and D2-like dopamine receptors. D2-like receptors, consisting of D2, D3, and D4,
couple to inhibitory G-proteins leading to the inhibition of adenylate cyclase activation. 
Members of the D1-like dopamine receptor family, referred to as D1 and D5, preferentially 
couple to stimulatory G-proteins resulting in an increase in cAMP accumulation. 
Molecular biology of D1-like dopamine receptors
The D1 receptor was cloned in 1990 (Dearry et al., 1990; Sunahara et al., 1990; 
Zhou et al., 1990) and the D5 subtype the following year (Sunahara et al., 1991; Tiberi et 
al., 1991). The D1 receptor is localized on chromosome 5 and D5 is on chromosome 4. In 
humans the D1 and D5 receptors consist of 446 and 477 amino acids, respectively. The 
receptors share approximately 60% acid amino identity overall, and 82% identity in the 
putative transmembrane-spanning regions (Jarvie and Caron, 1993). The D5 receptor 
displays higher constitutive activity than the D1 receptor, which may account for its 
higher affinity for most agonists (Tiberi and Caron, 1994). Currently, no selective ligands 
are available that can distinguish between the D1 and D5 receptor subtypes.
The human D1 receptor has two potential sites for N-linked glycosylation and 
several potential sites for phosphorylation by PKA, including Thr-136 and Thr-268. The 
human D5 receptor has a potential N-linked glycosylation site at Asn-7 and a second 
potential site in the third extracellular domain (Asn-194). Potential sites for 
phosphorylation by PKA exist at Thr-153 and Ser-260.
5Anatomical localization of D1-like dopamine receptors
Three methods have been used to determine the distribution of dopamine 
receptors in the body: i) receptor binding, ii) immunological methods, and iii) mRNA 
localization experiments. Studies utilizing quantitative receptor autoradiography to map 
the distribution of D1-like receptor binding sites within the brain revealed the highest 
levels of binding to be in the forebrain areas such as the caudate-putamen, olfactory 
tubercle, and nucleus accumbens (Boyson et al., 1986; Savasta et al., 1986; Wamsley et 
al., 1991). Binding was also observed in the basal ganglia pathways, as well in several 
limbic areas including the dentate gyrus of the hippocampus and amygdaloid nucleus. 
The lack of a subtype selective ligand precludes the use of autoradiography to determine 
the distribution of each D1 subtype. A study using D1 receptor null mutant mice, 
however, showed putative D5 binding sites in the hippocampus (Montague et al., 2001).
Cloning of the D1-like receptors enabled examination of D1 and D5 subtypes 
distribution using immunological and mRNA localization studies. D1 receptor mRNA 
was found to be most abundant in the neostriatum, whereas the presence of D5 receptor 
mRNA in the striatum is less than one-tenth the level of the D1 receptor. High levels of 
D5 receptor mRNA is present within other brain regions such as the hippocampus, 
hypothalamus, and mid-brain. The differential expression of D1 vs. D5 receptors in 
specific brain regions suggests that there may be a novel physiological role for the D5
receptor.
6D1-like dopamine receptor signaling
D1-like receptors and G proteins
The signaling pathway most commonly associated with the D1-like receptors is 
increased synthesis of adenylate cyclase. This action occurs via activation of specific G 
proteins. The inactive forms of G proteins are heterotrimers composed of α, β, and γ 
subunits. At least 21 Gα subunits, encoded by 16 genes, have been identified in the 
human genome (Hurowitz et al., 2000). The Gα units can be grouped into 4 main classes: 
Gαs, Gαi, Gq, G12. The D1-like receptors signal primarily through the activation of 
stimulatory G proteins, Gαs and Gαolf, which activate adenylate cyclase leading to an 
increase in intracellular cAMP (Corvol et al., 2001; Sidhu et al., 1991). Studies of 
neostriatum, a region with high D1 expression and low expression of Gαs and an 
abundance of Gαolf, have demonstrated that D1 receptors couple to Gαolf in this region of 
the brain (Le et al., 1991; Watson et al., 1994). Gαolf null mutant mice have a minimal 
response to dose-dependent adenylate cyclase activation and also lack behavioral 
responses attributed to D1 receptor stimulation, thereby suggesting that Gαolf is the 
primary G protein coupled to D1 in the basal ganglia nuclei (Corvol et al., 2001; Zhuang 
et al., 2000). Studies have shown that the D5 receptor signals via Gαs (Kimura et al., 
1995), but there is no evidence to indicate that D5 couples to Gαolf (Sidhu et al., 1998; 
Sidhu, 1998). Recent in vitro studies have suggested that the D1 receptor can couple to 
other G proteins, such as Gαz, Gαo, Gαi1 and Gαi2 (Sidhu and Niznik, 2000). The 
relevance of the ability of D1-like receptors to couple to G proteins other than Gαs and 
Gαolf has yet to be determined. 
To date, 6 Gβ and 12 Gγ subunit genes have been identified (Oldham and Hamm, 
2008). Gγ subunits exhibit considerable structural diversity, while the Gβ subunits are 
7structurally similar. Although little is known about the influence of Gβ and Gγ subunits 
on receptor-G protein interactions, studies using reconstitution systems (Corvol et al., 
2001; Figler et al., 1996; Kisselev et al., 1994; Butkerait et al., 1995) and reverse genetic 
approaches (Kleuss et al., 1993; Wang et al., 1997) indicate that the nature (i.e. subunit 
type and/or post-translational isoprenylation) of the Gγ subunit of the Gβγ dimer plays a 
role in receptor-G protein interaction. Using ribozyme-mediated suppression of Gβγ 
subunits, a recent study demonstrated that the depletion of Gγ7 in HEK293 cells reduces 
D1 receptor stimulation of adenylate cyclase but not D5 stimulation (Wang et al., 2001). 
The role of other Gγ subunits in diverse cell systems has yet to be elucidated but it is 
clear that Gγ, and perhaps Gβ, subunits can be important for D1 receptor signaling. 
Regulation of adenylate cyclase
Regulation of adenylate cyclase underlies several CNS functions such as learning, 
synaptic regulation, and signal transduction. Nine adenylate cyclase (AC) isoforms have 
been identified to date, and each isoform contains a binding site for Gαs. Cyclase activity 
can be modulated by Gαs, Gαi, and Gβγ subunits (Simonds, 1999). D1-like receptors 
activate adenylate cyclase in multiple cell lines (Cumbay and Watts, 2004) by coupling to 
Gαs and Gαolf.. A study using neostriatal tissue demonstrated that type 5 adenylate cyclase 
mediates dopamine receptor signaling in the striatum (Glatt and Snyder, 1993). This 
observation was supported by studies of adenylate cyclase type 5 null mice that showed 
greatly diminished D1 receptor stimulated cyclase activation (Lee et al., 2002; Iwamoto et 
al., 2003). 
8Stimulation of phospholipase C & D
Phospholipase C (PLC) hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) 
producing 1,2-diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3 then binds 
to the IP3 receptor, stimulating the release of Ca
2+ from intracellular stores within the 
endoplasmic reticulum. DAG recruits protein kinase C (PKC) to the membrane leading to 
downstream NF-κB activation and actin reorganization. 
Several studies have demonstrated D1 receptor regulation of the phospholipase 
C/inositol triphosphate pathway (PLC/IP3), but the mechanism(s) by which the D1
receptor couples to the stimulation of phospholipase C is unclear. Two distinct potential 
mechanisms for D1 linked PLC activation have been proposed. Investigators have 
postulated the existence of a novel D1-like receptor, distinct from the Gs-coupled D1
receptor, linked to PLC via Gαq (Pacheco and Jope, 1997; Undie and Friedman, 1990). 
However, the high concentration of agonist (100 M) used to elicit the response in these 
studies, one at which the agonist may bind other receptors, confounds interpretation. 
Recent studies, demonstrating the ability of D1 and D2 dopamine receptors to form 
functional hetero-oligomeric units that rapidly generate PLC-mediated calcium release 
via Gαq/11 (Lee et al., 2004), provide evidence for a novel mechanism of PLC signaling 
through D1 receptor oligomerization with the D2 receptor (Lee et al., 2004; Rashid et al., 
2007). Given the important role of calcium in neuronal function, this theory warrants 
further investigation. 
Bergson and colleagues (Lezcano et al., 2000) demonstrated intracellular calcium 
release when calcyon, a D1 receptor interacting membrane protein, is co-expressed with 
D1 and D5 receptors. The authors suggested that calcyon functions as a molecular switch 
9enabling signaling through either adenylate cyclase or PLC at a single D1 receptor, 
however the paper describing this observation was recently retracted (Lezcano et al., 
2006). Further evidence for a cAMP/PKA-independent signaling pathway was exhibited 
in studies with adenylate cyclase V deficient mice (Iwamoto et al., 2003; Lee et al., 
2002). While 85-90% of cyclase activity is abrogated, locomotion is enhanced. It is not 
clear from this study whether the behavioral effects are due to a non-cyclase dependent 
PLC pathway.
A recent finding suggests that the D5 dopamine receptor can regulate the activity 
and expression of phospholipase D2 (PLD2) (Yang et al., 2006). PLD2 and the D5
receptor are membrane bound proteins localized in the brush-border membrane of renal 
proximal tubules (Exton, 2002), indicating a role for the D5 receptor in the pathogenesis 
of hypertension.
Regulation of ion channels
D1-like receptors modulate numerous voltage- and ligand-gated ion channels via 
phosphorylase kinase A (PKA) phosphorylation and stimulation of DARPP-32 
(dopamine and cyclic AMP-regulated phosphoprotein, 32 kDa) (Neve et al., 2004). D1-
like receptor stimulation of cAMP production can lead to the activation of PKA, which 
can subsequently modulate ion channels by combinations of direct PKA-phosphorylation 
and DARRP-32 mediated inhibition of protein phosphatase 1 (PP1). DARRP-32, a 
neostriatum enriched signaling protein, is activated via PKA-stimulated protein 
phosphatase-2A (PP2A) and modulates ion channel function by inhibiting PP1 
(Greengard et al., 1999; Hemmings, Jr. et al., 1984). The exact mechanism(s) by which 
D1-like receptors regulate various ion channels is complex and ill-defined. 
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Regulation of other signaling pathways
Several reports indicate that D1-like receptors activate mitogen activated protein 
kinases (MAPK) including ERK1/2 (Chen et al., 2004), p38 MAPK, and c-jun amino-
terminal kinase (Zhen et al., 1998). Regulation of MAP kinase pathways appear to be 
PKA-dependent, but the prevalence of D1 receptor-mediated MAP kinase activation 
remains unclear and is likely system-dependent in vitro.
Evidence suggests that D1 receptors may modulate arachidonic acid (AA) release 
but data is ambiguous at best and requires further study. Piomelli et al. (1991)
demonstrated that expression of D1 receptors alone in CHO cells does not elicit AA 
release, but co-activation of D1 and D2 receptors in CHO cells resulted a synergistic 
response (Piomelli et al., 1991). Release of arachidonic acid via D1 receptors is likely 
dependent on co-activation of one or more additional receptors.
D1-like receptors are capable of forming functional interactions with several other 
membrane bound receptors. Studies have shown that D1 receptors can physically interact 
with NMDA receptors, as well as adenosine A1 receptors (Gines et al., 2000; Kreipke and 
Walker, 2004). D5 receptors can form a functional complex with GABAA receptors, 
thereby enabling D5 receptors to modulate synaptic strength independent of G proteins
(Liu et al., 2000). These data raise the possibility that D1 compounds may not only have 
utility in the treatment of disorders linked to dopamine dysregulation but those diseases 
attributed to receptors with which they form hetero-oligomers as well.
D1 receptor internalization
Internalization plays an important role in regulating D1 receptor responsiveness. 
Internalization in vivo has been observed in striatal neurons under hyperdopaminergic 
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conditions in both rats (Dumartin et al., 1998) and humans (Muriel et al., 1999). The 
process has been well studied for dopamine in various cell lines, and is mediated by the 
GRK/arrestin pathway (Tiberi et al., 1996; Zhang et al., 1999). Phosphorylation of the D1
receptor occurs within minutes of dopamine binding, allowing arrestin to bind to the third 
intracellular loop of the receptor thus leading to D1 receptor internalization. Characteristic 
of “Class A” GPCRs, arrestin is not trafficked into the cell with the D1 receptor (Oakley 
et al., 2001). The D1 receptor is recycled rapidly back to the cell surface following 
internalization caused by the endogenous ligand (Vargas and von Zastrow, 2004; Vickery 
and von Zastrow, 1999). However, recent studies in our lab have demonstrated 
differential ligand induced internalization and long-term trafficking with structurally 
diverse agonists. The experiments in this Dissertation explore the structural mechanisms 
responsible for this phenomenon.
Disorders of dopamine neurotransmission and the role of D1-like receptors
Dopaminergic systems have been the subject of extensive research over the past 
40 years as disruption of dopaminergic transmission has been implicated in the etiology 
of a variety of neurological and psychiatric disorders such as Parkinson’s disease, 
Huntington’s disease, dysfunction of learning and memory, schizophrenia, and attention 
deficit hyperactivity disorder (ADHD). While early research efforts focused on the role 
of D2 dopamine receptors in disorders of dopaminergic transmission, the development of 
high affinity, full D1 agonists has revealed an important role for D1 receptors in 
neurological disease. 
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Parkinson’s disease
Parkinson’s disease is caused by the progressive degeneration of dopaminergic 
neurons in the substantia nigra pars compacta. Ideally, Parkinson’s disease would be 
ameliorated by prevention of disease progression or replacement of lost neurons; 
unfortunately such treatments are not available. The standard treatment available to 
Parkinson’s disease patients is the use of pharmacotherapy to treat disease symptoms. 
The current gold standard, levodopa, is extremely effective in the early stages of the 
disease but loses efficacy and develops side effects after years of treatment. Observations 
that parkinsonism could be induced by typical antipsychotics, D2 receptor antagonists, 
lead to the hypothesis that the beneficial effects of levodopa were due to actions at the D2
dopamine receptor. As a result, research efforts have been focused on the development of 
D2 receptor agonists which have failed to dramatically ameliorate symptoms of 
Parkinson’s disease. 
Further elucidation of the role of D1 receptors in motor control led to the 
hypothesis that D1 receptors may in fact have utility as a PD therapeutic. The design and 
synthesis of the first D1 full agonist, dihydrexidine (Brewster et al., 1990; Lovenberg et 
al., 1989), permitted testing of the hypothesis that D1 agonists will be an effective PD 
therapeutic. In 1991, Taylor et al. (1991) demonstrated that the beneficial effects of 
levodopa in the treatment of Parkinson’s disease was in fact due to the activation of D1
receptors, not D2 receptors, resulting in the redirection of efforts towards the development 
of D1 receptor agonists to treat Parkinson’s disease (Mailman et al., 2001). Subsequent 
studies in MPTP-treated non-human primates, as well as two human clinical studies 
(Rascol et al., 1999; Rascol et al., 2001), have confirmed the effectiveness of full D1
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agonists as a symptomatic treatment for PD (Kebabian et al., 1992a; Shiosaki et al., 
1996). 
Despite the tremendous promise of full D1 agonists as a treatment for PD, there 
are no clinically available D1 receptor-selective drugs. Numerous issues such as 
development of tolerance, lack of oral bioavailability, and a requirement for full agonism 
have hindered the development of D1 receptor drugs. Several of these issues are explored 
by the work conducted for this Dissertation.
Memory and cognition
Stimulation of the prefrontal cortex potentiates neuronal signaling that is essential 
to the working memory process (Sawaguchi and Goldman-Rakic, 1991). D1 receptors are 
the predominant dopamine receptor subtype (20 times the density of D2 receptors) 
expressed in the prefrontal cortex in non-human primates (Goldman-Rakic et al., 1990; 
Lidow et al., 1991). In 1994, Sawaguchi and Goldman-Rakic demonstrated that local 
injection of a D1 antagonist into the prefrontal cortex produced working memory deficits 
in rhesus monkeys, subsequent studies showed that D1 agonists can improve cognitive 
function in rats (Hersi et al., 1995) and non-human primates (Arnsten et al., 1994; Cai 
and Arnsten, 1997). Dihydrexidine -- a compound used in the experiments in this 
Dissertation -- improved working memory in both aged monkeys and catecholamine 
depleted young monkeys (Arnsten et al., 1994), and also caused improved performance 
in MPTP-lesioned non-human primates (Schneider et al., 1994). Importantly, the effects 
of D1 stimulation in cognition and memory are dose-dependent with higher doses 
impairing working memory in aged monkeys (Castner et al., 2000). The exact 
mechanism(s) by which D1 receptors affect cognition and memory is not fully 
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understood, but it is clear that the D1 dopamine receptors have a prominent role in 
modulating cognitive performance.
Schizophrenia
The symptoms of schizophrenia can be grouped into positive (type I) symptoms, 
such as hallucinations, thought disorder, and delusions, and negative (type II) symptoms, 
which include poverty of speech, loss of drive and flattening of affect (Crow, 1980; 
Goldberg and Mattsson, 1967). Dopamine receptor antagonists, that primarily target D2
receptors, have been the most widely used therapeutic agents in the treatment of 
schizophrenia over the last four decades. These antipsychotic drugs ameliorate the 
positive symptoms of schizophrenia but have little effect on the primary negative 
symptoms. These negative symptoms have been identified as the primary reasons patients 
experience such difficulty reintegrating into society (Holden, 2003). 
Evidence that the negative symptoms manifested in schizophrenia patients are 
linked to dysfunction of the prefrontal cortex, or hypofrontality (Castner et al., 2000), 
suggests that D1 agonists may have utility in treating schizophrenia. Indeed, in 2003 the 
National Institute of Mental Health-sponsored MATRICS (Measurement and Treatment 
Research to Improve Cognition in Schizophrenia) program chose D1 agonists as the most 
promising therapeutic target for treating working memory disabilities in schizophrenics. 
Recent studies using the D1 full agonist dihydrexidine not only demonstrated that the 
compound was tolerated and safe in humans, but that D1 receptor agonists can increase 
prefrontal perfusion in patients with schizophrenia (George et al., 2007; Mu et al., 2007). 
Unfortunately the therapeutic utility of DHX is severely limited due to its short 
pharmacokinetic half-life thus eliminating it as a drug candidate.
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Substance abuse
In general, reward phenomena are mediated by dopaminergic pathways (Hiroi and 
White, 1991; Nakajima et al., 1993). The discovery that cocaine is a potent inhibitor of 
dopamine uptake indicated that dopaminergic actions are responsible for the pleasurable 
and reinforcing effects of this drug (Fibiger, 1978; Ranaldi and Beninger, 1994). 
Additionally, evidence has lead to the hypothesis that most drugs produce dependence by 
increasing dopaminergic transmission in the brain. Several reports have indicated that D1
agonists might decrease likelihood of relapse in the treatment of cocaine users (Self et al., 
1996), including a study by Haney et al. (1999) that demonstrated ABT-431 (a full D1
agonist) dose-dependently decreased the effects of cocaine and also reduced cocaine 
craving at the highest dose tested (4 mg/kg) in humans. Although the effects of selective 
dopamine agonists are not always clear (Caine et al., 2007; Caine et al., 2000b; Caine et 
al., 2000a), these preliminary data have made D1 agonists a high priority target for the 
treatment of cocaine abuse.
D1-like receptor selective compounds: Drug design and clinical applications
History
The first selective D1-like dopamine receptor agonist, SKF38393 (a member of 
the 1-phenyl-tetrahydrobenzazepine family), was developed by scientists at 
SmithKlineFrench laboratories in 1978 (Pendleton et al., 1978; Setler et al., 1978). The 
distinguishing feature of SKF38393 is a pendant phenyl ring that confers D1 vs. D2
selectivity by interacting with a “chirally defined accessory site” (Kaiser et al., 1982). In 
1983, the selective phenylbenzazepine compound SCH23390 was reported as the first D1
receptor antagonist (Cross et al., 1983; Iorio et al., 1983). This compound proved to be an 
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immensely important tool for the characterization of D1-like receptors and remains the 
primary antagonist used in the characterization of D1-like receptors. SKF38393 and 
SCH23390 were breakthroughs in the characterization of D1 receptor function, and were 
equally as important in understanding the structural determinants for ligand recognition at 
the D1 receptor. The most important structural feature of these two phenylbenzazepines is 
the appended pendant phenyl ring that confers D1 receptor selectivity, thus demonstrating 
the importance of exploiting this region for the development of D1 selective compounds. 
As discussed previously, the parkinsonian effects elicited by antipsychotic agents 
(i.e. D2 receptor antagonists) lead to the belief that D2 receptors were responsible for the 
beneficial actions of levodopa in Parkinson’s disease. Development of the selective D1
agonist SKF38393 allowed examination of a possible role for D1 receptors in PD 
however SKF38393 failed to produce anti-parkinsonian effects in both the MPTP primate 
model and humans (Boyce et al., 1990; Close et al., 1985; Falardeau et al., 1988), and 
even decreased the efficacy of levodopa (Nomoto et al., 1988). These results supported 
the notion that D2 receptors were of primary importance in PD, however the 
pharmacological ramifications of the low efficacy of SKF38393 at the D1 receptor were 
not appreciated at that time. The observation that apomorphine, a mixed dopamine 
agonist with full efficacy at D2 receptors and partial efficacy at D1 receptors, is 
efficacious in severe PD patients (Poewe et al., 1988) led some investigators to theorize 
that the effectiveness of this drug was due to D1, not D2, receptor agonism.
As the role of D1 receptor function in Parkinson’s disease and other neurological 
disorders was further elucidated, it became apparent that there was a lack of D1 receptor 
agonists for receptor characterization and clinical applications. The only available D1
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selective agonists were of the phenylbenzazepine class, whose utility is restricted by 
pharmacological limitations such as low efficacy (Andersen et al., 1987). For this reason, 
our lab began to investigate the molecular interactions governing ligand binding and 
activation at the D1 receptor. Knowledge of the structural interactions involved in the 
binding and activation of the phenylbenzazepines, combined with computer assisted drug 
design, led to hypotheses about the structural features that might yield a high affinity D1
full agonist (Nichols 1983). The ensuing D1 receptor model incorporated a few structural 
features thought to be necessary for high affinity and full intrinsic activity: the 
ethylamine fragment must be in a trans, extended beta conformation, and a hydrophobic 
accessory ring system near co-planar to the catechol ring (Charifson et al., 1988; 
Charifson et al., 1989). This knowledge resulted in the synthesis of the first high affinity 
full D1 agonist, dihydrexidine (DHX) (Lovenberg et al., 1989), a hexahydrobenzo-
[a]phenanthridine. Around the same time a second class of full D1 agonists was 
developed, the aminotetralins. The design and synthesis of DHX permitted testing of the 
hypothesis that full D1 agonists would cause significant antiparkinson effects, and indeed, 
DHX produced profound antiparkinson effects in MPTP-treated monkeys. This result 
was later confirmed in non-human primates using another full D1 agonist, ABT-431 
(Abbott Laboratories) (Shiosaki et al., 1996; Taylor et al., 1991).
Our group then used computer-aided conformational analysis, with DHX as a 
structural template, to refine the agonist pharmacophore for D1 recognition and activation 
(Mottola et al., 1996). The essential features of the D1 full agonist pharmacophore 
include two hydroxyl groups, an equatorially oriented electron lone pair on the basic 
nitrogen atom, and near co-planarity of the accessory ring system with the catechol ring 
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(Ghosh et al., 1996; Mottola et al., 1996) (see Figure 1.2). The orientation of the 
accessory ring system, and thus the nature of its interaction with the hydrophobic 
accessory region, is thought to be an important determinant of agonist efficacy. The D1
receptor full agonist dinapsoline (naphth[1,2,3-de]isoquinoline; DNS) was developed 
using this pharmacophore model, thereby demonstrating the utility of this approach. The 
rigid nature of DHX, DNS, and their congeners makes them invaluable tools for probing 
the molecular interactions governing binding and activation of D1 dopamine receptors. 
Several structurally and pharmacologically diverse D1-like receptor ligands, including 
DHX and DNS, were utilized for the work in this Dissertation (see Figure 1.3). 
Accessory Hydrophobic Region 
Steric Occlusion Region 
Amine binding site
Hydroxyl 
Binding 
Sites
Figure 1.2. Pharmacophore of the D1 dopamine receptor (adapted from Mottola et al., 1996)
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Figure 1.3. Ligands used in this dissertation.
Issues in the development of clinically useful D1 receptor agonists
Despite tremendous therapeutic promise for D1 dopamine receptor agonists, no D1
selective drugs are currently available for clinical use. Several factors have severely 
hindered the viability D1 receptor agonists as therapeutics. The first D1 full agonists, 
DHX, ABT-431 and the phenylbenzazepines, exhibit poor oral bioavailability and a short 
duration of action. Isochromans (e.g. A77636 & A68930), the second class of true full D1
agonists developed (Kebabian et al., 1992b), appeared to overcome the poor 
bioavailability plaguing DHX and ABT-431, but further development was precluded due 
to the rapid and profound behavioral tolerance A77636 produced when administered to 
animals or humans (Asin and Wirtshafter, 1993; Blanchet et al., 1996; Britton et al., 
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1991). DNS demonstrated improved oral bioavailability and good pharmacokinetic half-
life, but development of this compound was terminated for reasons thought to be related 
to toxicity. 
The design and development of clinically useful D1 receptor agonists is 
contingent on understanding the structural features responsible for both desirable (i.e. 
efficacy, bioavailability) and unwanted (i.e. tolerance, toxicity) properties. The degree of 
intrinsic activity produced by a D1 receptor agonist appears to be of particular therapeutic 
importance. For example, effective amelioration of PD symptoms requires full D1
agonism while evidence suggests that partial D1 agonists may be more effective in 
treating cognitive dysfunction. It is therefore important, for the design of effective D1
receptor drugs, to determine the molecular interactions responsible for conferring such 
properties. The goal of the work in this Dissertation was to provide insight into the design 
of D1 ligands that have specific functional characteristics (e.g. full agonist), and/or are 
selective for the D1/D5 subtype. 
STRUCTURE AND FUNCTION OF CLASS-A GPCRS
The G-protein-coupled receptor (GPCR) superfamily is one of the largest and 
most diverse protein families in mammals with almost 1,000 members (Takeda et al., 
2002; Takeda et al., 2002). GPCRs are comprised of seven stretches of membrane-
spanning α-helices, an intracellular C terminus and three interhelical loops. 
Understanding GPCR function is of great interest as ~30% of the pharmaceuticals 
currently on the market target these proteins (Hopkins and Groom, 2002). The rhodopsin-
like subfamily of receptors is the largest and most studied family of GPCRs, and 
provided some of the early insight into structural features of this receptor superfamily. 
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Rhodopsin crystal structure
Initial insight concerning the structure of GPCRs was derived from homology 
modeling using bacteriorhodopsin as a template. The low sequence similarity to 
mammalian GPCRs and the fact that bacteriorhodopsin is not coupled to G-proteins 
limits the utility of this protein as a template for other GPCRs. In 2000, the x-ray 
structure of bovine rhodopsin was solved (Palczewski et al., 2000), and until very 
recently (vide infra) served as the primary source of insight into GPCR structure and 
function. The structure of rhodopsin has provided a useful structural framework that has 
been used widely in the creation of homology models for other GPCRs. 
Helical structure of rhodopsin
The structure of rhodopsin is stabilized by seven intrahelical hydrogen bonds. In 
its ground state rhodopsin, the endogenous ligand 11-cis-retinal is bound within the 
binding site crevice. Several kinks, bends, and varying degrees of tilting within each helix 
have functionally important consequences in the activation of rhodopsin. Helix 1 is bent 
by 12o around a proline (Pro53) residue, and forms multiple hydrogen bonds with TM2, 7, 
and 8. TM2 is tilted ~25 perpendicular to the membrane surface and is bent by 30o due to 
a Gly-Gly motif (Gly89 and Gly90) (Okada et al., 2002; Palczewski et al., 2000). This 
helix forms intrahelical hydrogen bonding with TM1, TM3, and TM4. TM3, extremely 
important in rhodopsin, is the longest (48 A) and most tilted (33º) helix. This helix 
contains two bends, Gly120-Gly121 (12º) and Ser127 (11º), with the largest tilt facilitating 
multiple inter-helical interactions (TMs 2, 4, 5, 6, and 7). In the C-terminal of TM3 there 
is a E(D)RY motif (conserved among all class A GPCRs) that is critical for the regulation 
of the receptor-G protein interaction. Salt bridges between Glu134, Glu247, and Arg135 are 
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thought to play a critical role in restraining rhodopsin in an inactive conformation. TM4 
is the shortest and least tilted transmembrane helix. It has a bend due to the presence of 
two neighboring proline residues, Pro170 and Pro171. TM5 is highly tilted (~26º) and 
contains two small bends at Phe203 (25º) and His211 (15º) (Okada et al., 2002; 
Palczewski et al., 2000). Residues (Met207, His211, and Phe212) in this TM provide the 
binding site for the b-ionone ring of the chromophore. TM6 is the most bent and second 
longest helix. The 30o bend is caused by the highly conserved residue Pro267. 
Ionic/hydrogen bond interactions between TM6 with TM3 (in the DRY region) and TM7 
(Cys264-Thr297) constitute restraints important for an inactive conformation. An aromatic 
cluster (Tyr268, Phe261, and Trp265) surround the β-ionone ring, with indole ring Trp265
positioned in close proximity to the C13-methyl group of the chromophore. Tm7 contains 
a critically important residue (Lys296) that forms a link with the chromophore within the 
transmembrane region. Significant distortion around this portion of the helix 
accommodates the conformational changes needed during isomerization. Large bends 
around Pro291 (24º) and Pro303 (21º) permit accommodation of the linkage with the 
chromophore. The highly conserved NPXXY motif is located in the C-terminal of TM7. 
In addition to the transmembrane helices, a short helix (TM8) exists in the cytoplasm 
surface and forms the fourth cytoplasmic loop. This helix is connected to TM1 and TM7 
through ionic/hydrogen bonds and thought to be the site of non-covalent binding of all-
trans-retinal to opsin (Sachs et al., 2000). 
Activation of rhodopsin
Rhodopsin is unique among GPCRs in that the chromophore, 11-cis-retinal, is 
covalently bound within a binding crevice formed by the transmembrane helices, thus 
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restricting the receptor in an inactive conformation (Sakmar, 1998). The retinal binding 
cavity is largely surrounded by hydrophobic residues and 11-cis-retinal is covalently 
linked to Lys296 on TM7 by a protonated Schiff Base. There are several polar atoms 
nearby, such as Glu113, which is believed to serve as the counter-ion to the Schiff base. 
The β-ionone ring makes contact with a group of aromatic residues such as Trp265, Phe212, 
and Phe261. The inactive state of rhodopsin is stabilized by numerous interhelical 
interactions, some of which are mediated by water molecules (Okada et al., 2002). When 
exposed to light, 11-cis-retinal absorbs a photon and isomerizes to the all-trans-retinal 
conformation which triggers formation an active receptor state, metarhodopsin II 
(Sakmar, 1998). Meta II is the active form of the protein capable of interacting with the G 
protein transducin (Gt).
While the structure of rhodopsin in its ground state provides important insight into 
receptor structure, the lack of an x-ray structure of the active receptor state makes it 
difficult to elucidate the conformational changes that occur during activation. Recently, 
biophysical studies have been used to provide greater insight towards the structural 
rearrangements that occur during receptor activation. The use of techniques such as UV 
absorption spectroscopy (Lin and Sakmar, 1996) and site-directed spin labeling 
(Altenbach et al., 1996; Altenbach et al., 1999) have provided evidence that rhodopsin 
photoactivation involves rigid-body motion of TMs 3 and 6. Studies by Farrens et al.
suggest that TM6 moves counterclockwise when viewed from the extracellular side, 
resulting in an outward movement of the cytoplasmic end of TM6 away from TM3 
(Dunham and Farrens, 1999; Farrens et al., 1996). Further site-directed spin labeling 
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studies conducted by Altenbach et al. (2001b; 2001a) indicate that the cytoplasmic 
portion of TM7 moves away from TM1. 
β2-adrenergic receptor crystal structure
While bovine rhodopsin has served as a useful template for understanding GPCR 
structure, there are limitations to extrapolating its structure to other GPCRs. The most 
serious limitation is that, unlike other rhodopsin-like GPCRs, in its ground state 
rhodopsin is covalently bound to the inverse agonist 11-cis-retinal. Recently, a high-
resolution crystal structure of the β2-adrenergic receptor was obtained by engineering the 
receptor to include lysozyme or a monoclonal antibody to provide conformational 
stability (Cherezov et al., 2007; Rasmussen et al., 2007). 
Like rhodopsin, the β2-adrenergic receptor consists of 7TM helices, as well as a 
short segment that forms an eighth helix. The ligand-binding site of the β2-adrenergic 
receptor is located in a position similar to that of the covalently bound ligand of 
rhodopsin, Gt. Unexpectedly, the second extracellular loop (ECL2) of the β2-adrenergic 
receptor contains an extra short helical segment not present in rhodopsin. The apparent 
solvent accessibility of this segment lead the authors to hypothesize that it may help 
stabilize the receptor core and prevent ECL2 from hindering ligand access to the binding 
pocket (Cherezov et al., 2007). Several shifts in the structural alignment of the β2-
adrenergic receptor transmembrane helices were observed relative to rhodopsin, 
including TMs 1, 3, and 4, but the largest structural difference founds was in TM1 which 
lacks the proline-induced kink found in rhodopsin. The ramification of this difference in 
TM1 is not yet clear. Transmembrane alignment likely varies across different GPCR 
classes serving to accommodate binding of an assortment of structurally diverse ligands. 
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The crystal structure of the β2-adrenergic receptor is an important breakthrough 
towards understanding the structural features important in mammalian GPCRs. The 
structure alone, however, does not permit an understanding of the conformational 
changes that occur from ligand binding to receptor activation. Indeed, the structural 
engineering that was required for crystallization clearly causes perturbations from the 
“native” receptor that cannot be elucidated using current technology. Moreover, myriad 
conformational receptor states adopted upon ligand binding must be elucidated before a 
complete picture of the structural changes involved in the transduction of ligand-binding 
to receptor activation can be assembled. Furthermore, in order to gain complete 
understanding of GPCR function it may be necessary to obtain crystal structures of 
agonist bound not only to the GPCR, but to the GPCR-G-protein signaling complex.
Mutagenesis of catecholamine receptors
Nomenclature
Throughout this dissertation, I shall use the universal indexing system initially 
described by Ballesteros and Weinstein (1995) to describe amino acid positions. This 
system facilitates the comparison of analogous residues in different GPCRs. The single 
letter code for the amino acid is provided first followed by the residue position with 
respect to the most conserved amino acid in each transmembrane helix (designated X.50, 
where X is the transmembrane domain 1-7). The most conserved residue in each 
transmembrane is designated 0.50. The decimals are indexed positively (towards the 
carboxy-terminus) or negatively (towards the amino-terminus). Table 1.1 shows the most 
conserved residue in each TM helix in the D1 and D5 receptors, as well as the residues 
targeted in this research.
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Table 1.1. Most conserved residue in each TM helix in the D1 and D5 receptors and 
residues targeted in this research.
Universal Index D1 D5
Chapter where 
studied
N1.50 N41 N58 -
D2.50 D70 D87 -
R3.50 R121 R138 -
W4.50 W148 W165 -
P5.50 P206 P237 -
P6.50 P287 P311 -
P7.50 P328 P356 -
T3.37A T108A T125A Chapter 3
S5.46A S202A S233A Chapter 3
F6.51W/L/I/Y F288 F312 Chapter 4
W6.48A W285A W309A Chapter 5
N6.55A N292A N316A Chapter 5
V4.60A V159A V176A Chapter 6
W4.64A W163A W180 Chapter 6
L6.54A L291A L315 Chapter 6
X6.58A L295A V319 Chapter 6
Structure-function analysis of D1-like dopamine receptors
Few efforts have been made towards understanding the interactions governing 
ligand recognition and activation of the D1-like receptors, especially the D5 dopamine 
receptor. The following summarizes efforts that have been made to date using methods 
such as site-directed mutagenesis, molecular modeling, and receptor chimeras. 
The role of TM3 & TM5 in D1-like ligand-receptor interaction
Strader et al. (1988) was the first group to demonstrate that an aspartate residue at 
position 3.32 serves as the counter-ion to the amine of catecholamine ligands. As 
expected, studies have shown that D3.32 is critical for ligand interaction at both the D1
and D5 dopamine receptors (Pollock et al., 1992) (unpublished observations for D5). 
Abrogation of this interaction results in a complete loss of ligand binding as well as 
functional activity at D1-like receptors.
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The role of TM5 serines in ligand interaction with catecholamine receptors is well 
established (Strader et al., 1989) though specific interactions vary by receptor type and 
ligand structure. Pollack et al. demonstrated a role for S5.42 and S5.43 in D1 receptor 
recognition of the phenylbenzazepines, and for S5.46 in the interaction with dopamine. 
The knowledge that could be gleaned from this study, however, was limited by a lack of 
structurally diverse D1 ligands available to use as receptor probes. The synthesis of 
structurally and pharmacologically diverse classes of D1 compounds (i.e. DHX, DNS, 
and the isochromans) allowed additional insight to be gained concerning the molecular 
interactions involved in binding and activation at both D1 and D5 dopamine receptors. 
Studies in our lab, focused on the role of the three TM5 serines in the recognition of an
array of test compounds, established that S5.42 (and possibly S5.43) interacts with the 
meta-OH and that S5.46 interacts with the para-OH of catechol-containing compounds at 
the D1 and D5 dopamine receptors (unpublished observations). Our findings also indicate 
that S5.43 may be promiscuous and interact with the meta-OH and para-OH of the 
catechol through a bifurcated bond. Importantly, these findings demonstrated that 
compounds of different chemical classes (e.g. A77636 and SKF82958) have distinct 
modes of interaction with the TM5 serines of the D1-like receptors 
The work conducted for this Dissertation further examines the molecular 
interactions that contribute to binding of the catechols of D1-like compounds.
The role of TM6 & TM7 in D1-like ligand-receptor interaction
Several studies have demonstrated a critical role for TM6 residues in ligand 
recognition and subsequent receptor activation of catecholamine receptors, particularly 
those residues positioned in the rotamer toggle switch region. In a previous study we 
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examined the role of two phenylalanine (F6.51 & F6.52) residues in D1 and D5 receptor 
binding and activation. We constructed non-conservative point mutations (i.e. to alanine) 
in both residues and examined the effects on ligand-binding and receptor activation. The 
changes observed in the F6.52A mutant receptor were non-specific and appear to be the 
result of global changes in receptor structure, indicating that F6.52 does not play a 
prominent role in ligand binding or receptor activation of the D1-like receptors. The 
results obtained for the D1- and D5-F6.51A mutant receptors, however, indicate a critical 
role for this residue in ligand-binding and receptor activation. The F6.51A mutant 
receptor exhibited more dramatic effects in efficacy and potency for dopamine, A77636 
and the rigid ligands (i.e. DHX & DNS) than for the phenylbenzazepine compounds (i.e. 
SKF38393, SKF82526, & SKF82958), thus providing evidence for agonist-specific 
conformational states.
Hydrophobic residues in TM7 have been predicted to interact with the accessory 
ring system of dopaminergic compounds, and to possibly be involved in the distinction 
between receptor subtypes. To examine this hypothesis, experiments in our lab targeted 
three hydrophobic residues in TM7 (F7.35, F7.38, and W7.43) of the D1 and D5
dopamine receptors by mutating each residue to alanine (unpublished observations). The 
results indicate that F7.38 and F7.35 do not directly interact with any of the test 
compounds, however a reduction of basal cAMP accumulation suggests that F7.35 may 
be important for efficient coupling of the agonist-induced receptor to G-protein turnover. 
Mutation of W7.43 to alanine resulted in a dramatic loss in receptor expression 
suggesting that this residue is necessary for correct protein folding and/or processing of 
D1-like receptors. The work in this dissertation further investigates the role of F6.51 in 
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binding and receptor activation, and also examines the role of other TM6 residues 
positioned in and around the putative toggle switch region of D1-like receptors.
Mechanisms of ligand-dependent receptor activation
Activation of Class A GPCRs occurs when an agonist diffuses into an unliganded 
receptor and induces-or stabilizes- a structural rearrangement of the receptor resulting in 
activation of intracellular G-proteins. GPCRs are restrained in an inactive conformation 
by a network of non-covalent intramolecular interactions between the TM helices. 
Evidence suggests that all Class A GPCRs share, in general, a common activation 
mechanism. 
Many unliganded receptors have a basal level of G protein activation. The degree 
of inactivation can vary by receptor type, and even among subtypes of the same family as 
with the D1 and D5 dopamine receptors. There are numerous examples of discrete 
mutations in any receptor domain that can dramatically increase the constitutive activity 
of a receptor (Allen et al., 1991; Lefkowitz et al., 1993; Samama et al., 1993; Scheer et 
al., 1996). Until recently GPCR activation was viewed as a bimodal process, consisting 
of inactive or active receptor states. Recent evidence suggests that receptor activation is a 
multistep process consisting of several discrete receptor conformational states.
When an orthosteric agonist diffuses into the GPCR binding pocket, the 
restraining intramolecular interactions are broken and new interactions are formed that 
stabilize the receptor in an active conformational state. Recent studies indicate that GPCR 
activation occurs by the disruption and creation of specific highly conserved structural 
motifs that serve as molecular switches in GPCR activation (Kobilka and Deupi, 2007). 
The exact conformation of the receptor is dependent on the structure of the ligand, thus 
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its specific interaction with these molecular switches, and such distinct states may 
produce differential activation of signaling pathways (see section on Functional 
selectivity). Three of the more prominent examples of these molecular switches include: 
(i) Protonation of the highly conserved D/ERY motif at the cytoplasmic side of TM3. 
Mutation of Arg3.50 results in reduction or abolishment of ligand binding and receptor 
activation in most Class A receptors. In the 5HT-2A and β2-adrenergic receptors, ionic 
interactions between Arg3.50 and Glu3.49 and Glu6.30 stabilize the inactive state. These 
interactions are eliminated on receptor activation (Ballesteros et al., 2001a). (ii) The 
NPxxY motif, conserved in TM7 of rhodopsin-like receptors, serves to connect TM7 with 
the cytoplasmic helix 8. This connection is thought to be critical for regulation of C-
terminal interaction with intracellular signaling partners (Fritze et al., 2003). 
Additionally, mutations of the NPxxY motif have been shown to affect receptor 
expression, G-protein coupling, and ligand affinity (Barak et al., 1995; Mitchell et al., 
1998; Wess, 1993). (iii) A cluster of aromatic residues in TM6, surrounding the 
conserved proline, that has been coined the rotamer toggle switch. The rotameric 
conformations of a group of conserved aromatic residues (Phe6.51, Phe6.52, Phe6.44, 
Trp6.48) surrounding a proline (Pro6.50) in TM6 are postulated to be interrelated (Shi 
and Javitch, 2002). Agonist interaction with one or more of these aromatic residues in 
TM6 induces rearrangement of a Trp (6.48) residue that is proposed to cause a drastic 
reduction in the proline kink in TM6 (Huang et al., 2002), resulting in the movement of 
the cytoplasmic ends of TM6 away from TM3 (Ebersole et al., 2003). This action may 
serve to transduce agonist-induced conformational changes in the extracellular receptor 
region to changes in the cytoplasmic portion of the receptor that is involved in receptor-
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G- protein coupling (Chen et al., 2002b; Chen et al., 2002a). The ligand binding site is 
tightly coupled to the G-protein nucleotide binding site but the exact mechanism by 
which agonist binding is translated into structural changes that result in G-protein 
activation remains unclear. Until recently, ligand binding and receptor activation was 
considered a bimodal process. Recent studies have demonstrated that the receptor 
conformation is agonist specific and can exist in numerous conformations that may have 
diverse functional implications (vide infra). Ligands of different chemical structure can 
stabilize distinct receptor conformations and may thus engage the aforementioned 
molecular switches differentially, yielding differential functional responses.
Molecular modeling of GPCRs
Although many investigators have used bacteriorhodopsin as a template for 
modeling the TMs of GPCRs (Palczewski et al., 2000), bacteriorhodopsin is not a GPCR, 
even though it is a seven transmembrane-spanning protein. By contrast, a deduced GPCR 
template based on a comprehensive analysis of hundreds of GPCR sequences (Baldwin, 
1993) actually was found to agree reasonably well with the 2.8 Å crystal structure of 
rhodopsin (Palczewski et al., 2000). For the amine-like subfamily, there is general 
agreement about the broad generalities of mechanisms of ligand recognition and receptor 
activation. Small ligands bind primarily within the core of the seven transmembrane-
spanning helices (TMs), and subsequently induce conformational changes in the receptor 
that alters the relative positions of the seven TMs. The movements of the TMs produce 
changes in the three intracellular loops (ICLs) leading to efficient coupling to a 
heterotrimeric G protein(s) and/or activation of precoupled G proteins. It is the details 
about specific receptors and their ligands that remain unclear. The major issue in such 
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modeling is the reliability and predictability of a model, something often difficult to 
assess. 
Weinstein and colleagues (Zhou et al., 1994; Ballesteros et al., 1998) have used 
models of the GnRH receptor to note that the highly conserved pattern of N55 in TM1, 
D83 in TM2, and N302 in TM7 probably stabilizes the helical bundle, an idea confirmed 
by experiments using site-specific mutations of these residues and functional analyses. In 
the RH 3D crystal structure (Palczewski et al., 2000; Palczewski et al., 2000), the 
conserved N55 in TM1 interacts with the peptide backbone carbonyl of G51 and A299, 
whereas D83 in TM2 weakly interacts with N55 and with a structural water molecule that 
bridges between D83 and the backbone carbonyl of G120 in TM3. N302 in TM7 interacts 
with the backbone carbonyl of S298 in TM7, possibly with the OH of Y301, and also 
with the water molecule that bridges D83 with the backbone carbonyl of G120. 
Weinstein’s group also predicted that TM7 is not an ideal α-helix but contains a kink 
caused by the Asn-Pro/Asp-Pro motif (Konvicka et al., 1998). The RH structure, 
however, has the Asn-Pro-Xaa-Xaa-Tyr sequence and has a regular helical structure, with 
a kink further along the helix, as well as distortions in other parts of TM7 (e.g., around 
the Lys that covalently attaches to retinal).
The DRY motif (Asp/Glu-Arg-Tyr) at the intracellular end of TM3 often is 
considered important for receptor activation. It was initially shown that the charged pair
of Glu-Arg was needed for rhodopsin activation because double mutants of these residues 
failed to activate transducin (Franke et al., 1992). Scheer et al. (2000; 1996) and others 
have reported theoretical and experimental manipulations that have led to the hypothesis 
that inactive receptor is restrained by interactions between Arg of DRY and the 
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hydrophilic residues formed by TM1, 2, and 7. Possibly, when the Asp in DRY is 
protonated, it causes the Arg of the DRY to move out of the TM bundle, thereby 
changing the orientation of residues in IL2 and 3, in turn affecting G protein-coupling. A 
somewhat different hypothesis has been offered for the GnRH receptor in which Arg of 
the Asp-Arg-Ser sequence at the end of TM3 interacts with the adjacent Asp in the 
inactive state of the GnRH receptor. Activation involves release of the Arg from 
interacting with Asp by Asp protonation and promotes movement of the Arg into a 
hydrophilic pocket in the TM bundle. An Ile one helical turn above the Arg in TM3
sterically directs the Arg into the TM hydrophilic pocket (Ballesteros et al., 1998). In any 
event, Shapiro et al. (2002) hypothesized that E6.30 formed a strong ionic interaction 
with R173(3.50) of the D(E)RY motif in the 5-HT2A receptor. When they made the 
E318(6.30)R mutant, it had high constitutive activity and enhanced affinity for agonist. 
They concluded that the disruption of a strong ionic interaction between transmembrane 
helices 3 and 6 of 5-HT2A receptor is essential for agonist-induced receptor activation, 
and that this may represent a general mechanism of activation for many GPCRs. 
Whatever the difference, current models predict that movement of the Arg in the 
highly conserved D(E)RY sequence is a “switch” that converts a GPCR from an inactive 
to an active state in response to agonist-stimulated receptor protonation. More recent data 
suggest that the switch can be activated by more general mechanisms other than D-
protonation (Ghanouni et al., 2000). Transmembrane helix movement is also known to be 
important in GPCR activation, and is a mechanism we hypothesize is affected 
differentially by the rigid ligands on which we focus. In the case of RH, TM3 and 6 have 
relative motion upon light activation (Farrens et al., 1996) that is also predicted from the 
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crystal structure (Palczewski et al., 2000). Similar effects have been reported with the ß2-
adrenergic receptor (Gether et al., 1997b), and TRH-receptor (Colson et al., 1998), 
among others. On the other hand, some data suggest that these mechanisms are not 
universal (Angelova et al., 2000), with other possibilities including release of intrahelical
interactions (Fanelli, 2000), movement of TM3, 4, 5, and 6 (Fanelli et al., 1999), and 
movement of TM5 and 6 (Zhang and Weinstein, 1993). It is not surprising that the 
activation of each specific receptor, although following a similar general pattern, has 
critically important inter-individual differences. 
As these examples indicate, although there is a solid foundation for homology 
modeling of the D1 receptor, it is often difficult to explain the subtleties that are the focus 
of my goals. As will be detailed in the experimental methods, I have collaborated with 
the laboratory of William Goddard on some exciting new ways to approach these issues
RECEPTOR THEORY & RECEPTOR PHARMACOLOGY
The concept of a “receptor” is generally attributed to Paul Erhlich (1854-1915) 
whose studies lead him to the notion of selectivity and “receptive side chains”. Erhlich’s 
contemporary, John Langley, coined the term receptor in 1878 while studying the effects 
of nicotine and curare analogs on muscle contraction. 
Efficacy
Efficacy was first used by R.P. Stephenson to describe the property of a drug that 
caused receptor activation and produced a pharmacological response (Stephenson, 1956). 
His concept of efficacy allowed for separation of receptor activation from the tissue event 
of physiologic activity. Stephenson’s observations occurred in the context of tissue 
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response, however we now know that tissue response does not represent the entire 
repertoire of possible receptor responses (e.g., receptor internalization). 
Efficacy is defined as the property of a drug that causes its target receptor to 
change its functional actions, either stimulatory or inhibitory. Intrinsic efficacy was 
thought to be a property intrinsic to the ligand, independent of the system or receptor-
effector coupling, but data have since indicated that this concept is incorrect. We now 
know that a single ligand interacting with a single receptor type can elicit responses that 
cannot be accommodated by the concept of intrinsic efficacy. Thus, I will use the term 
intrinsic activity to describe the relative maximal functional response produced by the 
receptors characterized in response to test compounds. 
Drugs that elicit a response equivalent to that of the endogenous ligand are 
referred to as full agonists. Compounds that produce a response less than the tissue 
maximum are called partial agonists. A partial agonist can have high, medium, or low
intrinsic activity and can antagonize the response of a full agonist at appropriate 
concentrations. Compounds that do not elicit activity are termed antagonists, and those 
antagonists that decrease the functional response below basal levels are referred to as 
inverse agonists. The functional characteristics of a ligand can be tissue-dependent, 
receptor-dependent, and function-dependent at a given receptor in a given system. 
Models of receptor activation
Over the years several activation models have been developed to describe the 
relationship between ligand, receptor, and effector. Our understanding of how drugs bind 
and subsequently activate receptors has evolved and resulted in the revision and 
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expansion of activation models. The following provides an overview of the evolution and 
current state of receptor models.
Equilibrium models
Although numerous models have been developed, each is rooted in the theories 
described by Clark (1937) and the laws of mass action. In 1983, Black and Leff described 
a two-state model of receptor activation that proposed a receptor exists in either and 
active [R*] or inactive state [R]. In this model, the proportion of receptors existing in 
either state is in equilibrium and agonist binding to the receptor shifts the equilibrium to 
favor the active state (Black and Leff, 1983). 
The original two-state model was developed as a mechanistic model for ion 
channels and did not account for receptor-G-protein interaction (del Castillo and Katz, 
1957). To integrate the G-protein component, a ternary complex model was described 
that considered the agonist/receptor/G-protein complex (De Lean et al., 1980). 
Observations, such as the discovery of constitutive receptor activity (Costa and Herz, 
1989), revealed behavior that could not be adequately described by the original ternary 
complex model. The extended ternary complex (ETC) model was subsequently devised 
by Samama and colleagues (Samama et al., 1993) to allow for the formation of an active 
receptor/G-protein complex in the absence of agonist. The discovery of inverse agonism 
demonstrated the need to describe a receptor state in which the inactive receptor can 
couple with G-proteins. This led to the development of complex but more 
thermodynamically complete model, the cubic ternary complex (CTC) model.
Recent findings, such as the ability of agonists to selectively activate specific 
signaling pathways and not others, cannot be accommodated by traditional receptor 
37
theory (i.e. two state and ternary complex). Leff and colleagues attempted to explain such 
findings by expanding two-state theory to a “three-state receptor model” of agonist action 
(Leff et al., 1997). To account for the apparent ability of an agonist-bound receptor to 
activate specific signaling pathways, they proposed that a receptor can exist in two 
distinct receptor active states, [R*] and [R**], interacting with different G proteins. This 
model proposes that agonists can selectively interact with one active state over the other. 
More recent evidence that indicates receptors can couple to numerous G-proteins to elicit 
more than two functional responses clearly limits the utility of the three state model of 
receptor activation.
Agonist-specific receptor states: functional selectivity
Traditional receptor theory states that the relative degree of activation produced 
by an agonist binding to a receptor is independent of the effector pathway activated (28). 
This theory proposes that receptors can exist in two states: an active or inactive state. 
Activated receptors are postulated to exist in the same state regardless of the ligand 
bound. The intrinsic efficacy elicited by the ligand-receptor interaction is assumed to be a 
property of the ligand, independent of the pathway in which efficacy is measured. 
Traditional theory assumes that ligands differ only in strength of signal. Accordingly, 
ligands are classified based on their intrinsic efficacy as full agonists, partial agonists, or 
antagonists.
Over the past decade, multiple lines of evidence (in numerous receptor systems) 
have revealed that certain agonists selectively couple a single receptor subtype to specific 
functional pathways and not others (Berg et al., 1998; Kilts et al., 2002; Kenakin, 1995). 
This phenomenon has been termed “agonist-directed trafficking” (Kenakin, 1995), 
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“biased agonism” (Jarpe et al., 1998), “functional dissociation” (Whistler et al., 1999), 
“differential engagement” (Manning, 2002), and “functional selectivity” (Lawler et al., 
1994; Kilts et al., 2002). I shall use the term functional selectivity throughout this 
Dissertation. Functional selectivity postulates that the ability of a receptor to couple to an 
effector pathway is dependent on the conformation of the ligand-receptor complex 
(Kenakin, 1995). Therefore, an agonist is capable of selectively (or differentially) 
activating effector pathways at a single receptor subtype (see Figure 1.4). A study by 
Berg et al. (1998) demonstrated that agonist trafficking is not due to a difference in 
stimulus strength by showing a reversal in relative agonist potency for two effector 
pathways. This finding supports the notion that agonist efficacy is dependent on the 
pathway in which a response measured.
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Recent studies of the β2-adrenergic receptor have demonstrated that agonist 
binding occurs through a series of conformational intermediates and that structurally 
diverse agonists cause distinct conformational states (Ghanouni et al., 2001a; Swaminath 
et al., 2005). For example, the full agonist isoproteronol produced a conformational state 
distinct from that of the partial agonist salbutamol (Ghanouni et al., 2001a). It is not yet 
clear whether specific conformational states are responsible for differential activation of 
signaling cascades. These studies indicate that structurally diverse agonists engage with 
the receptor in a distinct manner, thus disrupting different combinations of intramolecular 
interactions resulting in differential activation of effector pathways. Such findings also 
demonstrate the need to build more complex ligand-receptor models that incorporate 
multiple receptor states. New models, such as steady-state and dynamic models, of GPCR 
activation may better accommodate functional selectivity (Christopoulos and Kenakin, 
2002; Lew et al., 2001).
Functional selectivity has important implications in the design and discovery of 
novel therapeutics, including D1 receptor agonists. Potentially effective compounds may 
be disregarded in the drug discovery process on the basis that intrinsic activity is not 
observed at a specific functional endpoint. However, this may simply imply that the assay 
is not designed to detect activity at the appropriate functional endpoint. It may be 
possible to design functionally selective drugs that preferentially activate a specific 
signaling pathway to enhance therapeutic benefits while ameliorating unwanted side 
effects.
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Evidence for functional selectivity at D1-like receptors
Functional selectivity has been difficult to demonstrate for D1-like dopamine 
receptors due to the lack of clear effectors coupled to the receptor. The clearest evidence 
of D1 functional selectivity was shown in two recent studies comparing the functional 
endpoints of adenylate cyclase activation and receptor internalization. The first study 
explored the relationship between agonist structure, receptor affinity, and efficacy of 
adenylate cyclase activation and receptor internalization in response to thirteen agonists 
from three different structural classes (Ryman-Rasmussen et al., 2005). This study 
identified several D1 agonists that activate adenylate cyclase with great efficacy but fail 
to cause receptor internalization. Interestingly, internalization efficacy was found to be 
independent of agonist structural class and agonist affinity. This study revealed 
interesting disparities in the ability of synthetic D1 agonists to regulate receptor 
trafficking, and suggested that, at least for the D1 receptor, functional selectivity is not 
predictable by simple structural examination. 
A subsequent study compared the ability of two structurally dissimilar agonists, 
A77636 (isochroman) and dinapsoline (DNS, isoquinoline), to regulate receptor 
internalization and trafficking with that of dopamine (Ryman-Rasmussen et al., 2007). 
These compounds are full agonists at activating adenylate cyclase, and reach steady-state 
internalization by 30 minutes. DNS exhibited efficacy similar to dopamine in causing 
internalization 1 hour after agonist treatment while A77636 caused significantly greater 
internalization. Investigation of post-endocytic agonist effects on receptor trafficking 
revealed significant differences in agonist regulation of receptor trafficking. Dopamine 
caused the D1 receptor to recycle back to the cell surface within 1h whereas the D1
receptor persisted intracellularly up to 48 h after removal of A77636. Surprisingly, DNS 
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caused the receptor to recycle back to the membrane after 48 h. Pulse chase experiments, 
and use of actinomycin D to inhibit new protein biosynthesis, demonstrated that cell 
surface recovery was not due to synthesis of new proteins. Together, these data indicate 
that these agonists target the D1 receptor to different intracellular trafficking pathways. 
Experiments revealed a slow dissociation rate of A77636 from the D1 receptor, 
suggesting that ligand-receptor interactions distal to the binding pocket may dictate the 
ability of an agonist to cause receptor internalization and regulate long-term receptor 
trafficking. While the mechanisms of tolerance are unknown, it is interesting to note that 
A77636 elicits profound in vivo tolerance within 24 h (Lin et al., 1996) whereas DNS 
does not induce such tolerance in a rat model of Parkinson’s disease (Gulwadi et al., 
2001).
Receptor reserve and functional effects of spare receptors
The intrinsic activity of a ligand is dependent on the efficiency of receptor-
effector coupling and therefore can be influenced by receptor concentration. Receptor 
reserve is defined as a system in which the stoichiometry of the receptor is of greater 
molar excess compared to the G protein subunits. According to theory, in such a system a 
ligand may produce a maximal response (full intrinsic activity) without occupying all 
receptors available. In some cases, a partial agonist may exhibit full intrinsic activity in a 
system with a high degree of spare receptors. Thus, a system with high receptor reserve 
may confound the ability to distinguish the true intrinsic activity of a ligand. Receptor 
reserve can be examined by titrating the number of available receptors, for example using 
either non-selective alkylating agents such as EEDQ or molecular approaches. The issue 
of spare receptors has been an important issue in understanding the action of D1
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dopamine agonists (Pifl et al., 1991; Watts et al., 1993; Gilmore et al., 1995; Watts et al., 
1995). One of the important lessons taught by this literature is that one can use 
SKF38393 as a monitor of whether one has receptor reserve to a degree that is “non-
physiological.” SKF38393 is a moderate intrinsic activity partial agonist in almost all in 
situ systems (Watts et al., 1995),  and thus an excellent control for studies in D1
heterologous systems. 
GOALS OF THIS DISSERTATION AND SPECIFIC AIMS
The overall goal of this research was to elucidate the molecular interactions 
governing ligand-binding and subsequent activation of the D1-like dopamine receptors. 
This work was based on a well-defined D1 agonist pharmacophore as well as structural 
information derived from studies of other catecholamine receptors. Target residues were 
identified rationally, based on a D1 receptor molecular model, and mutant receptors were 
characterized using an array of structurally diverse probe ligands. D1 receptor agonists 
have tremendous therapeutic potential in the treatment of numerous neurological 
disorders and it is therefore of great importance to understand the structural features 
conferring desirable therapeutic properties. The desired outcome of this work was to gain 
a greater understanding of the structural mechanisms responsible for binding and 
activation of the D1-like receptors and to use this information for the following: i) to 
generate novel findings that can be extended to the understanding of other catecholamine 
receptors; ii) to understand the structural basis of D1 receptor properties important for the 
design of clinically useful full D1 agonists (e.g. full efficacy, low tolerance, 
bioavailability, functionally selective properties); iii) to identify structural features of the 
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D1-like receptors that may aid in the design of a D1 vs. D5 receptor selective agonist. I 
pursued these objectives through the following aims:
Aim 1: Determine a more effective method for the quantification of GPCR-
mediated adenylate cyclase activation.
This aim sought to modify the standard laboratory technique of quantifying 
cAMP accumulation to expedite the time required to conduct the assay and to reduce 
costs. The work in this aim yielded a cAMP assay with improved costs and speed while 
maintaining sensitivity. 
Aim 2: Determine the role of a TM3 threonine residue (3.37) in the binding and 
subsequent activation of the D1-like dopamine receptors. 
Previous studies have elucidated the manner by which TM5 serine residues 
interact with the catechols of D1 receptor agonists. Our D1 molecular model predicts that 
a threonine residue in TM3 (3.37) is positioned to influence ligand-binding by interacting 
with the para-OH of D1 compounds. I sought to test this hypothesis by using a group of 
structurally and pharmacologically diverse D1 test compounds. 
Aim 3: Determine more specifically the role of phenylalanine 6.51 in the 
interaction of D1-like dopamine receptors with structurally diverse D1
agonists.
A previous study in our lab demonstrated an important role for F6.51 in D1-like 
receptor activation. The experiments in this aim sought to gain a detailed understanding 
of the role of F6.51 in receptor activation by creating several conservative (i.e. Ile and 
Leu) and non-conservative (i.e. Trp and Tyr) point mutations of the phenylalanine residue 
in both the D1 and D5 dopamine receptors. 
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Aim 4: Determine the role of two TM6 residues (W6.48 & N6.55) hypothesized 
to play an important role in the transduction of ligand-binding to receptor 
activation of the D1-like receptors.
Several studies have demonstrated that residues residing in the rotamer toggle 
switch region play an important role in receptor activation. The experiments in this aim 
sought to explore the role of two TM6 residues, one predicted to form part of the toggle 
switch region and the other to be positioned one turn above this region, involved in 
binding and activation of the D1-like dopamine receptors.
Aim 5: Determine the effects of the mutation of four residues distal to the 
binding site of the D1 dopamine receptor on ligand binding, receptor 
activation, and receptor internalization. 
In a recent study, we demonstrated differences in long-term trafficking of 
dopamine, dinapsoline, and A77636 at the D1 dopamine receptor. We hypothesize that 
differences in D1 receptor internalization and long-term trafficking are due to ligand-
receptor interactions distal to the binding pocket. This aim sought to explore this 
hypothesis by constructing non-conservative mutations of four residues thought to 
contribute to ligand stabilization in the D1 receptor. 
CHAPTER 2: 
RAPID, SEMI-AUTOMATED, AND INEXPENSIVE 
RADIOIMMUNOASSAY OF CAMP:  APPLICATION IN GPCR-MEDIATED 
ADENYLATE CYCLASE ASSAYS
PREFACE
The work presented in this chapter comprises the alterations made to improve the 
laboratory’s method of assessing cAMP accumulation.  Major modifications of the 
original cAMP assay include coupling the primary antibody directly to magnetic beads 
(opposed to the secondary antibody) and separating the antibody-bound magnetic beads 
from unbound marker using filtration on microplates. This work greatly improved speed 
and costs associated with the assay, while retaining the high levels of sensitivity 
associated with the original method.
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ABSTRACT
Cyclic AMP (cAMP) is an important signal transduction second messenger that is 
commonly used as a functional mirror on the actions of G protein-coupled receptors that 
can activate or inhibit adenylate cyclases. A radioimmunoassay for cAMP with 
femtomole sensitivity was first reported by Steiner more than 30 years ago, and there 
have been several subsequent modifications that have improved this assay in various 
ways. Here we describe additional improvement to existing methods that markedly 
improve speed and reduce cost without sacrificing sensitivity, and is also adaptable to 
analysis of cGMP. The primary antibody is coupled directly to magnetic beads that are 
then separated from unbound marker using filtration on microplates. This eliminates the 
need for a secondary antibody, and markedly increases throughput. In addition, we report 
a simple, reproducible, and inexpensive method to make the radiomarker used for this 
assay. Although still requiring the use of radioactivity, the resulting method retains a high 
degree of accuracy and precision, and is suitable for low-cost high-throughput screening. 
Use of aspects of this method can also improve throughput in other radioimmunoassays.
[Citation: Brown JT, Kant AC, Mailman RB. Rapid, semi-automated, and inexpensive 
radioimmunoassay of cAMP: Application in GPCR-mediated adenylate cyclase assays. J 
Neurosci Meth (2008) doi: 10.1016 jneumeth.2008.10.016 (epub)]
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INTRODUCTION
Cyclic AMP (3’,5’-cyclic adenosine monophosphate; cAMP) is a key second 
messenger involved in numerous intracellular signaling pathways (Antoni, 2000; McPhee 
et al., 2005). Production of cAMP is controlled by the membrane-bound family of 
adenylate cyclases (ACs) that convert adenosine triphosphate to cAMP. The activity of 
most of the ACs is regulated by heterotrimeric GTP-binding proteins (e.g., Gs/olf, Gi/o) 
that directly interact with the intracellular region of GPCRs and can both increase or 
decrease enzyme activity (Hanoune and Defer, 2001). In addition, phosphodiesterases 
can catalyze the degradation of cAMP (Weishaar, 1986).
The measurement of adenylate cyclase activity can be accomplished using 
radiometric assays that follow the incorporation of a radioactive precursor into cAMP 
(Salomon, 1979; Schulz and Blum, 1985). More commonly, however, a variety of 
methods that quantify cAMP have been used both for assessment of adenylate cyclase 
activity, as well as for measuring tissue content of cAMP or breakdown of this second 
messenger. A major advance for the field was the development by Steiner et al. (1972) of 
a radioimmunoassay (RIA) for cAMP that offered a high degree of sensitivity and 
specificity that was soon improved by Harper and Brooker (1975). Attempts at 
automating this assay actually led to a commercial instrument (Brooker et al., 1976), but 
this proved unwieldy. 
More recently, other methods for quantifying cAMP have used different 
radiometric or reporter gene strategies (Williams, 2004). Recently developed radiometric 
assays such as Flashplate technology (NEN/Perkin Elmer) and scintillation proximity 
assays (SPA, Amersham Biosciences) are based on the competition of [125I]-labeled 
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cAMP and analyte cAMP, resulting in the production of light when the labeled 
compound is in close proximity to a solid scintillant surface. These assays are convenient 
and reproducible, but are often more expensive than traditional radiometric methods and 
generally speaking less sensitive. Reporter-gene assays utilize cell lines expressing 
reporter enzymes such as luciferase, green fluorescent protein (GFP), and β-lactamase. 
Levels of intracellular cAMP are detected via the expression level of a reporter gene that 
is modulated by transcription factor binding to upstream cAMP response elements 
(CRE). Reporter-gene assay are generally less expensive than the radiometric assays 
discussed above, however, they are often plagued by high false-positive hit rates. Several 
novel, non-radiometric methods to quantify cAMP also have recently become available. 
These assays involve the use of luminescent proximity (ALPHAScreen®) (Ullman et al., 
1994), enzyme complementation technology (DiscoveRx, HitHunterTM EFC), or 
electrochemiluminescence (Meso Scale Discovery) to detect receptor-mediated changes 
in intracellular cAMP. Each method is readily compatible with automated high 
throughput screening (HTS), and often demonstrates a high level of sensitivity, but 
requires a high degree of instrumentation to maximize throughput putting it beyond the 
reach of most academic labs.
For this reason, the RIA (or to a lesser extent, protein binding assays using PKA-
enriched tissue) remains the most widely used technique. There has been a recent report 
detailing an improved procedure for this RIA (Post et al., 2000). Indeed, there are 
commercial kits available (e.g., Amersham Biosciences) that utilize secondary antibody 
bound to magnetizable polymer beads, and are separated by magnetic separation or 
centrifugation. Using the dopamine D1 receptor as a model system, we now describe 
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improvements to this procedure that decrease the number of experimental steps, the assay 
time, and the assay cost, without sacrificing accuracy or precision. In addition, we 
describe a rapid method for the routine production of the [125I]-labeled cAMP derivative 
that is used as the radiomarker in this RIA. 
EXPERIMENTAL PROCEDURES AND RESULTS
Materials and reagents
Dihydrexidine was synthesized according to procedures previously published 
(Brewster et al., 1990). Acetic anhydride, dopamine, IBMX, pargyline, propranolol, 
SKF38393, and triethyleneamine, and 2’-O-monosuccinyladenosine 3’:5’-
monophosphate tyrosyl methyl ester (ScAMP-TME) were purchased from Sigma-Aldrich 
(St. Louis, MO). HEPES was obtained from Research Organics, Inc. (Cleveland, OH). 
Dulbecco’s modified Eagle’s media (DMEM), penicillin/streptomycin, and fetal bovine 
serum (FBS) were purchased from Gibco/Invitrogen. UniFilter-96 GF/B RIA filter plates, 
Microscint™ 20, and Na125I were purchased from Perkin-Elmer (Waltham, MA, USA). 
Donkey anti-goat antibody was purchased from Jackson ImmunoResearch (West Grove, 
PA, USA). Amine terminated BioMag® beads were purchased from Polysciences, Inc. 
(Warrington, PA, USA), and pre-conjugated Biomagnetic Particles (BMP) to donkey 
anti-goat secondary was obtained from Rockland, Inc. (Gilbertsville, PA, USA). 
Sample generation and storage
cAMP is a relatively heat and acid stable compound that does not require special 
storage. The following procedure illustrates a common way that samples are generated 
from a GPCR-based cellular system, but the assay that follows can be used for almost any 
matrix. 
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Cell culture: Human epithelial kidney (HEK-hD1) cells transiently transfected 
with human D1 dopamine receptor using pcDNA3.1 vector (Invitrogen) cells were 
maintained using Dulbecco’s Modified Eagles’ Medium with 50 U/mL of penicillin, 50 
µg/mL of streptomycin (Gibco), and supplemented with 10% fetal bovine serum at 37°C, 
5% CO2. Saturation binding experiments with the D1-selective antagonist [
3H]SCH23390 
using membrane homogenates provided a Bmax of approximately 4.5 pmol/mg protein. 
Cell membrane adenylate cyclase assay: Assay buffer was prepared containing 
100 mM HEPES, 4 mM MgCl2, 2 mM EDTA, 100 mM NaCl 10 M pargyline, 500 M 
IBMX, 0.1% ascorbic acid, pH 7.4. Drug dilutions were prepared at a range of 10-4 to 
10-10 M with three replicates per drug treatment. Diluted drugs, ATP (2 mM), GTP (5 
M), phosphocreatine (20 mM), creatine phosphokinase (185 U/tube) and propranolol 
(100 M to block endogenous β1-adrenergic receptors) were added in a total volume of 
100 L in each well of a 48-well plate. The reaction was initiated by addition of HEK-
hD1 cell membranes. Plates then were vortexed briefly, and incubated at 30°C for 15 
min. The reaction was terminated with 500 L 0.1 M HCl, and stored at 4C. Prior to 
transferring samples for the RIA, plates are centrifuged for 5 min at 2,500 g using a 
RC-3B centrifuge from Sorvall Instruments (H2000B rotor) to pellet cellular debris. 
Plates will keep indefinitely at 4°C following the assay. 
cAMP Radioimmunoassay
Iodination reaction
The radiomarker 2′-O-[4-monosuccinyladenosine 3′:5′-cyclic monophosphate-3-
[125I]iodotyrosyl methyl ester (hereafter termed [125I]cAMP-ScTME) was first reported 
by Steiner et al. (1972) can be purchased commercially. For laboratories that will run a 
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reasonable number of such assays, it is technically simple and inexpensive to synthesize 
this in the laboratory as outlined below. The overall reaction scheme as outlined by 
Steiner and coworkers (Steiner et al., 1972) is shown in Figure 2.1.
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Figure 2.1: Reaction scheme for synthesis of 2′-O-[4-monosuccinyladenosine 3′:5′-cyclic 
monophosphate-3-iodotyrosyl methyl ester. Conditions described in Section 2 (molar excess of 
precursor) favor the formation of the monoiodinated product (see Figure 2.2).
The following reagents and buffers are required:
 0.5 M phosphate buffer, pH 7.6. We usually make this by titrating 15 mL of 0.5 
M K2HPO4 with ca. 1.5 mL of NaH2PO4 to pH 7.6. 
 0.05 M phosphate buffer (pH 7.6). This is prepared by adding 10 mL of the 0.5 M 
phosphate to 90 mL H2O.  
 Carrier-free Na125I. We usually use 2 or 5 mCi. If more than 5 mCi is used, the 
amount of precursor should be increased proportionally. 
 Precursor ScAMP-TME [2’-O-monosuccinyladenosine 3’:5’-monophosphate 
tyrosyl methyl ester; Sigma M2257]. From the 1 mg commercial size, we make 1-
1.5 mL of a stock solution containing 0.1 mg/mL of distilled water. Aliquots (50 
L) are added to microfuge tubes, labeled, and frozen at -20o C. A single aliquot 
is used for each radioiodination.  The frozen precursor appears stable for several 
years. 
 Chloramine-T: (20 mg/10 mL 0.05 M PO4).
 Sodium metabisulfite: (24 mg/10 mL 0.05 M PO4).
The reaction procedure is as follows. Briefly, 80 L of the 0.5 M phosphate buffer 
pH 7.6 is added directly to the container in which carrier-free Na125I (Perkin Elmer) 
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arrives. We usually iodinate with 5 mCi, but this can be varied. Then, the whole content 
of one of the thawed aliquots of ScAMP-TME (5 g/50 L H2O) is added, the cap 
screwed back on, and the vial mixed on a vortexer for 15 sec. Following this, Chloramine 
T (100 L of 2 mg/mL solution) is added, and timing begun as the mixture is vortexed. 
After ~45 sec, the reaction is terminated by addition of sodium metabisulfite (200 L of 
2.4 mg/mL solution). [Safety note: Unreacted 125I is potentially volatile, and a potential 
health hazard. The use of concentrated (0.5 M) phosphate buffer insures that the reaction 
solution does not become acidic, a condition favoring the liberation of molecular iodine. 
In addition, this reaction is done in a chemical hood.]
Purification of iodinated product
It is necessary to separate the monoiodinated cAMP-ScTME from free iodine, 
diiodinated cAMP-ScTME and other minor by-products. Although this can be done using 
batch chromatography with reverse phase Sep-Pak cartridges (Oehlenschlager et al., 
1990), we have dedicated an archaic isochratic HPLC system and fraction collector for 
this purpose. The total reaction volume (~500 L) is injected using a Rheodyne 7125 
Injector (500 L loop). The isocratic separation (0.8 mL/min) uses a C18 reverse phase 
column (Inertsil ODS 2-5 m, Metachem Technologies). A typical chromatogram is 
shown in Figure 2.2. The column effluent is collected by a fraction collector (0.5 min 
samples). As noted above, unreacted 125I is a potential health hazard, and for the 
separation, 100 L of 0.1 M sodium hydroxide is added to the first 10 tubes on the 
fraction collector to insure that all unreacted iodine remains in the form of soluble sodium 
iodide rather than molecular iodine. 
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Figure 2.2: Chromatogram of radioiodination. [Bottom tracing] shows injection of cAMP-Sc-
TME precursor alone using conditions as described in Methods using 254 nm UV detection. The 
solvent front emerges at ~ 2 min, and the precursor elutes at ~ 6min. The signal in the solvent 
front and a detectable shoulder on the major peak is consistent with the 95% purity estimated by 
the supplier. [Top tracing] Actual results from a radioiodination. The monoiodinated product 
that is immunologically recognized elutes at ~28 min, and is the fraction to be collected and used 
for the RIA. This fraction contains from 60 to70% of the radioactivity in a typical reaction. The 
fraction eluting at ~40 min also contains significant radioactivity (10-20%), and is presumably 
the diiodinated form. These two peaks account for ~80% of the total radioactivity injected, with 
the remainder of the radioactivity largely eluting in the solvent front (representing unreacted 
iodine or highly polar reaction by-products). 
The radioactivity is estimated using a hand-held radioactivity detector (or one can 
count 1 L aliquots), and the tubes with the highest radioactivity (usually 3-4 tubes) are 
pooled together, diluted with 1.5 volumes of methanol, and then divided into two or more 
aliquots for storage at -20°C. Under these conditions, the marker is usable for a minimum 
of four months, although there is a significant loss of material due to decay.  
Preparation of primary antibody conjugation to amine-terminated beads
The primary α-3’-5’-cyclic monophosphate antibody was conjugated to BioMag®
amine-terminated beads (50 mg/mL) as directed by the provided protocol (Polysciences, 
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Inc.). Lyophilized antibody was reconstituted in distilled water to a final concentration of 
0.5 mg/mL, and dialyzed in coupling buffer (0.01 M pyridine in distilled water, pH 6.0), 
changing the buffer three-times over a 9 h period. The beads then were prepared by 
washing with coupling buffer, and magnetically separating three times. Glutaraldehyde
solution (5% glutaraldehyde in coupling buffer) was mixed with the BioMag® beads, and 
reacted for 3 h with rotation. The beads were washed four times with coupling buffer, and 
antibody was added to the beads with rotation for 16-24 hrs. Glycine quenching solution 
(1 M glycine, pH 8.0) was combined with beads and rotated for 30 min. Primary α-
cAMP-beads were mixed a volume of 20 mL of storage buffer (0.01 M Tris, 0.1% NaN3, 
0.1% (w/v) BSA, 0.15 M NaCl, 1 mM EDTA, pH 7.4), and stored at 4°C. The antibody-
bead conjugate was used for up to 3 months with no appreciable sign of degradation. 
Fidelity of the conjugate was assessed by determining the ratio of binding between two 
sets of tubes, one containing radiolabeled cAMP bound to primary antibody and the other 
containing only radiolabeled cAMP.  A ratio of 0.2-0.3 was found to be ideal while less 
than 0.2 led to inconsistent replicates.
Radioimmunoassay
cAMP standards (2 nM-500 nM) and sample aliquots (5 L) were transferred 
from the 48-well microplate in which the cAMP formation was performed to 96-well 
Skatron plates containing Macrowell tube strips. Sodium acetate buffer (50 mM, pH 
6.75) was added to the sample wells to bring the total volume up to 50 L. Samples that 
contain cAMP outside of the range of the standard curve can be diluted with additional 
sodium acetate. An acetylating mixture of TEA/AA (2:1 ratio) was added (5 µL) to the 
wells and vortexed. Acetylation increases assay sensitivity presumably by creating a 
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structure that more closely resembles the original hapten. 125I-cAMP was then added 
within 30 minutes of acetylation. Optimal ranges for radioactivity were determined to be 
between 280 cpm/L and 320 cpm/L for iodinated 125I-cAMP-scTME. An aliquot (20 
L) of conjugated-primary antibody then was added to bind labeled and unlabeled cAMP 
(in 50 mM sodium acetate, 0.1% BSA, pH 4.75). Plates were incubated overnight at 4°C. 
Radioimmunoassay reactions were terminated by filtration with UniFilter-96 plates 
(Perkin-Elmer) with dH2O. Plates were washed three times and then dried at 50°C for 1 
hour. Microscint™ 20 fluid (50 L) was added to the wells and counted on a TopCount 
NXT (Perkin-Elmer) for 2 min or 2σ = 5%. 
Data analysis
Standard data were fit to a one-site binding competition model using Prism 4 
(GraphPad Inc., San Diego, CA, USA). Sample data were fit by interpolation using 
standard data to obtain fmol cAMP values. A sigmoidal regression model was used to fit 
the data to obtain EC50 and maximal efficacy values over the complete dose range (10-4
to 10-10 M). 
DISCUSSION
It should be underscored that the radiosynthesis of the marker does not require a 
UV detector or radioactivity detector to perform this separation, as a lab radioactivity 
monitor can easily distinguish the tubes that contain the desired material. Moreover, 
although we use a dedicated HPLC system for this work, the separation could be 
optimized for a SepPak, although the disadvantage is that it is difficult to verify the 
separation. This would not save significant time, but does not require a dedicated “hot” 
HPLC. 
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Elimination of secondary antibody allows direct detection
All prior procedures have used secondary antibodies to separate free and 
antibody-bound 125I-cAMP-ScTME after the incubation of the analytical samples with the 
primary antibody. Techniques have included ammonium sulfate precipitation (Steiner et 
al., 1972), charcoal-albumin (Harper and Brooker, 1975), and more recently, 
polyethylene glycol-assisted secondary separation of bound and unbound 125I-cAMP 
(Amersham Biosciences) in which samples are pelleted by centrifugation, excess fluid in 
each tube decanted or aspirated, and bound radioactivity quantified. Subsequent 
modifications of this method have used secondary antibody conjugated to magnetic beads 
for detection of cAMP. All of these procedures are relatively laborious and we therefore 
examined whether both cost and time savings might result from elimination of the use of 
secondary antibody. We hypothesized that the primary antibody could be conjugated 
directly to Biomag® amine-terminated beads (see Section 2), and then used in a one-step 
assay. We therefore used the beads prepared as described above. 
To expedite the radioimmunoassay (RIA), we attempted to eliminate the use of 
secondary antibody by conjugating anti-succinyl-cAMP antiserum to Biomag® amine-
terminated beads (see Section 2). Following the conjugation of antiserum to Biomag®
beads, we compared the ability of cAMP antiserum to bind cAMP standards. After 
incubation, the free radiomarker and that bound to the primary antibody-conjugated 
BioMag® beads were separated using a 96-well harvester and UniFilter-96 GF/B plates (1 
µm pore size, PerkinElmer), thus enabling detection of bound radioactivity using a high 
throughput plate counter (Perkin-Elmer TopCount NXT). Samples (10 µL) were 
transferred to Macrowell tube strips (using a 12-channel electronic pipette) and necessary 
reagents were added as described in the Section 2. Following overnight incubation with 
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30 µL of primary antibody (1:40 dilution), samples were harvested using Filtermate 
Harvester (Packard) and plates were dried for ~1 h. Scintillation fluid (50 µL) was added 
to each well, and plates were counted on a TopCount NXT. Cross-well variation was 
corrected for following the manufacturer’s protocol. Not only does this result in useful 
standard curves, but application to a well-characterized system (the dopamine D1
receptor) results in EC50 values consistent with earlier literature. Our results demonstrate 
that cAMP antiserum conjugated to beads can be used to separate bound and free 125I-
cAMP with the method of separation utilized in this study. 
Optimization of cAMP antiserum conditions
To determine optimal conditions for cAMP antiserum binding, we assessed the 
ability of the antibody to bind cAMP under variable assay conditions. cAMP standards 
were incubated with antiserum volumes of 50 µL and 10 µL (1:40 dilution in 50 mM 
sodium acetate, pH 6.75) for 2 h at room temperature, and overnight at 4ºC. All assay 
conditions yielded viable standard curves (Figure 2.3). As anticipated, the total amount of 
cAMP bound was greater for samples incubated with a 50 µL volume of cAMP 
antiserum than samples incubated with 10 µL. Incubation overnight resulted in increased 
levels of binding for both dilutions compared to the samples incubated for 2 h at room 
temperature. These results indicate that antiserum conditions (i.e. dilution, volume, and 
time of incubation) can be altered according to individual preference and assay 
requirements. For future experiments we chose to use an overnight incubation using 30 
µL (per well) of cAMP antiserum at a 1:40 dilution.
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Figure 2.3.  cAMP standard curves generated under varying assay conditions. Standards were 
incubated for 2 hrs. at room temperature with 50 L (A) and 10 L (B)   primary antibody and 
overnight at 4o C [50 L (C), 10 L (D)].  Each assay condition yielded a viable standard curve, 
indicating that the conditions can be tailored according to the user’s needs.
Assay precision and accuracy
To assess the feasibility of our new cAMP method, we performed an RIA using 
assay conditions as described by Amersham and our new method. The adenylate cyclase 
portion of the assay was conducted as described in Section 2. Samples were drawn from 
the same adenylate cyclase plate and cAMP concentrations were measured using both 
RIA methods. We determined that the intrinsic activity (Figure 2.4) and potency of 
dopamine and SKF38393 were the same for the old method and our new method (Figure 
2.4). In light of the fact that some assays are limited by their ability to distinguish full and 
partial agonists (Williams, 2004), it is noteworthy that our method easily detects 
compounds with partial agonist activity (e.g., SKF38393). 
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Figure 2.4. Measurement of D1 dopamine receptor-mediated cAMP accumulation utilizing [left 
panel] secondary antibody-PEG assisted RIA method, and [right panel] our new RIA method 
(primary antibody conjugated to beads). cAMP production was measured using HEK293 cell 
membranes transiently expressing human D1 dopamine receptors.  Data are expressed as % 
maximal cAMP stimulation caused by dopamine.  The curves shown represent mean + S.E.M. for 
quadruplicate determinations of cAMP accumulation from four separate experiments.
To assess the between-assay reproducibility for our method we pooled the 
standard deviation of duplicate samples for 20 assays (Figure 2.5). The Coefficient of 
Variation (CV) ranged from 7 to 13%, with the CV being 10% or less over a dynamic 
range of more than two orders of magnitude. This is an acceptable value for an assay 
based on protein binding that uses radioactivity as its endpoint. It should be noted that a 
significant portion of the experimental variance is due to counting error (Mailman and 
Boyer, 1997; Motulsky, 2007), a factor that can be decreased by longer counting times if 
desired. It is known that this assay employs very good precision, and these data also show 
that it has good accuracy, both of which could be improved by longer counting time at 
the tradeoff of throughput. 
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Figure 2.5. Precision profile demonstrates the Coefficient of Variation as a function of the 
concentration of cAMP standards. 
Cost issues and alternative technology
In this study we have demonstrated an improved method of cAMP detection that 
allows for the quick, accurate measurement of femtomole levels of cAMP. A flowchart of 
this method is shown in Figure 2.6. We have eliminated the need for secondary antibody 
and time-consuming separation techniques. By altering the mode of detection and assay 
format, we have increased throughput and excluded laborious steps inherent to the 
previous method. Although our research focus is on whole-cell and membrane assays of 
Gs/OLF, Gi/o and Gq/11 coupled GPCRs, the method is applicable to any measurement 
of cAMP and can be easily adapted for cGMP.
The method summarized in Figure 2.6 significantly reduces the costs required to 
perform the assay. Modification of the assay format and method of detection has yielded 
a substantial reduction of the time, labor, and costs, as well as a decrease in reagents used 
for the previous method. At the time of submission of this manuscript, [125I]cAMP-
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ScTME cost $1,517 for 50 Ci (Perkin Elmer; NEX130050). Reagents suitable for 
dozens of radioiodinations cost less than $200, and 5 mCi of Na125I can be purchased 
from Perkin Elmer for $155 yielding a total cost of finished product for a single 
iodination of < $100/mCi, several-hundred-fold less than the commercial cost. 
1. Assay (Source of Samples)
2. cAMP Acetylation
3. cAMP Radioimmunoassay
4. Filtration (Cell Harvester)
5. Quantification (Counter)
125I-cAMPscTME
Conjugated anti-cAMP
Figure 2.6. Schematic flowchart of the described method. 
For the overall assay system we estimate our cost to be ca. $0.50/sample, several-
fold less expensive than competing commercial systems. For example, one commercial 
ELISA assay costs $310 for a single 96 well assay plate, and also has a sensitivity of at 
least an order of magnitude less than the method we describe.  Protein binding assays 
have also been used in the assay of cAMP for decades ((Brown et al., 1972; Ekins and 
Brown, 1972). Such protein binding assays are fast and suitable for high throughput, but 
are of much lower sensitivity, and also require preparation of the cAMP binding protein 
preparation and the use of a long-lived relatively expensive radioactive marker (i.e., 3H-
cAMP). Finally, it should be obvious that this method could be easily adapted to the 
radioimmunoassay of cGMP. Indeed, the general approach used can also improve the 
throughput of any radioimmunoassay.
CHAPTER 3: INVESTIGATION OF THE ROLE OF THREONINE 3.37 IN 
LIGAND-BINDING AND RECEPTOR ACTIVATION.
PREFACE:
Previous studies have demonstrated the importance of TM5 serine residues for 
interaction with catechol hydroxyls.  These serines form a network of hydrogen bonds 
that serve to anchor the ligand in the binding pocket.  We hypothesize that T3.37 is 
positioned to contribute to the network of hydrogen bonds, specifically by influencing the  
para-OH of D1 agonists.  This chapter focused on exploring the role of T3.37 in ligand 
binding and activation of D1-like receptors.
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ABSTRACT
Molecular modeling of the D1-like receptors led to the hypothesis that T3.37 is 
positioned to interact with the para-OH group of D1 receptor ligands. To test this 
hypothesis, we constructed a non-conservative mutation (to alanine) of T3.37 and 
determined its effects on ligand binding and receptor activation. Rationally-selected, 
structurally dissimilar probe ligands [e.g., SCH23390, dopamine, dihydrexidine (DHX), 
A77636, SKF38393] were used to characterize mutant receptors. The T3.37A mutation 
had marked effects on affinity, potency, and intrinsic activity of rigid D1-like ligands, but 
only minimal changes in affinity were observed for the more conformationally flexible 
phenylbenzazepines. The changes in both affinity and efficacy of the test ligands in these 
experiments exhibit a strikingly similar trend to the decreases in ligand binding observed 
at the S5.46A mutant receptor, suggesting that similar ligand-receptor contact points were 
affected by these mutations. We constructed a double mutation of T3.37A(108) 
/S5.46A(202) to explore further the molecular interactions involved in catechol binding 
in this region. The D1-like T3.37A(108) /S5.46A(202) mutant receptors resulted in a loss 
of affinity greater than that of the T3.37A mutant receptor for all test compounds, DA, 
DNS, DHX and A77636 were markedly affected. All test compounds lost the ability to 
activate adenylate cyclase at the D1-T3.37A(108)/S5.46A(202) mutant receptor. The loss 
of cyclase activation at this mutant receptor establishes a requirement for the T3.37 and 
S5.46 residues for receptor activation. Conversely, the D5-T3.37A(125)/S5.46A(233) 
mutant receptor retained its ability to activate cAMP accumulation, suggesting the 
molecular interactions necessary for receptor activation may differ between the D1 and D5
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receptors. These studies are helping to define why there is an absolute requirement, at 
least at present, for a catechol function in all full D1 agonists.
INTRODUCTION
G protein-coupled receptors (GPCRs) are integral membrane proteins that 
mediate signal transduction in response to an array of extracellular stimuli. These 
proteins are important pharmaceutical targets as approximately 30% of approved 
therapeutics act selectively on members of the GPCR family (Hopkins and Groom, 
2002). Based on sequence conservation, human GPCRs can be classified into five distinct 
subfamilies: rhodopsin, secretin, glutamate, adhesion, and frizzled-taste-2 (Fredriksson et 
al., 2003). Rhodopsin-like GPCRs are further divided into several subclasses with 
particular ligand specificity, including the peptide, biogenic amine, opsin, and olfactory 
receptors. 
The catecholamine-binding GPCRs represent a subset of the biogenic amine 
receptors consisting of the adrenergic, serotonergic, and dopaminergic receptors. These 
GPCRs share a highly conserved binding core in which the endogenous ligand is 
anchored in the binding pocket by two conserved polar regions: i) an aspartate at position 
3.32 that makes direct contact with the protonated amine of aminergic ligands, and ii) two 
catechol hydroxyls that hydrogen bond with serine residues at position 5.42 and 5.46 (and 
5.43 when present) in TM5 (Kristiansen, 2004). This network of hydrogen bonds in TM5 
is critical for ligand recognition and receptor activation. The specific mode of ligand 
engagement with these serine residues is dependent on receptor type and structural 
features of the ligand. 
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Mutagenesis studies of the D1 dopamine receptor have demonstrated that residues 
D3.32, S5.42, S5.46, as well as S5.43 are critical for binding and receptor activation 
(Pollock et al., 1992). D3.32 is the ionic binding partner for the amine nitrogen of D1
receptor compounds, S5.42 (and possibly S5.43) hydrogen bond with the meta-hydroxyl, 
while S5.46 forms a hydrogen bond with the para-hydroxyl of catechol-containing 
compounds. We have evidence that these molecular interactions are equally as important 
for binding and activation of the D5 dopamine receptor (unpublished observations). 
Binding and functional data of the D1-like receptors indicates that the exact nature of an 
interaction of ligand and receptor is dependent on the structural features of each ligand 
that can vary by structural class. The catechol requirement for full D1 agonism makes it 
critical to fully understand the molecular interactions involved in catechol recognition at 
D1-like receptors.
We hypothesize that a threonine in TM3 (T3.37) is positioned to interact with the 
para-hydroxyl of the catechol ring of D1 receptor agonists. T3.37 is completely 
conserved across catecholamine receptors, yet to date no published studies have
investigated the role of this residue in ligand recognition and receptor activation. In 
rhodopsin, the protonated carboxylate of E3.37 hydrogen bonds with the main chain 
carbonyl of H5.46, thus forming an important link between TM3 and TM5 (Palczewski et 
al., 2000). Recent NMR studies have demonstrated that this interaction is disrupted upon 
receptor activation. Interestingly, SCAM studies by Javitch et al. (1995) indicated that 
T3.37 is not accessible in the D2 dopamine receptor binding pocket. 
To test the hypothesis that T3.37 interacts with the para-hydroxyl of D1 agonists, 
we constructed a non-conservative point mutation of threonine to alanine in the D1 and 
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D5 dopamine receptors, and subsequently created D1- and D5- T3.37A/S5.46A double 
mutant receptors. We utilized an array of structurally and pharmacologically diverse D1-
like receptor test compounds to assess ligand-binding and activation of wild-type and 
mutant receptors. The results of this study support the hypothesis that T3.37 influences 
receptor interaction with the para-hydroxyl of D1 receptor ligands. Furthermore, this 
study provides evidence of possible structural differences between the D1 and D5 receptor 
subtypes. 
RESULTS
Effect of T.3.37A and T3.37A/S5.46A mutations on D1-like receptor expression 
and ligand binding
The wild-type and mutant D1-like dopamine receptors were transiently expressed 
in HEK293 cells and tested for their ability to bind [3H]SCH23390. The dissociation 
constant (KD) of [
3H]SCH23390 was 1.5 nM and 2.5 nM for the D1-wt and D5-wt 
receptors, respectively, and the receptors were expressed at 3,611 (D1) and 3,042 (D5) 
fmol/mg protein. The D1- and D5-T3.37A mutant receptors were expressed at 2,218 and 
2,049 fmol/mg protein with KD’s slightly higher than that of the wild-type receptors (D1= 
2.1, D5= 3.9). The D1- and D5-T3.37A/S5.46A mutant receptors were expressed at a 
somewhat lower density (1,166 and 1,352 fmol/mg protein for D1 and D5 receptors, 
respectively), and had similar lower KD’s (1.2 KD for D1 and 1.5 KD for D5) compared to 
the wild-type receptors (Figure 3.1 and Table 3.1). 
Cell-surface radioimmunoassays (RIA) were performed to assess the cell-surface 
expression of each HA-tagged mutant receptor to that of wild-type. Figure 3.2 
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demonstrates that the D1- and D5-T3.37A and T3.37A/S5.46A mutant receptors were 
expressed at the cell surface at levels comparable to that of the wild-type receptors.
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Figure 3.1. Saturation assays for D1/D5-WT and mutant receptors labeled with [
3H]SCH23390. 
HEK293 cell membranes transiently expressing wild-type or mutant receptors were tested in 
radioreceptor saturation isotherm experiments with increasing concentrations of [3H]SCH23390. 
Non-specific binding was determined with 1μM cold SCH23390. Data were analyzed using a 
one-site hyperbolic curve fitting function (Prism 4.0) to obtain the KD and Bmax for 
[3H]SCH23390 at wild-type and mutant receptors. Data are mean ± S.E.M. ND= Not 
Determinable.
Table 3.1. KD and Bmax of D1/D5-WT and mutant receptors labeled with 
[3H]SCH23390.
Receptor Type N KD Bmax
D1 (nM) (fmol/mg protein)
Wt 12 1.5 ± 0.2 3,600 ± 560
T3 .37A(108) 2 2.1 ± 0.9 2,200 ± 260
T3.37A(108)/S5.46A(202) 3 1.2 ± 0.2 1,200 ± 600
D5
Wt 13 2.5 ± 0.5 3,040 ± 740
T3.37A(125) 2 3.9 ± 0.5 2,050 ± 70
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T3.37A(125)/S5.46A(233) 2 1.5 ± 0.1 1,350 ± 120
Figure 3.2. Cell surface expression of D1-like mutant receptors. HEK293 cells transiently 
expressing HA tagged D1-like mutant receptors, exhibiting decreased [
3H]SCH23390 binding, 
were tested for cell surface expression relative to each respective wild-type receptor via RIA. 
Data are representative of 2-3 independent experiments run in quadruplicate. 
Effect of D1 and D5 T3.37A (D1-T108A & D5-T125A) on agonist affinity 
The affinity of each probe ligand for the wild-type and mutant receptors was 
determined in cell membranes using competition radioreceptor assays with 
[3H]SCH23390 as the radioligand. To determine apparent affinity constant, K0.5, 
experimental IC50 values were corrected for radioligand KD and concentration using the 
bimolecular Cheng-Prusoff relationship (Cheng and Prusoff, 1973). The rank order of 
affinities for compounds at the wild-type receptors was as follows, D1: SCH23390 > 
A77636 > SKF82958 > SKF82526 > DNS = DHX > SKF38393 > DA; D5: SCH23390 > 
A77636 > SKF82958 > DNS = DHX > SKF38393 > DA. These data are consistent with 
previous reports of for the D1 and D5 receptors, but include ligands not reported in those 
earlier studies (Sunahara et al., 1991; Dearry et al., 1990). Binding assays revealed a 
decrease in affinity for all agonists tested (Figures 3.3 and 3.4, and Table 3.2). 
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Figure 3.3. Binding of probe ligands to the D1-WT and single and double-mutant receptors. 
Membrane preparations of D1-wild type [A], T3.37A [B], and T3.37A/S5.46A [C] mutant 
receptors were incubated with [3H]SCH23390 for 15 min with varying concentrations of test 
compound.  Analysis was conducted using non-linear regression and a sigmoidal equation to 
determine IC50s, reported as corrected affinity values (K0.5) using Prism 4.0.  Assays were 
conducted in duplicate or triplicate and data represents 2-3 independent experiments.
At the D1- and D5-T3.37A mutant receptors, affinity of the phenylbenzazepine 
(SKF38393, SKF82526, & SKF82958) compounds were affected minimally, whereas 
there were dramatic decreases in the affinity of DA, A77636, DHX, and DNS, 
particularly at the D5 mutant receptor. The affinity of dopamine was most severely altered 
(40-fold) at the D1-T.3.37A
(108) mutation, whereas the decreases for DHX, DNS, and 
A77636 were more modest. At the D5-T3.37A
(125) mutant receptor, losses in affinity were 
most dramatic for DA, DHX, and DNS, with decreases of 100-, 140-, and 220-fold, 
respectively. Binding of the antagonist SCH23390, a compound with a para-Cl instead of 
a hydroxyl, was unaffected at the D1-like T3.37A mutant receptors, consistent with the 
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data from the saturation studies (Figure 3.1). The rank order of binding affinities at the 
T3.37A mutant receptors was as follows, D1: SCH23390 > SKF832958 > SKF82526 > 
A77636 > SKF38393 > DHX > DNS > DA; D5: SCH23390 > SKF82958 > A77636 >
SKF82526 > SKF38393 > DHX = DNS > DA.
A B
C
Figure 3.4. Binding of probe ligands to the D5-WT and single and double-mutant receptors. 
Membrane preparations of D5-wild type [A], T3.37A [B], and T3.37A/S5.46A [C] mutant 
receptors were incubated with [3H]SCH23390 for 15 min. with varying concentrations of test 
compound.  Analysis was conducted using non-linear regression and a sigmoidal equation to 
determine IC50s, reported as corrected affinity values (K0.5) using Prism 4.0.  Assays were 
conducted in duplicate or triplicate and data represents 2-3 independent experiments.
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Table 3.2. Affinity of test ligands for the D1- and D5-WT and mutant receptors 
labeled with [3H]SCH23390.
D1
Ligand wt T3.37A(108) T3.37A(108)/S5.42A(202)
SCH23390 0.24±0.03 0.24± 0.02 (1) 0.2± 0.05 (1)
Dopamine 2,550 ±390 103,000 ± 27,000 (40) 1,850,000 ± 72,000 (60)
DHX 177 ±125 847 ± 26 (5) 3,240 ± 620 (18)
DNS 148 ±7.5 1,110 ± 116 (7) 2,790 ± 480 (16)
A77636 5.2 ±2.1 46.3 ± 3.4 (9) 428 ± 68 (75)
SKF38393 220 ±18.6 284 ± 52 (1) 1110 ± 190 (5)
SKF82526 35.3 ±3.4 72 ± 7.9 (2) 271 ± 24 (7)
SKF92958 7.5 ±1.8 21.8 ± 2.6 (3) 103 ± 7 (13)
D5
Wt T3.37A(125) T3.37A(125)/S5.42A(233)
SCH23390 0.35±0.07 0.44± 0.02 (1) 0.42 ±0.17 (1)
Dopamine 238 ±49 124,000 ± 1,600 (100) N.D.
DHX 10.2±2.0 1,430 ± 340 (140) 5,650 ± 1150 (552)
DNS 6.1±0.8 1,360 ± 1,200 (220) N.D.
A77636 1.8±0.01 21 ± 4.5 (12) 694 ± 32 (397)
SKF38393 100 ±15.7 657 ± 27 (7) 2,330 ± 290 (23)
SKF82526 10.2±1.5 35 ± 7.1 (3) 130 ± 14 (13)
SKF92958 4.1±0.8 7.6 ± 1.4 (2) 74 ± 5.2 (18)
HEK293 cell membranes containing D1/D5-wt or mutant receptors were incubated with one 
concentration of [3H]SCH23390 and 7-12 concentrations of test compound. Dose-response 
curves were analyzed by non-linear regression using a sigmoidal equation (Prism 4.0) to obtain 
estimates for apparent affinity (K0.5) using the Cheng-Prusoff equation. Values are expressed as 
mean ± S.E.M. (nM). In parentheses is the fold change value as compared to the K0.5 of each drug 
at the wild type receptor. Data are representative of 3-10 experiments run in triplicate.
Effect of D1 and D5 T3.37A/S5.46A (D1-T108A/S202A & D5-T125A/S233A) on 
agonist affinity
As with the D1-like T3.37A mutant receptors, the alterations in agonist binding 
affinity (Table 3.2 and Figures 3.3 and 3.4) at the D1- and D5-T3.37A/S5.46A double-
mutants can be grouped according to structural class (Figure 1.3). As expected from the 
saturation assays (Table 3.1), binding of SCH23390 was unaffected at the D1-
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T3.37A(108)/S5.46A(202), whereas dopamine and A77636 had large affinity decreases of 
60- and 75-fold, respectively, and the phenylbenzazepines (SKF38393, SKF82526, & 
SKF82958) displayed modest decreases in affinity. As with the D5-T3.37A
(125) mutant, 
the decreases in affinity at the D5-T3.37A
(125)/S5.46A(233) mutant receptor were more 
dramatic than those at the D1-T3.37A
(108)/S5.46A(202) mutant receptor. The losses in 
binding affinities at the D5 double mutant receptor ranged from no effect for SCH23390, 
to 552- and 397-fold for DHX and A77636 respectively. The severe decrease in the 
affinities of DA and DNS at D5-T3.37A/S5.46A precluded accurate assessment of 
affinity constants for these compounds. The rank order of binding affinities was as 
follows, D1: SCH23390 > SKF82958 > SKF82526 > A77636 > SKF38393 > DNS > 
DHX > DA; D5: SCH23390 > SKF82958 > SKF82526 > A77636 > SKF38393 > DHX > 
DNS = DA.
Functional effects of D1/D5-T3.37A and T3.37A/S5.46A mutant receptors
We utilized a number of structurally and pharmacologically diverse agonists to 
assess the mutational effect on receptor activation. Wild-type and mutant receptors were 
stimulated with a range of agonist concentrations to stimulate adenylate cyclase. The 
cAMP accumulation was produced by treatment with agonist and expressed as % 
maximal stimulation produced by dopamine at each receptor type. The effects on the 
action of dopamine are summarized in Table 3.3. These data highlight the fact that 
T3.37A alone had little effect on maximal efficacy, whereas the double-mutant  
T3.37A/A5.46A had small significant effects on the D5 double mutant yet abolished 
dopamine induced stimulation for the D1. 
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Table 3.3. Dopamine-induced stimulation of cAMP synthesis for the D1-like WT and 
mutant receptors.
D1
Activity
(fmol cAMP/mg/min) D5
Activity
(fmol cAMP/mg/min)
Basal Dopamine Basal Dopamine
wt 2966 ± 309 6431± 447 wt 2977 ± 179 6409 ± 366
T3.37A 2371 ± 497 5211± 603 T3.37A 2135 ± 139 6579 ± 121
T3.37A/S5.46A 901 ± 51 793± 32 T3.37A/S5.46A 1388 ± 173 4832 ± 322
The rank order of potency at the D1 and D5 wild-type receptors was as follows, 
D1: SKF82526 > SKF82958 > A77636 > DHX > DNS > SKF38393 > DA; D5: A77636 >
SKF82526 = SKF82958 > DHX = DNS > SKF38393 > DA. At the D1 receptor 
dopamine, DHX, DNS, and A77636 were all full agonists produced cAMP accumulation 
equal to that of dopamine. SKF38393 was a partial agonist producing approximately 36% 
of the maximal activity of dopamine, while SKF82526 and SKF82958 were partial 
agonists of high intrinsic activity of approximately 87% and 90% of dopamine. Similar to 
the D1 receptor, at the D5-wt receptor DNS, DHX, and A77636 were full agonists. 
SKF38393 displayed partial agonist activity with 40% activity of that of DA. SKF82526 
and SKF82958 were high intrinsic activity partial agonists producing approximately 73% 
and 86% of dopamine.
T3.37A mutant receptors (D1-T108A & D5-T125A)
Mutation of T3.37 to alanine in both D1-like receptors resulted in changes in the 
intrinsic activity of all test compounds. SKF82958 and SKF82526 also exhibited intrinsic 
activity greater than that of dopamine at the D1- and D5- T3.37A mutant receptors, while 
A77636, DNS (excluding the D5 mutant receptor), and DHX were reduced from full to 
partial agonists (relative to dopamine). Specifically, the intrinsic activity of SKF82526 
and SKF82958 at the D5-T3.37A
(125) mutant receptor increased dramatically from 73% 
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and 86% of dopamine in the wild-type receptor to 156% and 159% of dopamine in the 
mutant receptor. Changes in potency were modest at both the D1- and D5-T3.37A mutant 
receptors. At the D1 mutant receptor, dopamine, DHX, and DNS (from 11- to 7-fold) 
displayed the greatest decreases in potency, whereas A77636 (22-fold) and DHX (14-
fold) were most affected at the D5-T3.37A
(125) receptor. The potency and intrinsic activity 
of SKF38393 was affected modestly at both D1-like mutant receptors. 
Table 3.4. Agonist potency and intrinsic activity at the D1/D5-WT and mutant 
receptors.
D1 wt T3.37A T3.37A/S5.46A
Ligand EC50 (nM) IA EC50 (nM) IA EC50 IA
Dopamine 545 ± 300 100 5972 ± 751 (11) 100 N.D. N.D.
DHX 48 ± 20 99 332 ± 56 (7) 41 N.D. N.D.
DNS 70 ± 26 101 454 ± 56  (7) 70 N.D. N.D.
A77636 24 ± 8 97 49 ± 4.5 (2) 65 N.D. N.D.
SKF38393 298 ± 37 36 728 ± 356 (2) 29 N.D. N.D.
SKF82526 3 ± 0.4 87 4.9 ± 2.4 (1) 117 N.D. N.D.
SKF82958 25 ± 11 90 103 ± 35 (4) 112 N.D. N.D.
D5 wt T3.37A T3.37A/S5.46A
Ligand
EC50 
(nM)
IA EC50 (nM) IA EC50 (nM) IA
Dopamine 390 ± 34 100 1630 ± 442 (4) 100 5676 ± 757 (15) 100
DHX 12 ± 1.8 100 172 ± 43 (14) 69 556 ± 212 (45) 81
DNS 13.1± 2.4 98 105 ± 9 (8) 102 538 ± 109 (40) 85
A77636 2.2 ± 0.2 102 48 ± 24 (22) 65 357 ± 106 (162) 84
SKF38393 52.3± 8.6 40 268 ± 122  (5) 43 92 ± 21 (2) 27
SKF82526 9.6± 4.4 73 23 ± 7.6 (2) 156 77 ± 20 (8) 206
SKF82958 9.7± 2.8 86 56 ± 13 (6) 159 507 ± 71 (53) 167
IA = Intrinsic activity, based on dopamine.
N.D.= not determinable due to a lack of measurable intrinsic activity.
HEK293 cell membranes containing D1/D5-wt or mutant receptors were incubated with 7 
concentrations of test ligand. Dose-response curves were analyzed by non-linear regression using 
a sigmoidal equation (Prism 4.0) for best fit to obtain EC50 values. Values are expressed as 
mean ± S.E.M. (nM). Fold change value as compared to the EC50 of each drug at the wild-type 
receptor is listed in parentheses. 
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Figure 3.5. Ligand effects on cAMP accumulation at D1-WT, T3.37A, and T3.37A/S5.46A 
mutant receptors. The ability of test compound to stimulate cAMP production was measured 
using HEK293 cell membranes transiently expressing mutant receptors. Membranes were 
incubated with drug for 15 min at 37oC. Dose-response curves were generated using 7 
concentrations of test compound at the: [A] D1- wild-type; [B] T3.37A; and [C] T3.37A/S5.46A, 
mutant receptors. Results were analyzed by non-linear regression using a sigmoidal equation for 
best fit to obtain potency (EC50) and intrinsic activity values (Prism 4.0). Data are expressed as 
% maximal stimulation by 1 mM DA at each receptor type. Data are representative of 3-5 
independent assays run in quadruplicate and each value represents the mean ± S.E.M.
T3.37A/S5.46A mutants (D1-T108A/S202A & D5-T125A/S233A) 
Figure 3.5 shows that a double mutation of T3.37 and S5.46 to alanine in the D1
dopamine receptor resulted in a complete loss in the activation of adenylate cyclase for 
all test compounds (Figure 1.3). As shown in Table 3.3, the basal level of cAMP was 
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reduced from 2966 fmol/mg/min at the D1 wild type receptor to 901 fmol/mg/min at the 
mutant receptor.
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Figure 3.6. Ligand effects on cAMP accumulation at D5-WT, T3.37A, and T3.37A/S5.46A 
mutant receptors. The ability of test compound to stimulate cAMP production was measured 
using HEK293 cell membranes transiently expressing mutant receptors. Membranes were 
incubated with drug for 15 min at 37o C. Dose-response curves were generated using 7 
concentrations of test compound at the D5- wild-type [A], T3.37A [B], T3.37A/S5.46A [C], mutant 
receptors. Results were analyzed by non-linear regression using a sigmoidal equation for best fit 
to obtain potency (EC50) and intrinsic activity values (Prism 4.0). Data are expressed as % 
maximal stimulation by 1 mM DA at each receptor type. Data are representative of 3-5 
independent assays run in quadruplicate and each value represents the mean ± S.E.M. 
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Based on the results for the D1 mutant receptor, we anticipated a complete loss of 
cAMP accumulation at the D5-T3.37A/S5.46A mutant receptor. However, all test 
compounds stimulated cAMP accumulation above basal at the D5 mutant receptor (Table 
3.3, Figure 3.6). As observed at the D5-T3.37A mutant receptor, A77636, DHX, and DNS 
exhibited decreases in intrinsic activity at the D5-T3.37A/S5.46A mutant receptor, while 
the intrinsic activity of SKF82526 and SKF82958 was increased greatly (206% and 167% 
of dopamine). All test compounds exhibited reduced potency at the mutant receptor with 
A77636 experiencing the most dramatic loss (162-fold). The rank order potency of test 
compounds at the D5-T3.37A/S5.46A mutant receptor was as follows, SKF38393 >
SKF82526 > A77636 > SKF82958 = DHX = DNS > DA. 
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Figure 3.7.  Fold loss in affinity of ligands at the D1- T3.37A, S5.46A, and T3.37A/S5.46A 
mutant receptors. HEK293 cells transiently expressing HA tagged D1-like mutant receptors, 
exhibiting decreased [3H]SCH23390 binding, were tested for cell surface expression relative to 
each respective wild-type receptor via RIA. Data are representative of 2-3 independent 
experiments run in quadruplicate. 
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DISCUSSION
Despite the highly conserved nature of T3.37 among catecholamine GPCRs, to 
our knowledge the involvement of this residue in ligand binding and receptor activation 
has not been explored experimentally in any aminergic receptors. We hypothesized that 
T3.37 is positioned to influence the binding of agonists by interacting with the para-OH 
of the catechol ring of D1 receptor ligands. The work in this Chapter provides evidence 
that T3.37 plays an important role in ligand-binding and activation of the D1-like 
receptors. 
Strader et al. (1988; 1989), using the β2-adrenergic receptor, was the first to 
demonstrate a critical role for catechol interaction with TM5 serine residues (S5.42 and 
S5.46) in ligand interaction of catecholamine GPCRs. Specifically, the authors 
demonstrated that S5.42 interacts with the meta-hydroxyl and S5.46 with the para-
hydroxyl of isoproterenol. Since then, these TM5 serines residues (including S5.43) have 
been shown to be critical for recognition of the endogenous ligand in most Class A 
GPCRs, including the D1-like dopamine receptors. These serine residues form a network 
of H-bonds that serve to anchor the endogenous ligand in the receptor binding pocket.
Previous mutagenesis studies in our lab, using the structurally diverse D1 agonists 
utilized in this study, have shown that ligands of different structural classes have 
differential dependence on the TM5 serines (unpublished observations). A77636 is most 
dependent on S5.46 for binding and receptor activation, likely due to the adamantly 
substituent that positions the ligand in a slightly different mode from other D1 receptor 
full agonists. DHX and DNS are highly dependent on S5.46, whereas the 
phenylbenzazepine compounds are less reliant on S5.46 for receptor interaction than the 
other D1 agonists. Despite sharing a similar structural backbone, the pattern of interaction 
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with the TM5 serines is different for SKF38393 than SKF82526 and SKF82958. The 6-
chlorine substituent on the catechol ring of SKF82526 and SKF82958 is thought to orient 
these ligands in the binding pocket in a manner that greatly reduces their reliance on 
S5.46.  These studies have greatly aided in refinement of the D1 agonist pharmacophore, 
leading to a more comprehensive understanding of how structurally diverse agonists 
dock, invaluable data for the experiments described in this Chapter.
A T3.37 mutation was shown to abolish ligand-receptor interactions without 
affecting global receptor conformation (Fersht, 1987). The structurally diverse agonists 
used in the current study caused differential affects between ligand classes, indicating 
that the mutation caused regional, rather than global, changes in receptor conformation. 
Based on our hypothesis, I expected ligand-binding and activation at the D1-like T.3.37A 
mutant receptors to yield results similar to those observed at the D1- and D5-S5.46A 
mutant receptors. Indeed, as illustrated in Tables 3.2 and 3.4, the trend in ligand affinity 
and potency paralleled those changes observed at the S5.46A mutant receptors. The 
affinity and potency of phenylbenzazepines compounds- which have minimal 
dependence on S5.46 for binding and receptor activation- were less affected than the 
more rigid compounds (i.e. DHX, DNS, and A77636) at both the D1- and D5- T3.37A and 
T3.37A/S5.46A mutant receptors.  As shown in Figure 3.7, the fold change (vs. wild-
type) decrease in ligand affinity at the D1-T3.37A, D1-S5.46A, and D1-T3.37A/S5.46A 
mutant receptors are progressively more dramatic. The decrease in agonist affinity for the 
experiments in this work exhibit a strikingly similar trend to the decreases in ligand 
binding observed at the S5.46A mutant receptor suggesting that similar ligand-receptor 
contacts were affected in each mutation. 
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The changes exhibited in the intrinsic activity of test compounds at the D1-like 
mutant receptors further support our hypothesis T3.37 is positioned in the region of the 
receptor binding para-OH of the D1 compounds. The relative intrinsic activity of the rigid 
compounds at the D1- and D5-T3.37A receptors was decreased compared to wild-type. 
The intrinsic activity of A77636 and DNS was decreased ~30%, whereas that of DHX 
was reduced more than 50%. Conversely, the high efficacy partial agonists SKF825626 
and SKF82958 were altered from high efficacy partial agonists at wild-type to greater 
than full agonists at the D1-T3.37A, D5-T3.37A and T3.37A/S5.46A mutant receptors. 
These changes were greatest at the D5-T3.37A/S5.46A mutant receptor, as the relative 
intrinsic activity of SKF82526 and SKF82958 increased to 206 and 167 percent 
respectively of that of the D5 wild type receptor. Increases in the intrinsic activity of 
SKF82958 and SKF82526, and a decrease for DHX, were also observed at the D1- and
D5-S5.46A mutant receptors in previous mutagenesis experiments. The change in the 
intrinsic activity of SKF82526 and SKF82958 at the D1 and D5 mutant receptors is 
relative to dopamine. These changes reflect a decrease in absolute cAMP accumulation 
caused by dopamine not an increase in cAMP formation by SKF82526 and SKF82958.  
In fact, the fmol of cAMP/mg/min elicited by SKF82526 and SKF82958 was minimally 
altered between the wild-type and mutant receptors. 
The most remarkable result of this study was the complete loss of cyclase 
activation for all test compounds at the D1-T3.37A/S5.46A mutant receptor. Despite 
normal cell-surface expression and ligand-binding, D1 agonists did not stimulate cAMP 
formation at the D1-T3.37A/S5.46A mutant receptor. This result was entirely unexpected 
given the ability of all test compounds to stimulate adenylate cyclase activation at both 
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the D1-T3.37A and S5.46A mutant receptors. Given this finding, I anticipated similar 
results for the D5-T3.37A/S5.46A mutant receptor. Unexpectedly, the D5 double mutant 
receptor retained the ability to stimulate cAMP accumulation upon agonist binding. The 
loss of cyclase activation at the D1-T3.37A/S5.46A mutant receptor establishes a 
requirement for the T3.37 and S5.46 residues for receptor activation, at least at this 
signaling pathway. Furthermore, this finding provides insight into possible structural 
differences between the D1 and D5 dopamine receptors. 
Whether T3.37, along with S5.46, interacts directly with the para-OH of D1
receptor ligands or with the main-chain carbonyl of S5.46 remains unclear. Threonine 
residues often form intra- and interhelical hydrogen bonds in α-helical environments 
(Ballesteros et al., 2000). It is possible that T3.37 stabilizes the carbonyl group of S5.46 
for interaction with the para-OH group, thereby forming a functional link between TM3 
and TM5 important for receptor activation. Alternatively, our D1 molecular model 
indicates that T3.37 may hydrogen bond with S5.42.  This hypothesis requires additional 
investigation (discussed in the future studies section in Chapter 7) and is the subject of 
current modeling studies. While the exact mechanism is unclear, the experiments in this 
Chapter provide convincing evidence that T3.37 contributes to a complex network of H-
bonds involved in stabilizing the catechol hydroxyls in binding to the D1-like dopamine 
receptors. 
T3.37 is highly conserved in aminergic GPCRs and is likely to be involved in the 
binding and activation process of many other aminergic receptors. To our knowledge, the 
role of T3.37 in ligand-binding and activation in catecholamine receptors has yet to be 
examined experimentally. Several molecular modeling studies, however, have predicted 
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an important role for T3.37 in ligand recognition. Docking studies with the 5-HT2A
receptor have suggested that the 5-OH substituent of the serotonin analog 3-(2-
(methylamino)ethyl)-1H-indol-5-ol (termed N-ω-methyl-5-HT by the authors) forms a 
hydrogen bond with the hydroxyl group of T3.37 (Shapiro et al., 2000). A computational 
study using the β2-adrenergic receptor predicted that T3.37 forms a hydrogen bond with 
T4.56 in the inactive state; docking simulations show that this bond is broken by 
salbutamol (Bhattacharya et al., 2008a). Xhaard et al. (2006) predicted that T3.37 is part 
of a large conserved “binding core” present in catecholamine-binding GPCRs. Recent 
computational studies of bovine rhodopsin have proposed a central role for 3.37 
(glutamine in bovine rhodopsin) in formation of the active receptor state (Bhattacharya et 
al., 2008b). In addition to the hydrogen bond between E3.37 and backbone carbonyl of 
H5.46 demonstrated in the crystal structure of inactive rhodopsin, Bhattacharya et al.
(2008b) observed another hydrogen bond between E3.37 and C4.56 on TM4. In the 
predicted active receptor state of rhodopsin, the interaction of E3.37 with the carbonyl of 
H5.46 is disrupted when TM5 rotates in a clockwise fashion, and forms a new hydrogen 
bond with the nitrogen of H5.46. NMR experiments have demonstrated that the hydrogen 
bond between E3.37 and the carbonyl of H5.46 is broken upon receptor activation (Patel 
et al., 2005). Bhattacharya et al. (2008b) propose that movement of the β-ionone ring 
towards TM5 causes a conformational change in M5.42 that disrupts the interaction 
between E3.37 and H5.46. The loss of two hydrogen bond contacts, E3.37 and E3.28, 
causes TM3 to rotate clockwise 15º thus breaking the important salt bridge between 
R3.50 and E6.30.
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In conclusion, the current data supports the hypothesis that T3.37 participates in 
ligand-binding and receptor activation in the D1-like dopamine receptors by influencing 
binding of the para-OH group of D1 agonists. In light of the requirement of catechol 
moieties for full agonism at the D1 receptor, this study is important for further 
understanding this constraint. While the exact nature of the interaction (i.e. whether 
T3.37 interacts with the carbonyl of S5.46, with the para-OH of D1 agonists, or possibly 
S5.42) remains to be determined, it is clear that T3.37 plays an important role in 
positioning the D1 agonists in the binding pocket and is required for high affinity full 
agonism. Understanding the nature of this interaction will impact our general 
understanding of D1 receptor activation, as well as aid in the design of novel D1-like 
agonists. Furthermore, given the highly conserved nature of T3.37 in catecholamine 
receptors we anticipate that these findings can be extended to other aminergic GPCRs. 
CHAPTER 4: DETERMINE MORE SPECIFICALLY THE ROLE OF 
PHENYLALANINE 6.51 IN THE INTERACTION OF D1-LIKE DOPAMINE 
RECEPTORS WITH STRUCTURALLY DIVERSE D1 AGONISTS.
For publication in:
Molecular Pharmacology
PREFACE:
F6.51 resides in the cluster of aromatic amino acid residues (i.e. ‘rotamer toggle 
switch’) located around the proline kink in TM6. Studies of several aminergic receptors 
have shown that this switch region plays a key role in transducing ligand binding to 
receptor activation. Prior studies in our lab, involving the mutation of F6.51 and F6.52 to 
A, suggested a key role for F6.51, but not F6.52, in the activation of D1-like receptors. 
Employing the structurally diverse set of D1 agonists used in Chapter 3, the experiments 
in this chapter explore in more detail how F6.51 contributes to formation of an active 
receptor state. 
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ABSTRACT
The molecular mechanisms by which agonists bind and activate GPCRs in 
general, and the D1 and D5 dopamine receptors in particular, is largely unknown. 
Previous studies of F6.51 using non-conservative mutations (i.e. F6.51A) provided 
evidence that this residue influences receptor activation by interacting with the catechol 
ring of D1 agonists. In this chapter, conservative (to tryptophan and isoleucine) and non-
conservative mutations (to leucine and isoleucine) of F6.51 were made to examine further 
the intermolecular forces involved in ligand binding and receptor activation. After site-
directed mutagenesis, selected probe ligands [e.g., SCH23390, dopamine, dihydrexidine 
(DHX), SKF38393] were used to characterize the mutant receptors [i.e., hD1-
F6.51(288)I/W]. The mutant receptors bound [3H]SCH23390 with decreased affinity. 
Although all three agonists had decreased potency at the mutant vs. WT receptors, 
SKF38393 had a large increase in intrinsic activity at the hD1-F6.51(288)I and L mutant 
receptors. In general, the potency of rigid compounds at each mutant receptor (i.e. DHX, 
DNS, and A77636) was decreased to a far greater extent than were phenylbenzazepines. 
Although the ligands stimulated cAMP accumulation at the D1-F6.51W, D1-F6.51Y, and 
the D5-F6.51Y mutant receptors, the D5-F6.51W mutation resulted in a complete loss of 
cAMP accumulation for all test compounds. To our knowledge, this is the single greatest 
difference seen between these two receptors. These data may offer insight into the 
structural requirements that play a role in D1-like receptor activation, and may possibly 
assist in the design of novel D1-like ligands.
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INTRODUCTION
Despite enormous efforts, knowledge of the molecular requirements involved in 
GPCR activation remains inadequate, particularly for the D1-like dopamine receptors. In 
an inactive state GPCRs are constrained by non-covalent interactions between helical 
side chains that act to stabilize a conformational state favoring an inactive state. Agonist 
binding to the transmembrane region disrupts the intramolecular interactions that stabilize 
the inactive state, thereby facilitating the formation of interactions that favor an active 
receptor conformational state. In order to better understand the mechanism by which 
agonist binding elicits the conformational changes that lead to receptor activation, it is 
imperative to elucidate the ligand-receptor interactions responsible for creating and 
stabilizing an active receptor state. 
The current activation model for rhodopsin-like GPCRs proposes the involvement 
of several molecular switches that act in concert to restrict the receptor to a basal state in 
the absence of ligand-induced activation. These non-covalent interactions are disrupted 
upon agonist binding, and new intramolecular interactions are formed that favor active 
receptor conformations. One prominent molecular switch -- coined the ‘rotamer toggle 
switch’-- is comprised of a cluster of aromatic residues (i.e. Phe6.44, Trp6.48, Phe6.51,
Phe6.52) surrounding a highly conserved proline in the TM6 helix. Agonist binding to a 
residue or residues in this cluster induces a coordinated movement of these residues 
around the proline kink resulting in the counterclockwise rotation of the cytoplasmic end 
of TM6 away from TM3 (Farrens et al., 1996; Shi et al., 2002). The agonist-induced 
rotation of the cytoplasmic portion of TM6 away from the receptor core and upwards 
towards the membrane bilayer is thought to be an important step in GPCR activation 
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(Ghanouni et al., 2001b; Hamdan et al., 2002; Jensen et al., 2001). The nature of the 
interaction of an agonist with the aromatic residues in the switch region is believed to be 
an important determinant of the degree of receptor activation.
In a recent study of D1-like dopamine receptors (unpublished results), we 
examined the role of two TM6 phenylalanine residues (F6.51 & F6.52) that are 
hypothesized to reside in the toggle switch region. Both of these residues were mutated to 
alanine, and ligand-binding and receptor activation examined using the group of probe 
compounds that have been used throughout this Dissertation (see Figure 1.3). These 
experiments indicated a key role for F6.51, but not F6.52, in the activation of D1-like 
receptors. The phenylalanine residue at position 6.51 is highly conserved across 
aminergic receptors and has been demonstrated to play a role in receptor activation in 
several GPCRs. Substituted cysteine accessibility studies in the D2 dopamine receptor 
provided evidence that F6.51 is solvent accessible in the binding site crevice, suggesting 
its potential involvement in ligand binding and receptor activation (Javitch et al., 1998). 
Molecular modeling and mutagenesis studies in the 5-HT2A (Braden et al., 2006; 
Choudhary et al., 1993; Roth et al., 1997), muscarinic acetylcholine (Ward et al., 1999), 
adrenergic (Chen et al., 1999; Peltonen et al., 2003), histamine (Wieland et al., 1999), 
and D2/D3 dopamine receptors (Boeckler et al., 2005; Cho et al., 1995) also are consistent 
with a role for F6.51 in ligand-binding and activation.  Our D1 molecular modeling 
studies suggest that F6.51 is positioned to form aromatic interactions with the catechol 
ring of D1 agonists.
The current experiments were designed to explore further the role of F6.51 in the 
activation of D1-like receptors. I constructed non-conservative (Ile, Leu) and conservative 
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(Trp, Tyr) point mutations in both the D1 and D5 dopamine receptors and used an array of 
structurally and pharmacologically diverse test compounds to probe binding and 
subsequent activation. These findings provide evidence that F6.51 is a key residue in 
ligand-induced activation of the D1-like receptors, and also unearthed a major difference 
between the D1 and D5 receptors..
RESULTS
Binding characteristics of F6.51 mutant receptors in HEK293 Cells.
The D1/D5 wild-type and mutant dopamine receptors were transiently expressed in 
HEK293 cells, and then tested for their ability to bind the D1-selective antagonist 
[3H]SCH23390. The characteristics of the D1-wt (KD = 1.5 ± 0,2; Bmax = 3,600 ± 600 
fmol/mg) and D5-wt (KD = 2.5 ± 0,5; Bmax = 3,040 ± 740 fmol/mg) were consistent with 
data reported in earlier chapters. As can be seen in the left panel of Figure 4.1, the 
saturation experiments indicated that the affinity of specific binding of [3H]SCH23390 
for the D1- and D5- F6.51I/L/Y/W mutants was decreased to such a degree that it was 
impossible to determine values for KD and Bmax. 
To determine whether the loss of binding was due to a decrease in cell-surface 
expression of the mutant receptors or effects on the interaction of SCH23390 with these 
receptors, I performed cell surface radioimmunoassay (RIA) experiments with HA-
tagged receptors, and assessed the cell-surface expression of mutant receptors relative to 
each wild-type receptor. The results of these experiments indicate that despite the 
apparent loss of binding sites (Figure 4.1 left), there was no significant decrease in cell-
surface expression for any of the D1 or D5 mutant receptors compared to wild type (Fig. 
4.1, right panel). 
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Figure 4.1. D1/D5-F6.51 mutations result in a loss of [
3H]SCH23390 binding but do not alter 
cell-surface expression. HEK293 cell membranes transiently expressing wild-type or mutant 
receptors were tested in radioreceptor saturation isotherm experiments with increasing 
concentrations of [3H]SCH23390. Non-specific binding was determined with 1 μM unlabeled 
SCH23390. Data were analyzed using a one-site hyperbolic curve fitting function (Prism 4.0) to 
obtain the KD and Bmax for [
3H]SCH23390 at wild-type and mutant receptors. Data are mean ± 
S.E.M. HA-tagged mutant receptors were subsequently tested for cell-surface expression relative 
to wild-type receptors via RIA. Data are representative of 2-3 independent experiments.
Functional effects of D1-like mutant receptors
I next examined the ability of agonists to stimulate adenylate cyclase at the wild-
type and mutant D1 and D5 dopamine receptors. cAMP accumulation was measured using 
membrane preparations expressing wild-type or mutant receptors, and full dose-response 
curves for adenylate cyclase activation were generated for all test compounds.  These 
data are summarized in Table 4.1. 
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Figure 4.2. Agonist-mediated cAMP accumulation at the D1-WT and F6.51 mutant receptors. 
The ability of test compound to stimulate cAMP production was measured using HEK293 cell 
membranes transiently expressing mutant receptors. Membranes were incubated with drug for 15 
min at 37o C. Dose-response curves were generated using 7 concentrations of test compound at 
the D1- wild-type and mutant receptors. Results were analyzed by non-linear regression using a 
sigmoidal equation for best fit to obtain potency (EC50) and intrinsic activity values (Prism 4.0). 
Data are expressed as % maximal stimulation by 1 mM DA at each receptor type. Data are 
representative of 3-5 independent assays run in quadruplicate and each value represents the 
mean + S.E.M.
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Figure 4.3. Agonist-mediated cAMP accumulation at the D5-WT and F6.51 mutant receptors.
The ability of test compound to stimulate cAMP production was measured using HEK293 cell 
membranes transiently expressing mutant receptors. Membranes were incubated with drug for 15 
min at 37o C. Dose-response curves were generated using 7 concentrations of test compound at 
the D5- wild-type and mutant receptors. Results were analyzed by non-linear regression using a 
sigmoidal equation for best fit to obtain potency (EC50) and intrinsic activity values (Prism 4.0). 
Data are expressed as % maximal stimulation by 1 mM DA at each receptor type. Data are 
representative of 3-5 independent assays run in quadruplicate and each value represents the 
mean + S.E.M.
Table 4.1. Agonist potency and intrinsic activity at the D1-WT and mutant receptors.
Ligand IA Fold IA Fold IA Fold IA Fold IA
Dopamine 550 ± 120 100 15,000 ± 1.3 27 100 4,000 ± 1,000 8 100 3,000 ± 800 6 100 N.D. N.D. N.D.
DHX 10.6 ± 0.3 97 560 ± 127 52 85 915 ± 58 75 81 280 ± 130 23 93 N.D. N.D. N.D.
DNS 12.5 ± 3.2 102 540 ± 85 43 97 273 ± 67 21 114 14,000 ± 4,000 1,060 105 N.D. N.D. N.D.
A77636 2 ± 0.2 97 133 ± 20 66 76 117 ± 16 64 104 3,100 ± 1,000 1,700 107 N.D. N.D. N.D.
SKF38393 46 ± 7 44 277 ± 57 4 98 71 ± 20 2 91 1,170 ± 160 25 54 N.D. N.D. N.D.
SKF82526 9.6 ± 4.4 70 17.4 ± 4.2 1 97 12 ± 2 1 109 433 ± 155 45 67 N.D. N.D. N.D.
SKF82958 3.6 ± 0.7 87 31 ± 11 10 100 152 ± 24 16 90 11 ± 5 1 80 N.D. N.D. N.D.
Ligand IA Fold IA Fold IA Fold IA Fold IA
Dopamine 870 ± 180 100 85,000 ± 12,000 98 100 35,000 ± 15,000 40 100 7,200 ± 2,900 8 100 103,000 ± 20,000 118 100
DHX 115 ± 43 99 3,000 ± 735 10 88 743 ± 120 5 81 1,350 ± 390 9 86 711 ± 207 2 141
DNS 82 ± 49 97 3,800 ± 1,600 46 112 2,700 ± 1,100 28 102 15,000 ± 6,000 156 32 5,300 ± 1,300 65 110
A77636 24 ± 9 100 1,080 ± 317 38 119 405 ± 156 17 84 6,700 ± 3,100 283 70 11,500 ± 5,900 415 141
SKF38393 440 ± 340 35 2,750 ± 550 6 127 498 ± 55 1 96 9,500 ± 2,400 17 60 16,900 ± 5,400 38 36
SKF82526 32 ± 10 81 311 ± 142 10 124 14 ± 4 1 98 3,100 ± 1,200 96 71 1,780 ± 680 54 80
SKF82958 30 ± 15 90 122 ± 56 4 132 232 ± 160 8 96 555 ± 400 18 90 51 ± 18 2 99
EC50 (nM)
hD1-F6.51W
EC50 (nM)
hD5-F6.51W
EC50 (nM)
EC50 (nM)
hD1-F6.51Y
hD5-F6.51Y
EC50 (nM)
hD1-F6.51L
EC50 (nM)
hD5-F6.51L
hD1-wt
EC50 (nM)
EC50 (nM)
EC50 (nM)
hD1-F6.51I
EC50 (nM)
hD5-wt hD5-F6.51I
IA = Intrinsic activity.
Fold = the fold change value as compared to the EC50 of each drug at the wild type receptor. Fold changes were calculated from raw data, not 
from rounded values in Table. 
HEK293 cell membranes containing D1-wt or mutant receptors were incubated with 7 concentrations of test compound. Dose-response curves 
were analyzed by non-linear regression using a sigmoidal equation (Prism 4.0) for best fit to obtain EC50 values. Data are representative of 3-6 
individual experiments run in quadruplicate. Values are expressed as mean + S.E.M. 
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The rank order of potency at the wild-type D1 receptor (Figure 4.2 and Table 4.1) 
was: D1: SKF82958 > SKF82526 = A77636 > DHX > DNS > SKF38393 > DA. For the 
D5, there were differences in the rank order, with A77636 > SKF82958 > DHX = DNS > 
SKF82526 > SKF38393 > DA (Figure 4.3 and Table 4.1).
I also assessed the intrinsic activity (relative to dopamine) of each ligand at each 
receptor. At the D1-wt receptor, DHX, DNS, and A77636 were full agonists. The 
phenylbenzazepine SKF38393 was a partial agonist (46% intrinsic activity), whereas 
SKF82526 and SKF82958 had higher intrinsic activity (84% and 91%, respectively). At 
the D5-wt receptor, as with the D1-wt, DHX, DNS, and A77636 were full agonists. 
SKF38393 was a partial agonist (52% intrinsic activity), and SKF82526 and SKF82958 
were partial agonists with somewhat higher intrinsic activity (62% and 86%, 
respectively). With both receptors, the D1-like-selective antagonist SCH23390 
completely attenuated the functional effects of the highest concentration of each agonist 
(data not shown).
Leu and Ile mutation of F6.51 provide evidence of a structural basis for 
efficacy.
Point mutations of Leu and Ile in the D1 and D5 receptors were constructed as 
these residues eliminated aromaticity, but still provided steric bulk and hydrophobicity. 
The alterations in potency and intrinsic activity were comparable at the D1 and D5
receptors in both the Ile and Leu mutant receptors. The potency of the phenylbenzazepine 
compounds (SKF38393, SKF82526, and SKF82958) was less affected by either of these 
mutations than was that of the rigid compound. The decrease in potency of DA at the D1
Ile (98-fold decrease) and Leu (40-fold decrease) mutants, however, was greater than that 
of the D5 mutant receptors (27-fold decrease at Ile, 8-fold at Leu). Additionally, the 
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decreases in potency of DHX for the D1-F6.51I/L mutant receptors were much less than 
that of the D5-F6.51I/L mutants. With one exception, the intrinsic activity of the probe 
ligands was not significantly affected.
Figure 4.4. SKF38393 exhibits a dramatic increase in intrinsic activity at the D1-F6.51I and L 
mutant receptors. Data are expressed as fmol of cAMP produced per mg per minute in response 
to 100 μM drug treatment. Basal levels of cAMP have been subtracted out.
As shown in Figure 4.4, the exception was SKF38393 whose intrinsic activity was 
altered from that of poor partial agonist at both the D1/D5 wild-type receptors to a full 
agonist at both the Ile and Leu mutants in the D1 and D5 receptors. Its potency at both the 
D1 and D5 receptors was affected only minimally, the ability of SKF38393 to stimulate 
cAMP synthesis, however, increased from 35% intrinsic activity at D1 and 40% at D5 in 
the wild-type receptor to levels equal to dopamine in the D1/D5 mutant receptors (98% at 
D1-Leu mutant, 91% and 98% at Leu and Ile respectively at the D5 receptor), and even 
greater than dopamine (128% intrinsic activity) with the D1-Ile mutant. As can be seen in 
Figures 4.2 and 4.3, the increase in cAMP accumulation was both relative (i.e., vs. 
dopamine) and absolute. The intrinsic activity of two other phenylbenzazepines used in 
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this study, SKF82526 and SKF23958, was not significantly affected at either the Ile or 
Leu mutants in the D1 and D5 dopamine receptors.
Conservative mutations of F6.51 reveal structural differences in D1-like 
receptors.
Tyrosine mutation
Unlike the Leu and Ile mutant receptors, mutational effects of F6.51 to Tyr were 
not dependent on the structural class of the compound. A77636 displayed dramatic losses 
of potency (283-fold decrease at D1 receptor, 1,700-fold at D5 receptor), but less 
pronounced changes in intrinsic activity. The potency of dopamine was minimally 
affected at both the D1 (8-fold decrease) and D5 (6-fold decrease) receptors. There was no 
change in the absolute cAMP accumulation of dopamine at the Tyr mutant receptor 
versus the wild-type receptor. The potencies of SKF38393 and SKF82526 were modestly 
affected at both the D1 and D5 receptors, whereas SKF82958 had much lower potency 
(95-fold decrease at D1, 45-fold at D5). The intrinsic activity of the phenylbenzazepines at 
D1- and D5-F6.51Y mutant receptors was affected only minimally. 
DHX and DNS, despite their structural similarity, were differentially affected at 
the Tyr mutant receptor in the D1 and D5 receptors. The potency of DNS (155-fold 
decrease at D1 receptor, >1,000-fold at hD5 receptor) for the Tyr mutant receptor 
decreased dramatically, whereas the decrease for DHX (9-fold decrease at D1 receptor, 
23-fold at D5 receptor) was modest. Additionally, the intrinsic activity of DNS decreased 
from a full agonist to partial agonist, particularly in the D1 mutant receptor (33% of 
maximal dopamine stimulation), whereas DHX retained full intrinsic activity. 
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Figure 4.5. Dinapsoline and dihydrexidine are affected differentially at the Tyr mutant 
receptor. The ability of test compound to stimulate cAMP production was measured using 
HEK293 cell membranes transiently expressing mutant receptors. Membranes were incubated 
with drug for 15 min at 37o C. [Panel A] Data shows the fmol cAMP produced per milligram of 
protein per minute by 100 M DNS, DHX, and DA at wild-type and mutant receptors.  All data 
are representative of 3-5 independent assays run in quadruplicate and each value represents the 
mean + S.E.M. [Panel B] Energy-minimized structures of DHX and DNS. 
Trp mutation
Unexpectedly, mutation of F6.51 to Trp in the D5 dopamine receptor resulted in 
the failure of all test compounds to stimulate cAMP accumulation above basal (Figure 
4.3). Conversely, all test compounds elicited cAMP accumulation at the D1-F6.51Y 
mutant receptor. Unlike the Leu and Ile mutant receptors, the phenylbenzazepines were 
differentially affected yielding 44-fold, 2-fold, and 54-fold decreases in potency for 
SKF38393, SKF82958, and SKF82526 respectively. The intrinsic activity of the 
phenylbenzazepines at the Trp mutant receptor was also affected minimally. A77636 
resulted in the greatest loss in potency compared to the wild type receptor (634-fold). The 
intrinsic activity of A77636, however, was increased above that of dopamine.  
As observed for the Tyr mutant receptor, the potency of DHX (2-fold decrease) 
and DNS (56-fold decrease) was differentially affected in the Trp mutant receptor; 
however DNS retained full agonist activity. The loss of potency for dopamine at the Trp 
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(188-fold decrease) was much greater than at the Tyr mutant receptor (8-fold) while the 
intrinsic activity was unaffected.
DISCUSSION
In a prior study we demonstrated that mutation of F6.51 to alanine affected the 
functional potency and efficacy of an array of structurally dissimilar D1 agonists 
according to chemical class. Specifically, the receptor interactions of dopamine, DHX, 
DNS and A77636 were markedly affected by the F6.51A mutant receptor whereas the 
phenylbenzazepines (SKF38393, SKF82958, & SKF82526) were affected minimally by
this mutation.  The goal of this chapter was to probe further the role of F6.51 in the 
transduction of ligand binding to receptor activation. This was accomplished by 
constructing conservative (Trp and Tyr) and non-conservative (Leu and Ile) mutations of 
F6.51 in the D1 and D5 dopamine receptors.
Based on our studies of the F6.51A mutant receptor we anticipated that the D1
antagonist SCH23390 would have significantly decreased affinity at many of the mutant 
D1-like receptors. Indeed, all mutant receptors resulted in a dramatic loss in affinity for 
SCH23390, thus precluding the assessment of agonist binding affinities. Cell surface RIA 
experiments in Figure 4.1 demonstrated protein folding and membrane expression was 
not affected by any of the D1 or D5 receptor mutants. Concerns about mutational affects 
on global structure of the receptor were addressed by using several different chemical 
classes of D1 agonists. 
Mutation of 6.51 in a variety of GPCRs has suggested that the residue is solvent 
accessible (Chen et al., 1999; Javitch et al., 1998) and may form a π-π interaction with 
both agonists and antagonists (Braden et al., 2006; Cho et al., 1995; Huang et al., 1995; 
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Nardone and Hogan, 1994). Studies of catecholamine receptors indicate that F6.51 is 
located in the cluster of aromatic residues that comprises the rotamer toggle switch (ref). 
Javitch et al. (1998) found that F6.51 was accessible in the D2 receptor binding site 
crevice. Chen et al. (1999) showed that F6.51 is not only solvent accessible but is a key 
switch residue in α1B-adrenergic receptor activation. Based on these findings and D1
molecular modeling studies, we hypothesized that F6.51 forms an aromatic interaction 
(π-π or CH-π interaction) with the catechol ring of D1 agonists. 
Semi-conservative mutations of phenylalanine to leucine and isoleucine were 
made to eliminate aromaticity while conserving steric bulk and hydrophobicity. Similar 
to the findings observed at the F6.51A mutant receptor, agonist interactions with the D1-
and D5-F6.51I/L mutant receptors were affected according to chemical class. The potency 
and intrinsic activity of the rigid compounds (DHX, DNS, and A77636) was less affected 
at the D1-like F6.51I and L receptors than the phenylbenzazepine compounds 
(SKF38393, SKF82526, and SKF82958). This finding suggests that mutational effects 
are not due to global changes in receptor structure, thus assuaging concerns about global 
structural changes that affect all ligand classes. Remarkably, the intrinsic activity of 
SKF38393 at the D1/D5-F6.51I/L mutant receptors was altered from that of a low efficacy 
partial agonist (at wild-type) to a full agonist (or greater). A lesser increase in intrinsic 
activity was observed for SKF82526 and SKF82958 but not for the rigid agonists. The 
removal of aromaticity appears to orient SKF38393 in a position that favors a receptor 
active state, by altering the nature of the interaction of the pendant phenyl ring with the 
so-called “hydrophobic accessory region” of the D1 receptor (Mottola et al., 1996). 
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Figure 4.6 shows the bound conformations of the full agonist dopamine and 
partial agonist SKF38393. In the dopamine bound conformation, the side chain of F6.51 
makes an aromatic contact with the catechol ring of dopamine, while in the SKF38393 
bound conformation F6.51 interacts with the catechol ring and also the azepine moiety of 
the ligand.  Cysteine scanning experiments involving rhodopsin, and also from previous 
simulation studies (Bhattacharya et al., 2008a), show that TM6 rotates in the clockwise 
direction in order to fully activate the receptor. Therefore, on full activation F6.51 should 
move closer to TM5. 
SKF38393
azepine
F6.51
Dopamine
Figure 4.6. Modeling of the bound conformations of the full agonist dopamine and partial agonist 
SKF38393 .
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In the dopamine bound conformation, F6.51 could move towards TM5 and at the 
same time maintain favorable contact with the catechol ring. In SKF38393 bound
conformation, F6.51 shows favorable contact with the azepine ring in the partially active 
state.  This interaction is lost when F6.51 moves towards TM5, and SKF38393 stabilizes 
a partially active state of the receptor. Aromatic interaction with the azepine moiety is 
lost when F6.51 is substituted with non-aromatic residues such as Leu and Ile.  As a 
result, TM6 shows less preference for the partially active state and is free to move to the 
fully active state. Therefore SKF38393 behaves as a full agonist in the F6.51L/I mutants.
This finding is particularly important as full agonism is required for D1 receptor-mediated 
therapeutic effects in Parkinson’s disease (Taylor et al., 1991). 
To evaluate further the molecular interactions between F6.51 and the test 
compounds we constructed conservative mutations of phenylalanine to tryptophan and
tyrosine. Mutation of F6.51 to tyrosine, which has similar steric bulk and an aromatic 
side chain, led to dramatic potency losses for DNS and A77636 but not for DHX and 
dopamine. At the D5-F6.51Y mutant receptor, the fold change decrease in potency for 
A77636 and DNS was ~50- to 200-fold greater than that of dopamine and DHX; however 
these compounds exhibited only minor changes in intrinsic activity. Tryptophan, although 
slightly larger than phenylalanine, preserves its hydrophobicity and aromaticity. The 
complete loss of cAMP accumulation for all test compounds at the D5-F6.51W mutant 
receptor was entirely unexpected. All test compounds elicited activation at D1-F6.51W 
and Y mutant receptors, as well as at the D5-F6.51Y mutant receptor. Cell surface 
expression of the D5-F6.51W mutant receptor was unaffected compared to the D5 wild-
type receptor indicating that the mutant receptor is properly folded and expressed. These 
101
data indicate that, in the D5 receptor, the F6.51W mutation is disrupting the molecular 
interactions necessary for formation of an active receptor state. Additionally, the loss in 
the ability of the D5-F6.51W mutant receptor but not the D1-F6.51W mutant receptor 
provides evidence of possible structural differences between the receptor subtypes. The 
transmembrane regions (TMs 3, 5, 6 and 7) with which D1 agonists interact are highly 
conserved among D1 and D5 receptors.  An alternatively, the EC-II loop between TMs 4 
and 5, which our D1 model predicts to interact with all the test compounds, is not 
conserved among D1 and D5 receptors. Therefore, the interaction of the EC-II loop with 
the ligands could be the contributing factor to the difference among the two mutant 
receptors. However, accurate conformation of the EC-II loop is difficult to determine 
given the lack of homology of the loops among the GPCR crystal structures. Further 
examination of these structural differences may aid in the design of a D1 vs. D5 selective 
compound. 
DNS and DHX, structurally similar compounds that have almost identical binding 
and functional profiles at the D1 wild-type receptor, were affected differently at D1 Trp 
and Tyr mutant receptors. Specifically, the potency and intrinsic activity of DNS was 
altered dramatically at the F6.51Y mutant receptor while that of DHX was affected 
minimally (Figure 4.5). Also, at the D5-F6.51Y mutant receptor we observed a 1060-fold 
potency loss (vs. wild-type) for DNS while that of DHX was decreased only 23-fold. 
Unlike phenylalanine and tryptophan, tyrosine is unlikely to be planar and has H-bonding 
potential. Docking studies show that the interaction of F6.51 with DNS was 2Kcal/mol 
stronger than with DHX.  This may explain the larger loss of potency of DNS compared 
to that of DHX in the F6.51Y/W mutant receptors.  Docking of DHX and DNS into a D1
102
receptor model that has Tyr and Trp substituted for Phe will provide important details of 
the molecular interactions responsible for this phenomenon. These findings demonstrates 
that minor structural changes can have profound effects on receptor activation (even 
between two structurally similar compounds) and underscore the importance of 
understanding the structural features responsible for ligand recognition and receptor 
activation. 
The phenylalanine at position 6.51 is highly conserved in aminergic GPCRs and 
is part of a cluster of aromatic residues critical for ligand recognition and receptor 
activation in catecholamine receptors. This residue is located in a motif known as the 
‘rotamer toggle switch’, which is comprised of a cluster of aromatic residues (F6.44, 
W6.48, F6.51, F6.52) surrounding a highly conserved proline kink in the sixth 
transmembrane helix (TM6) (Shi et al., 2002). Agonist interaction with a residue or 
residues in this switch region has been proposed to trigger a coordinated rearrangement 
of the other aromatic residues of the ‘toggle switch’ that act to modulate the bend angle 
of TM6 around the proline kink, subsequently resulting in the movement of the 
cytoplasmic end of TM6 away from TM3 (Bissantz et al., 2003; Visiers et al., 2001). The 
intracellular loop of TM3 has been implicated as an important region G-protein 
interaction and thus second messenger activation (Wess et al., 1989). Weinstein 
(Weinstein, 2006) proposed that the degree of interaction with residues in the toggle 
switch determines it efficacy of a ligand. Shi et al. (2002) showed that the rotameric 
positions of F6.52 and W6.48 are coupled in the 2-adrenergic receptor and act in a 
coordinated fashion to modulate configuration of the conserved proline kink at 6.50.  
Molecular modeling and docking studies of the β2-adrenergic receptor predict that the 
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interaction between ligand and W6.48 is mediated by F6.52, which is thought to reside 
between the ligand and W6.48 rotamer (Bhattacharya et al., 2008a). The authors propose 
that upon ligand binding F6.52 alters its rotameric conformation to form a π-π interaction 
with the ligand, which in turn leads to alteration of the W6.48 rotamer and subsequent 
movement of TM3 away from TM6. The role of F6.51 and F6.52 in rotamer toggle 
switch appears to vary across catecholamine GPCRs, prior studies in our lab have 
demonstrated that F6.52 does not directly interact with D1 agonists (unpublished 
observations). 
Based on the findings in this chapter, as well as studies of the cognate residue in 
other catecholamine receptors, we propose that F6.51 serves as a key switch residue in 
the D1 receptor that can trigger the transduction of agonist binding to W6.48. Our 
findings support the notion that F6.51 and W6.48 are coupled in the D1-like receptors, 
and play a key role in coupling ligand binding to receptor activation. The molecular 
interactions between an agonist and F6.51 appear to be a key determinant efficacy. We 
hypothesized that F6.51 resides lower in the binding pocket, positioned to form aromatic 
interactions with the catechol ring of D1 agonists, and the findings in this study can be 
interpreted based on this hypothesis. Alternatively, a few homology modeling and 
docking studies of catecholamine receptors predict that F6.51 is positioned higher in the 
binding crevice (Peltonen et al., 2003; Xhaard et al., 2006), in a position to interact with 
the accessory ring system of D1 agonists. The orientation of the pendant phenyl ring is 
thought to be important for D1 receptor activation (Mottola et al., 1996). This hypothesis 
is intriguing as it may reconcile the differences between DHX and DNS observed at the 
D1-F6.5Y and W mutant receptors. The azepine ring of DNS allows the β-phenyl moiety 
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to twist orthogonally by about 18o with respect to the catechol ring, and 28o with respect 
to the β-phenyl of dihydrexidine (Negash et al., 1997). The twist may orient the pendant 
phenyl moiety such that DNS interacts with the F6.51Y and W mutant receptors 
differently than DHX. D1 receptor molecular modeling and docking studies will lend 
additional insight to the location of F6.51.
In conclusion, the results of this study provide convincing evidence that, in the 
D1-like dopamine receptors, F6.51 plays a key role in coupling agonist binding to the TM 
helical movement that lead to G-protein activation. These data demonstrate that subtle 
changes in ligand-receptor interactions can have large, unanticipated effects on functional 
activity, and underscore the importance of understanding the molecular interactions 
governing functional effects. Detailed knowledge of the nature of the conformational 
changes leading to receptor activation is critical for the design of effective therapeutics. 
This study provides important insight into the structural mechanisms responsible for full 
agonism at the D1-like receptors. Furthermore, we demonstrate what we believe to be the 
largest difference ever seen between the D1 and D5 receptors. 
CHAPTER 5: DETERMINE THE ROLE OF TWO TM6 RESIDUES (W6.48 & 
N6.55) HYPOTHESIZED TO PLAY AN IMPORTANT ROLE IN THE 
TRANSDUCTION OF LIGAND-BINDING TO RECEPTOR ACTIVATION 
OF THE D1-LIKE RECEPTORS.
PREFACE: 
The work presented in Chapter 4 provided a detailed investigation of the role of 
F6.51 in D1-like receptor activation. Previous studies of other aminergic receptors have 
demonstrated the importance of W6.48 and N6.55 in ligand-binding and receptor 
activation. This chapter will focus on these two TM6 residues that have been 
hypothesized to make important contributions to the formation of an active receptor 
conformational state. 
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ABSTRACT
Studies of numerous GPCRs have suggested that the residues surrounding the 
proline kink in TM6 play a central role in the transduction of agonist binding to receptor 
activation. W6.48 has been shown to serve as a key residue in this process in several 
catecholamine receptors while N6.55 has an important role in ligand recognition and 
receptor activation of the β2-adrenergic receptor. The work in this chapter is the first 
effort to understand the role of W6.48 and N6.55 in D1-like receptor activation. “Non-
conservative” (i.e. Ala) mutations of N6.55 and W6.48 were constructed in both D1 and 
D5 receptors. Mutant receptors were characterized using an array of functionally and 
pharmacologically diverse test compounds in an adenylate cyclase assay to examine the 
functional consequences of each mutation. All mutant receptors exhibited a dramatic loss 
in affinity for the D1 receptor antagonist SCH23390. The N6.55A mutation led non-
specific changes in the D5 receptor but not the D1 receptor, suggesting possible structural 
differences between the two receptor subtypes. The D1- and D5-W6.48A mutant receptors 
exhibited greatly decreased basal (and ligand stimulated) levels of cAMP accumulation. 
Additionally, the intrinsic activity of two phenylbenzazepine compounds (SKF82526 & 
SKF82958) was greatly reduced at the D1 and D5 mutant receptors. These findings 
support the notion that W6.48 plays a central role in formation of the active receptor state 
of D1-like receptors. The data in this chapter provide important knowledge of how N6.55 
and W6.48 contribute to activation of the D1-like receptors, and will aid in understanding 
the structural mechanisms required for D1 receptor activation.
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INTRODUCTION
The experiments in this Chapter continue our efforts to understand how agonist 
binding triggers the conformational changes that lead to the active state of D1-like 
dopamine receptors. As discussed in the Introduction of this Dissertation, numerous 
studies have shown that TM6 amino acids play a key role in the transduction of agonist 
binding to GPCR activation. In particular, the aromatic residues that comprise the 
rotamer toggle switch (i.e. W6.48, F6.51, and F6.52) are thought to function as sensors 
for agonist binding (Jongejan et al., 2005; Shi et al., 2002; Singh et al., 2002). In the 
experiments performed in Chapter 4, I investigated the role of one of these residues-
F6.51- in D1-like receptor activation. My findings demonstrate that the nature of agonist 
interaction with F6.51 is a key determinant of agonist efficacy. In addition to this detailed 
study of F6.51, I have previously shown that F6.52 does not directly interact with D1
agonists (unpublished results). To explore the role of TM6 residues in ligand-binding and 
activation of D1-like receptor further, I targeted two amino acids (W6.48 and N6.55) 
hypothesized to make important contributions in this region of the D1-like receptor 
agonist binding site. 
The tryptophan residue at position 6.48 is completely conserved across all 
catecholamine receptors and has been implicated as a key residue for the transduction of 
ligand binding to receptor activation (Bissantz et al., 2003; Roth et al., 1997; Shi et al., 
2002). In rhodopsin, the β-ionone ring of 11-cis-retinal interacts with the indole of 
W6.48, restricting the receptor in an inactive conformational state (Lin and Sakmar, 
1996). Upon photoisomerization of retinal, the β-ionone ring moves away from W6.48, 
whose enhanced freedom permits the structural rearrangements necessary for receptor 
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activation (Lin and Sakmar, 1996). SCAM studies of the D2 dopamine receptor found 
that W6.48 faces the binding crevice, and predicted this residue to reside in the aromatic 
cluster of residues that comprises the rotamer toggle switch (Shi and Javitch, 2004). 
Studies of the β2-adrenergic and α1B-adrenergic receptors indicate that agonist binding 
affects the rotameric configuration of W6.48, thereby modulating the bend of TM6 
around the proline kink that subsequently results in receptor activation (Chen et al., 1999; 
Gentili et al., 2004; Shi et al., 2002).
The amino acid at position 6.55 varies across catecholamine receptors: tyrosine 
(α2-adrenergic), histidine (D2-like receptors) and asparagine (β-adrenergic and D1-like 
receptors). Studies of bovine rhodopsin suggest that W6.55 forms a direct interaction 
with retinal (Nakayama and Khorana, 1991). SCAM studies predict that H6.55 is 
accessible in the hD2L receptor binding pocket (Javitch et al., 1998), and experimental 
data suggests an interaction between H6.55 and dopamine antagonists (Woodward et al., 
1994). In the β2-adrenergic receptor, N6.55 has been implicated in agonist recognition by 
interacting with the β-OH group in the aliphatic side chain of isoproterenol (Wieland et 
al., 1996; Zuurmond et al., 1999).
To examine the role of W6.48 and N6.55 in the D1-like receptors, we constructed 
non-conservative point mutations to alanine and assessed binding and subsequent 
activation of wild-type and mutant receptors using a diverse group of D1 agonists. We 
used a battery of ligands (Figure 1.3) that include full and partial agonists from the 
phenylbenzazepine class (SKF38393, SKF82526, SKF82958), an isochroman (A77636), 
and rigid D1 agonists from two different chemical classes (DNS and DHX). The study is 
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the first to examine the role of W6.48 and N6.55 in binding and activation of the D1-like 
dopamine receptors.
RESULTS
Binding characteristics of TM6 mutant receptors in HEK293 cells
 Wild-type and mutant HA-tagged hD1/hD5 dopamine receptors were expressed in 
HEK293 cells and tested for their ability to bind the D1 antagonist [
3H]SCH23390. The 
characteristics of the D1-wt (KD = 1.5 ± 0,2; Bmax = 3,600 ± 600 fmol/mg) and D5-wt (KD
= 2.5 ± 0,5; Bmax = 3,040 ± 740 fmol/mg) were consistent with data reported in earlier 
chapters. Binding of [3H]SCH23390 was significantly decreased for both D1- and D5-
W6.48A and N6.55A mutant receptors such that KD and Bmax was unable to be 
determined (Figure 5.1). These saturation binding experiments (see Figure 5.1) indicated 
that there was a marked decrease in the affinity of [3H]SCH23390 for the D1- and D5-
F6.51I/L/Y/W mutants such that  receptors such that the KD and Bmax values could not be 
calculated.
To determine whether this loss of binding was due to a decrease in expression of 
the mutant receptors or a loss of SCH23390 binding, we conducted cell surface RIA 
experiments with the HA-tagged receptors to assess the cell surface expression of mutant 
receptors relative to the wild-type receptors. The results of these experiments revealed a 
significant decrease in cell-surface expression of the D1-W6.48A mutant receptor to 37% 
of wild-type receptor expression (Figure 5.2). There was no significant decrease in cell-
surface expression for any of the other D1 and D5 mutant receptors compared to wild 
type. The loss of [3H]SCH23390 binding for mutant receptors precluded assessment of 
the ligand-binding characteristics for all D1 and D5 mutant receptors.
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Figure 5.1. KD and Bmax of D1/D5-WT and mutant receptors labeled with [
3H]SCH23390. 
HEK293 cell membranes transiently expressing wild-type or mutant receptors were tested in 
radioreceptor saturation isotherm experiments with increasing concentrations of [3H]SCH23390. 
Non-specific binding was determined with 1μM cold SCH23390. Data were analyzed using a 
one-site hyperbolic curve fitting function (Prism 4.0) to obtain the KD and Bmax for 
[3H]SCH23390 at wild-type and mutant receptors. Data are mean ± S.E.M. ND= Not 
Determinable.
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Figure 5.2. D1-W6.48A mutant receptor cell surface expression is decreased compared to 
the D1-wild type receptor. HEK293 cells transiently expressing HA tagged mutant receptors, 
showing decreased [3H]SCH23390 binding, were tested for cell surface expression relative to 
each respective wild-type receptor via RIA. [A] D1 dopamine receptor, [B] D5 dopamine 
receptor. Data are representative of 2-3 independent experiments run in quadruplicate.
Effect on W6.48A and N6.55A mutations on potency and efficacy of dopamine 
at the D1 and D5 receptors 
I next examined if agonists were capable of stimulating adenylate cyclase at the 
mutant D1 and D5 dopamine receptors. cAMP accumulation was measured using 
membrane preparations expressing wild-type or mutant receptors, and full dose-response 
curves for adenylate cyclase activation were generated for dopamine. The stimulation of 
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cAMP synthesis caused by dopamine was completely inhibited by the D1-selective 
antagonist SCH23390 (data not shown). As can be seen in Table 5.1, dopamine as 
expected caused nearly a five-fold increase in cAMP production in the D1-wt and a three-
fold increase in the D5-wt. The N6.55A mutation of both D1-like receptors had no 
appreciable effect on the maximal fold-stimulation induced by dopamine, although it did 
seem to decrease the constitutive activity of the D5-N6.55A mutant receptor. The 
W6.48A mutation also decreased the basal activity significantly, but markedly reduced 
the fold-stimulation, especially relative to the D1-wt (Table 5.1) 
Table 5.1. Basal and dopamine stimulated cAMP levels for D1-like wild-type, W6.48, 
and N6.55 mutant receptors.
cAMP Production 
(fmol cAMP/mg/min)
Basal DA
D1-wt 2,020 + 230 9,510 + 830
W6.48A 1,200 + 100 2,600 + 340
N6.55A 2,210 + 550 11,400 + 1030
D5-wt 3,390 + 370 9,560 + 330
W6.48A 1,050 + 80 2,600 + 210
N6.55A 1,610 + 100 7,380 + 300
Basal cAMP levels as fmol/mg protein/min are compared to cAMP levels over basal in response to 1 mM 
DA treatment. Values are expressed as mean + S.E.M.
Effect of W6.48A and N6.55A mutations on ligand potency and efficacy at the 
D1 and D5 receptors 
Full dose-response curves were generated for all of the test ligands. The cAMP 
accumulation produced by treatment with agonist was expressed as % maximal 
stimulation produced by dopamine at each receptor type. The rank order of potencies at 
the wild-type receptors was as follows: D1: A77636 > SKF82958 = SKF82526 > DHX >
DNS > SKF38393 > DA; 
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Figure 5.3. SKF82958 & SKF82526 have decreased relative intrinsic activity at the D1-
W6.48A(285) mutant receptor. The ability of test compound to stimulate cAMP production was 
measured using HEK293 cell membranes transiently expressing mutant receptors. Membranes 
were incubated with drug for 15 min at 37o C. Dose-response curves were generated using seven 
concentrations of test compound at the D1- wild-type and mutant receptors. Results were 
analyzed by non-linear regression using a sigmoidal equation for best fit to obtain potency 
(EC50) and intrinsic activity values (Prism 4.0). Data are expressed as % maximal stimulation by 
1 mM DA at each receptor type. Data are representative of 3-5 independent assays run in 
quadruplicate and each value represents the mean ± S.E.M. 
113
Table 5.2. Agonist potency and intrinsic activity at the D1 -WT and mutant 
receptors.
hD1-wt hD1-W6.48A hD1-N6.55A
Ligand EC50 (nM) IA EC50 (nM) Fold IA EC50 (nM) Fold IA
Dopamine 868 ± 175 100 5,720 ± 650 6 100 3,430 ± 908 4 100
DHX 84 ± 30 99 715 ± 309 9 111 844 ± 164 10 78
DNS 94 ± 28 100 1,180 ± 90 13 112 90 ± 24 1 129
A77636 27 ± 12 97 417 ± 200 18 79 121 ± 27 4 80
SKF38393 229 ± 95 46 2,080 ± 570 11 51 5,720 ± 1.13 25 44
SKF82526 32 ± 10 84 760 ± 340 23 18 702 ± 188 22 85
SKF82958 30 ± 15 91 152 ± 410 50 23 845 ± 362 28 103
HEK293 cell membranes containing D1-wt or mutant receptors were incubated with 7 concentrations of 
test compound. Dose-response curves were analyzed by non-linear regression using a sigmoidal equation 
(Prism 4.0) for best fit to obtain EC50 values. Values are expressed as mean + S.E.M. (nM). In parentheses 
is the fold change value as compared to the EC50 of each drug at the wild-type receptor. Data are 
representative of 3-6 individual experiments run in quadruplicate.
D5: A77636 > SKF82958 > DHX = DNS > SKF82526 > SKF38393 > DA. At the 
D1-wt receptor DHX, DNS, and A77636 were full agonists, producing cAMP 
accumulation equal to dopamine. SKF38393 was a partial agonist producing ~ 46% of 
the maximal intrinsic activity of dopamine, while SKF82526 and SKF82958 were high 
efficacy partial agonists producing ~ 84% and 91% of maximal dopamine respectively. 
At the D5-wt receptor, as in the D1-wt receptor, DHX, DNS, and A77636 were all full 
agonists. SKF38393 was a partial agonist of ~ 52% of the maximal efficacy produced by 
dopamine; SKF82526 and SKF82958 were both high efficacy partial agonists producing 
~ 62% and 86% of the maximal efficacy produced by dopamine. Receptor activation at 
the highest concentration of each agonist was inhibited using the D1-selective antagonist 
SCH23390 (data not shown).
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Figure 5.4. D5-N6.55A
(316) results in an increase in relative intrinsic activity for all test 
compounds. The ability of test compound to stimulate cAMP production was measured using 
HEK293 cell membranes transiently expressing mutant receptors. Membranes were incubated 
with drug for 15 min at 37o C. Dose-response curves were generated using seven concentrations 
of test compound at the D5- wild-type [A], W6.48A [B], and N6.55A [C] mutant receptors. 
Results were analyzed by non-linear regression using a sigmoidal equation for best fit to obtain 
potency (EC50) and intrinsic activity values (Prism 4.0). Data are expressed as % maximal 
stimulation by 1 mM DA at each receptor type. Data are representative of 3-5 independent assays 
run in quadruplicate and each value represents the mean ± S.E.M. 
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Table 5.3. Agonist potency and intrinsic activity at the D5 -WT and mutant 
receptors.
hD5-wt hD5-W6.48A hD5-N6.55A
Ligand EC50 (nM) IA EC50 (nM) Fold IA EC50 (nM) Fold IA
Dopamine 471 ± 85 100 1,310 ± 141 3 100 6,820 ± 934 15 100
DHX 12.2 ± 1.6 99 552 ± 155 45 88 482 ± 82 40 132
DNS 13.1 ± 2.4 100 459 ± 56 35 136 178 ± 68 14 120
A77636 1.8 ± 0.4 97 124 ± 33 68 103 459 ± 101 251 97
SKF38393 52.3 ± 8.6 52 607 ± 160 12 59 3,150 ± 1,680 60 66
SKF82526 52.3 ± 8.6 62 491 ± 190 51 48 869 ± 26 90 97
SKF82958 9.7 ± 2.8 86 144 ± 40 15 27 218 ± 48 23 120
HEK293 cell membranes containing D5-wt or mutant receptors were incubated with 7 concentrations of 
test compound. Dose-response curves were analyzed by non-linear regression using a sigmoidal equation 
(Prism 4.0) for best fit to obtain EC50 values. Values are expressed as mean + S.E.M. (nM). In parentheses 
is the fold change value as compared to the EC50 of each drug at the wild type receptor. Data are 
representative of 3-6 individual experiments run in quadruplicate.
N6.55A Mutant Receptor
Mutation of N6.55 to Ala in the D1 receptor resulted in a 20-30 fold decrease in 
the potency of the phenylbenzazepines (i.e. SKF38393, SKF82958, and SKF82526) 
while DA, DHX, DNS, and A77636 were affected minimally (Figure 5.3). As shown in 
Figure 5.3 and Table 5.2, the maximal activity produced in response to DNS and 
SKF82958 was greater than that produced by dopamine while the intrinsic activity of all 
other test compounds was relatively unaffected. Unlike that of the D1 mutant receptor, 
changes in the potency of test compounds at the D5-N6.55A mutant was not dependent on 
compound structural class. A77636 displayed the greatest loss in potency (251-fold 
decrease relative to wild-type), followed by SKF82526, SKF38393 and DHX with 90-, 
60-, and 45-fold respectively. The potency of SKF82958, DNS, and DA at the D5-
N6.55A mutant receptor was affected minimally. The maximal activity of all test 
compounds at the D5-N6.55A mutant receptor increased to levels greater than that at the 
D5-wild-type receptor. The intrinsic activity of DNS, DHX, and SKF82958 at the D5
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mutant receptor increased to levels above that of dopamine (120-, 132-, and 120-fold 
respectively). 
W6.48A Mutant Receptor
The data with the W6.48A mutant D1-like receptors indicate that this tryptophan 
residue is critical for receptor activation. The cAMP accumulation produced in response 
to 1 mM dopamine at the W6.48A mutant receptors was a fraction of that produced by 
the wild-type receptors (Table 5.1). Interestingly, the intrinsic activity (both relative and 
absolute) of SKF82958 and SKF82526 was most affected by this mutation. As shown in 
Table 5.2, the D1-W6.48A mutant receptor showed modest decreases in potency for DA, 
DHX, DNS, A77636 and SKF38393, and more severe potency losses for both SKF82526 
and SKF82958 (23- and 50-fold respectively). The intrinsic activity of SKF82526 and 
SKF82958 dramatically decreased from 84% and 91% (of maximal DA stimulation) 
respectively at the wild-type receptor to 50% and 23% at the mutant receptor. The 
maximal activity of DNS and DHX at the D1-W6.48A mutant receptor increased ~10% 
above that of their levels at the D1 wild-type receptor while the intrinsic activity of 
A77636 decreased from 100% to 79%. 
Table 5.3 indicates that mutation of W6.48 to alanine at the D5 receptor resulted 
in 30-70 fold losses in potency for DHX, DNS, A77636, and SKF82526. The potency of 
SKF82958 and SKF38393 was decreased by 15- and 12-fold respectively, while 
dopamine was unaffected. As with the D1 mutant receptor, the intrinsic activity of 
SKF82526 and SKF82958 at the D5-W6.48A mutant receptor decreased dramatically, 
from 62% and 86% respectively at the wild-type receptor to 49% and 25% at the mutant 
receptor. 
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DISCUSSION
This chapter examined the role of two TM6 amino acid residues- N6.55 and 
W6.48- in binding and activation of the D1-like receptors. Several studies have suggested 
a central role for W6.48 in formation of the active receptor state. Studies of the β2-
adrenergic receptor (Wieland et al., 1996; Zuurmond et al., 1999), bovine rhodopsin 
(Sakmar, 1998), and D2 dopamine receptor (Javitch, 1998; Woodward et al., 1994)
provide support for agonist-receptor residue interactions at 6.55. The role of these 
residues in ligand recognition and receptor activation has yet to be explored in D1-like 
receptors. To explore the role of these TM6 residues, we made non-conservative point 
mutations of N6.55 and W6.48 to alanine and subsequently probed the mutant receptors 
with an array of structurally and pharmacologically diverse compounds. 
Mutation of N6.55 to Ala resulted in a dramatic decrease the affinity of the 
antagonist SCH23390 for the D1 and D5 receptors, precluding competition binding 
studies that could provide detail into the contribution of this residue to agonist binding. 
Cell-surface radioimmunoassays demonstrated that the D1- and D5-N6.55A mutant 
receptors were expressed on the cell membrane at levels comparable to the wild-type 
receptors, and cAMP assays revealed that the mutant receptors retained functional 
activity.
The D1-like receptors are highly similar to the β2-adrenergic receptor and share an 
asparagine residue at position 6.55. Studies of the β2-adrenergic receptor show that N6.55 
interacts with the β-hydroxyl group of norepinephrine (Wieland et al., 1996; Zuurmond et 
al., 1999). Our D1 molecular model predicts that N6.55 participates in interhelical 
hydrogen bonds that could be the driving force for the rotation of TM6 leading to rotamer 
toggle and hinge bending motion of TM6. We anticipated compounds would be affected 
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by the N6.55A mutation according to structural class. Indeed, at the D1-N6.55A mutant 
receptor we observed a modest decrease (22- to 28-fold loss) in the potency of all 
compounds with the phenylbenzazepines (SKF38393, SKF82526, and SKF82958) and 
slight decreases (1- to 10-fold loss) in the potency of the more rigid compounds (DHX, 
DNS, and A77636). Conversely, a ligand-specific trend in potency and/or intrinsic 
activity changes was not observed at the D5-N6.55A mutant receptor. These non-specific 
changes indicate that the N6.55A mutation in the D5 receptor is causing more global 
changes in receptor activation, and may provide hydrophobic packing that supports 
ligand-receptor interaction. For example, N6.55 is predicted to reside one helical turn 
above F6.51 and may influence the interaction of F6.51 with agonists through helical 
packing (Xhaard et al., 2006).
As with the N6.55A mutant receptor, the D1- and D5-W6.48A mutant receptors 
displayed a dramatic decrease for SCH23390. Cell surface RIAs revealed a decrease in 
the expression of the D1-W6.48 mutant, but not for the analogous D5 mutant receptor, 
indicating that, at the D1 receptor, W6.48 may have an important role in stabilizing the 
receptor for proper folding and membrane expression. Shi et al. (2002) proposed that 
W6.48 is a central residue in the putative ‘rotamer toggle switch’ of amine receptors. The 
rotamer configuration of W6.48- in coordination with other aromatic amino acid residues 
surrounding the TM6 proline kink- has been proposed to modulate the bend of TM6, 
leading to the movement of TM6 away from TM3 that is necessary for receptor activation 
(Kobilka and Deupi, 2007; Shi et al., 2002). In rhodopsin, the rotamer configuration of 
W6.48 changes from g+ to t during the transition from the inactive to active state (Chabre 
and Breton, 1979). Lin and Sakmar (1996) demonstrated that photoisomerization of 
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retinal moves the β-ionone ring away from W6.48, leading to the rearrangement 
necessary for activation. Vilardaga et al. (2006) suggest that the rotamer configuration of 
W6.48 changes upon the activation of rhodopsin. Alteration of the rotamer conformation 
of W6.48 from g+ to t in β2-adrenergic receptor has been proposed to cause a 
corresponding change of F6.52 to g+ from t to avoid steric clash. Conversely, alteration 
of F6.52 from t to g+ is accompanied by a change of W6.48 to t (Shi et al., 2002). This 
coordinated rearrangement of rotamer configurations is thought to transduce agonist 
binding, and trigger the movement of TM6 away from TM3 (Visiers et al., 2002). Thus, I 
expected that mutation of this tryptophan to alanine, a residue incapable of forming the 
active rotamer, would lead to a decrease in receptor activation regardless of the agonist 
bound. Mutation of phenylalanine to alanine should disrupt the ability of W6.48 to 
participate in the cascade of rotamer reconfigurations that occurs in the toggle switch 
region thus affecting receptor activation. Indeed, basal and ligand stimulated levels of 
cAMP accumulation were greatly reduced at the D1- and D5-W6.48A mutant receptors. 
Bhattacharya et al. (2008a) showed in rhodopsin that water molecules mediate rotamer 
toggling of W6.48. This rotamer toggling process is connected to hinge bending around 
the highly conserved TM6 proline kink, an important part process in the creation of an 
active receptor state. When W6.48 is mutated to alanine the water assisted rotamer 
toggling process is lost, thereby decreasing modulation of hinge bending of TM6, 
resulting in decreased activation of the D1 and D5 dopamine receptors.
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W6.48
3Å
Figure 5.5. Bound conformation of SKF82526 in D1 receptor showing the hydrogen bond 
between the chlorine group and W6.48. 
The decreases in basal and agonist-stimulated levels of cAMP accumulation 
provide evidence that W6.48 does indeed serve a central role in formation of an active 
receptor state. Our D1 molecular model predicted that SKF82526 and SKF82958, but not 
the other compounds used in this study, interact directly with W6.48 (Figure 5.5). The 
dramatic reduction in cAMP accumulation mediated by SKF82526 and SKF82958 at the 
D1-like mutant receptors supports this hypothesis. Previous studies in our lab provided 
evidence of a unique binding position for SKF82526 and SKF82526 due to the 6-Cl 
substituent appended to the catechol ring. In the predicted docked conformations, this 
chlorine group hydrogen bonds with the indole nitrogen of W6.48. Mutating W6.48 to 
Ala removes the hydrogen bond, leading to dramatic losses in the intrinsic activity of the 
two ligands.
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In conclusion, these data suggest a key role for W6.48 in the transduction of 
ligand-binding to receptor activation. W6.48 appears be a key residue in the putative 
toggle switch region and is highly involved in creation of an active receptor 
conformation. The exact role of N6.55 in the D1-like receptors is less clear, but our 
findings suggest that this residue plays an indirect role in D5 receptor activation, perhaps 
by contributing to hydrophobic binding core. These findings provide important insight 
into the molecular mechanisms involved in activation of the D1-like dopamine receptors.
CHAPTER 6: INVESTIGATION OF THE ABILITY OF LIGAND-RECEPTOR 
INTERACTIONS TO AFFECT AGONIST-SPECIFIC DIFFERENCES IN 
RECEPTOR INTERNALIZATION AND TRAFFICKING.
PREFACE: 
A prior study in our lab found that two structurally dissimilar agonists (A77636 & 
DNS) cause different degree of D1 receptor internalization and display divergent patterns 
of long-term receptor trafficking.   Experiments revealed a slow dissociation rate of 
A77636 from the D1 receptor and modeling studies predicted that the adamantly group of 
A77636 is stabilized by V159, W163 on TM4 and L291, L295 on TM6. These contacts 
are predicted to be sufficient to eliminate the slow dissociation of A77636.  This chapter 
examined the role of each of these residues in ligand-binding, receptor activation, and 
internalization of the D1 receptor.
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ABSTRACT
Recently, we demonstrated that dopamine, DNS, and A77636 cause different 
levels of D1 receptor internalization and also target the receptor to divergent intracellular
trafficking pathways, thereby demonstrating functional selectivity at the D1 receptor.  
Experiments revealed that A77636 persists on the receptor for long periods of time, 
indicating that ligand dissociation may influence receptor trafficking.  Docking studies of 
A77636 in the D1 receptor model predict that the accessory adamantly group of A77636 
is stabilized by residues distal to the binding pocket sufficient to eliminate dissociation.  
The experiments in this Chapter tested our hypothesis that differences in major effects on 
internalization and receptor trafficking can be produced by specific ligand-receptor 
interactions distal from the binding site and not critical for binding or activation. Four 
amino acid residues were mutated to alanine and the effects of dopamine, A77636, and 
DNS on binding, activation, and receptor internalization were examined at the D1 wild 
type and mutant receptors. Mutant receptors did not cause dramatic losses in affinity, 
potency, or efficacy for any of the test compounds.  Unexpectedly, the mutant receptors 
exhibited non-specific effects on receptor internalization 1 h after agonist removal. The 
work in this Chapter provides the foundation for future studies to explore whether these 
residues influence long-term receptor trafficking of the D1 dopamine receptor.
INTRODUCTION
The experiments in this Chapter build on recent studies in our lab concerning 
differences in ligand-induced receptor internalization and long-term trafficking. Receptor 
trafficking is a major mechanism by which GPCRs are regulated, allowing for the fine-
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tuning of signal magnitude (Hicke, 1999; von Zastrow, 2003).  As discussed in the 
Introduction of this Dissertation, internalization is an important mechanism in the 
regulation of D1 receptor responsiveness and is likely to have important physiological 
relevance.  Recently, we explored the relationship between agonist structure, receptor 
affinity, and efficacy of adenylate cyclase activation and receptor internalization for 13 
agonists from three different chemical families (Ryman-Rasmussen et al., 2005). This 
study revealed interesting disparities in the ability of synthetic D1 agonists to regulate 
receptor trafficking, indicating that functional selectivity cannot be predicted by simple 
structural examination.  These findings demonstrated clearly that D1 agonists can cause 
functional selectivity at the endpoints of adenylate cyclase and receptor internalization.
In a subsequent study we further investigated D1 receptor functional selectivity by 
examining the ability of structurally dissimilar agonists to regulate receptor trafficking 
following internalization (Ryman-Rasmussen et al., 2007). We compared the ability of 
two structurally distinct agonists, A77636 (an isochroman) and DNS (an isoquinoline), to 
induce receptor internalization with that of dopamine. Our study revealed that, in the 
HEK293 cell line, steady state levels (1h) of receptor internalization differ significantly 
between dopamine, DNS, and A77636.  We next investigated post-endocytic agonist 
effects on receptor trafficking and discovered that these agonists were functionally 
selective in regulating long-term receptor trafficking.  Dopamine caused the D1 receptor 
to recycle back to the cell surface within 1h of removal.  The D1 receptor was retained 
intracellularly up to 48 h after removal of A77636, whereas DNS caused the receptor to 
recycle back to the membrane after 48 h.  Additional experiments revealed a slow 
dissociation rate of A77636 from the D1 receptor. To explore possible structural 
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differences in binding modes we examined the predicted binding site of dopamine, 
A77636, and DNS. The D1 model indicates that the accessory hydrophobic adamantyl 
group of A77636 is stabilized by V159, W163 on TM4 and L291, L295 on TM6. These 
contacts are predicted to be sufficient to eliminate the slow dissociation of A77636.  The 
results of this study indicate that ligand-receptor interactions distal to the binding pocket 
may dictate the ability of an agonist to induce receptor internalization and regulate long-
term receptor trafficking.
The work in this chapter tested the hypothesis that differences in major effects on 
receptor internalization can be produced by specific ligand-receptor interactions distal 
from the binding site and not critical for binding or activation.   To test this hypothesis, 
amino acid residues V159, W163, L295, and L291 were mutated to alanine and assessed 
for effects on receptor binding, adenylate cyclase activation, and receptor internalization.   
The work in this Chapter indicates these residues do not dramatically influence ligand-
binding or receptor activation, but have a non-specific effect on receptor internalization.
RESULTS
Expression of Mutant Receptors
To assess the effects of point mutations on antagonist binding affinity and Bmax
wild-type and mutant D1-like dopamine receptors were expressed in HEK293 cells and 
tested for their ability to bind [3H]SCH23390.  The KD and Bmax of [
3H]SCH23390 was 
1.5 nM and 3,600 fmol receptor/mg protein at the D1-wt receptor.  The KD and Bmax for 
the D1-L295A and L291A mutant receptors were very similar from that of the wild-type 
receptor. Conversely, the W163A and V159A mutant receptors bound [3H]SCH23390 
with an affinity approximately 5-6 fold lower than the D1-wt receptor and were expressed 
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at approximately 830 fmol receptor/mg protein (Table 6.1).  However, as shown in Figure 
6.1, cell-surface radioimmunoassays (RIA) indicate that the cell surface expression of all 
D1 mutant receptors did not diverge significantly from that of the D1-wild type receptor. 
Table 6.1. KD and Bmax of D1-like wild-type and mutant receptors labeled with 
[3H]SCH23390.
Receptor Type N KD (nM)
Bmax
(fmol R/mg protein)
D1-wild type 12 1.5 ± 0.2 3,600 ± 600
D1-W163A 4 5.2 ± 0.2 820 ± 7
D1-V159A 4 6.8 ± 1.3 870 ± 120
D1-L295A 3 0.9 ± 0.1 3,900 ± 600
D1-L291A 3 2.2 ± 0.5 3,700 ± 600
HEK293 cell membranes transiently expressing wild-type or mutant receptors were tested in 
radioreceptor saturation isotherm experiments with increasing concentrations of [3H]SCH23390.  
Non-specific binding was determined with 1μM cold SCH23390. Data were analyzed using a 
one-site hyperbolic curve fitting function (Prism 4.0) to obtain the KD and Bmax for [
3H]SCH23390 
at  wild-type and mutant receptors. Data are mean ± S.E.M.  
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Figure 6.1. Cell surface expression of D1-WT and mutant receptors. HEK293 cells transiently 
expressing HA tagged D1-WT and mutant receptors, exhibiting decreased [
3H]SCH23390 
binding, were tested for cell surface expression relative to each respective wild-type receptor via 
RIA.  Data are representative of 2-3 independent experiments run in quadruplicate. 
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Effects of D1 Receptor Mutants on Ligand Affinity
The affinity of dopamine, A77636, and DNS for the wild-type and mutant 
receptors was determined by competition radioreceptor assays versus [3H]SCH23390 
using cell membranes.  To determine apparent affinity constant, K0.5, experimental IC50 
values were corrected for radioligand KD and concentration using the bimolecular Cheng-
Prusoff relationship (Cheng and Prusoff, 1973).  The rank order of affinities for 
compounds at the D1 wild-type receptor was as follows, D1: SCH23390 > A77636 > DNS 
> DA. 
As shown in Table 6.2 and Figure 6.2, there were modest alterations (4-5 fold) in 
the affinity of DNS and dopamine for the V159A mutant receptor, and the binding of 
SCH23390 was reduced 23-fold at the V159A mutant receptor.  No notable changers in 
affinity were observed for DNS, A77636, or dopamine at any of the other D1 receptor 
mutants.  
Table 6.2. Affinity of test ligands for the D1-WT and mutant receptors labeled with 
[3H]SCH23390.
SCH23390 Dopamine A77636 DNS
hD1-wt 0.1 ± 0.01 2600 ± 146 11.7± 2.3 215 ± 15
hD1-L291A
0.02 ± 0.03
(1)
4655 ± 138
(2)
8.7± 1.2
(1)
259 ± 24
(1)
hD1-L295A
0.07 ± 0.03
(1)
3086 ± 153
(1)
9.6± 1.4
(1)
219 ± 22
(1)
hD1-V159A
2.2 ± 0.12
(23)
11674 ± 1282
(4)
31 ± 4.2
(3)
957 ± 289
(4)
hD1-W163A
0.72 ± 0.27
(7)
7271 ± 1373
(3)
9.9± 3.5
(1)
1022 ± 493
(5)
HEK293 cell membranes containing D1-wt or mutant receptors were incubated with one 
concentration of [3H]SCH23390 and 7-12 concentrations of test compound.  Dose-response 
curves were analyzed by non-linear regression using a sigmoidal equation (Prism 4.0) to obtain 
estimates for apparent affinity (K0.5) using the Cheng-Prusoff equation.  Values are expressed as 
mean + S.E.M. (nM).  In parentheses is the fold change value as compared to the K0.5 of each 
drug at the wild type receptor.  Data are representative of 3-10 experiments run in triplicate.
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Figure 6.2.  Ligand-induced cAMP accumulation at D1-WT and mutant receptors. The ability 
of test compound to stimulate cAMP production was measured using HEK293 cell membranes 
transiently expressing mutant receptors. Membranes were incubated with drug for 15 min at 37o
C.  Dose-response curves were generated using 7 concentrations of dopamine, A77636, or DNS 
at the D1- wild-type and mutant receptors.  Results were analyzed by non-linear regression using 
a sigmoidal equation for best fit to obtain potency (EC50) and intrinsic activity values (Prism 
4.0).  Data are expressed as % maximal stimulation by 1 mM DA at each receptor type.  Data are 
representative of 3-5 independent assays run in quadruplicate and each value represents the 
mean + S.E.M.
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Effects of D1 Mutant Receptors on ligand-induced cAMP accumulation
Next, we examined the effect mutant receptors had on the ability of test 
compounds to elicit receptor activation. Wild-type and mutant receptors were incubated 
for 15 min with a range of agonist concentrations and subsequent cAMP accumulation 
measured by RIA and expressed as % maximal stimulation produced by dopamine at 
each receptor type.  The rank order of potencies at the D1 wild-type receptor was as 
follows, A77636 > DNS > DA.  At the D1 receptor DNS and A77636 were full agonists 
producing cAMP accumulation equal to that of dopamine.  Receptor stimulation was 
blocked using the antagonist SCH23390 (data not shown).
Table 6.3. Agonist potency and intrinsic activity of test compounds at the D1-WT 
and mutant receptors.
Drug Dopamine A77636 DNS
hD1-wt EC50 (nM) 640 + 150 23 + 9 87 + 24
Intrinsic Activity 100 100 97
hD1-W163A EC50 (nM) 1,040 + 440 (1) 112 + 28 (5) 457+319 (5)
Intrinsic Activity 100 80 97
hD1-V159A EC50 (nM) 1060 + 230 (2) 35 + 19 (1) 453 + 208 (5)
Intrinsic Activity 100 63 112
hD1-L295A EC50 (nM) 790 + 290 (1) 4.6+ 3.4 (0.19) 237+135 (3)
Intrinsic Activity 100 85 84
hD1-L291A EC50 (nM) 430 + 130 (1) 15 + 5.0 (1) 84 + 21 (5)
Intrinsic Activity 100 85 100
HEK293 cell membranes containing D1 -wt or mutant receptors were incubated with seven concentrations 
of test compound.  Dose-response curves were analyzed by non-linear regression using a sigmoidal 
equation (Prism 4.0) for best fit to obtain EC50 values.  Values are expressed as mean + S.E.M. (nM).  In 
parentheses is the fold change value as compared to the EC50 of each drug at the wild type receptor.  Data 
are representative of 3-6 individual experiments run in quadruplicate.
A77636, DNS, and DA exhibited slight losses in potency at the D1 receptor 
mutants (Table 6.3). Modest decreases in the intrinsic activity of A77636 occurred at the 
D1-W163A, L295A, and L291A mutant receptors, while a more dramatic decrease in 
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maximal activity was observed for A77636 at the V159A mutant (63% of dopamine) 
(Table 6.3). 
D1 Mutants Resulted in Non-specific Effects on Ligand Internalization
To examine the ability of test compounds to cause receptor internalization, wild-
type and mutant receptors were incubated with agonist for 1 h at 37 C.  Following the 
incubation period cells were fixed with PFA and treated with HA-antibodies to measure 
the degree of receptor internalization.  Receptor internalization was measured by RIA and 
expressed as % of control.  The rank order of receptor internalization efficacy at the D1
wild-type receptor was as follows, A77636 > DNS > dopamine.  Receptor internalization 
caused by each agonist was blocked by the antagonist SCH23390.
Figure 6.3 and Table 6.4 show the changes in receptor internalization at each D1
mutant receptor.  There was a significant decrease (compared to internalization of the D1-
wt receptor) in the receptor internalization elicited by dopamine at the L291A and V159A 
mutant receptors, for A77636 at the L291A, L295A, and V159A receptors, and for DNS 
at the V159A mutant receptor.  
Table 6.4. Recovery of cell surface D1-WT and mutant receptors after 1 h agonist 
removal.
SCH23390 Wild-type L291A L295A V159A W163A
Dopamine 99 80 89* 89 98* 85
A77636 100 66 76* 78* 81* 68
DNS 100 74 86 84 90* 79
HEK293 cells expressing HA-hD1-WT or mutant receptors were treated with 10 M dopamine, A77636, or 
DNS for 1 h.  A cell surface HA tag was used to measure cell surface HA-hD1 1 h after agonist removal. 
Data are expressed as % control and are mean + S.E.M. *p>0.01
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Figure 6.3. Recovery of cell surface HA-hD1 receptors 1 h after agonist removal. HEK293 cells 
transiently expressing HA-tagged D1-WT and mutant receptors were treated with 10 M 
dopamine, A77636, or DNS for 1 h in quadruplicate. Data are expressed as a percentage of no 
drug and are the means and standard errors of three to four independent experiments.  
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DISCUSSION
Dinapsoline and A77636 were utilized for these studies because they are 
structurally dissimilar full agonists that are of therapeutic interest.  Previous studies have 
shown that A77636 induces profound behavioral tolerance in vivo within 24 h, thereby 
precluding its use in Parkinson’s disease therapy (see Background) (Lin et al., 1996). 
Dinapsoline, however, does not elicit tolerance in a rat model of Parkinson’s disease 
(Gulwadi et al., 2001). Several promising D1 agonists such as A77636 demonstrate rapid 
and profound tolerance when administrated in human and non-human primates, thereby 
prohibiting their use as therapeutics (Asin and Wirtshafter, 1993; DeNinno et al., 1991; 
Kebabian et al., 1992a; Lin et al., 1996). Understanding the cellular events that contribute 
to tolerance may be important in the development of clinically relevant D1 agonists that 
are less prone to the development of tolerance. Although the nature of the relationship 
between agonist-induced receptor internalization and the development of tolerance is 
unclear, early regulatory responses to continuous D1 receptor activation may be 
important steps leading to motor tolerance.  
Mutational effects on ligand binding, adenylate cyclase activation, and receptor 
internalization for dopamine, A77636, and DNS were examined for each D1 mutant 
receptor.  The Bmax for the W163A and V159A mutant receptors were reduced ~ 3-fold, 
however cell surface RIAs showed that all mutant receptors were expressed at levels 
comparable to that of the wild-type receptor.  This result suggests that the reduction in 
Bmax is likely due to the decreased affinity of SCH23390 for the W163A and V159A 
mutant receptors and not a decrease in cell surface expression. Modest alterations in the 
binding affinity of DNS, A77636, and dopamine occurred at the D1 receptor mutants.  
The decrease in affinity of the antagonist SCH23390 at the V159A (23-fold) mutant 
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receptor was unexpected, however, due to the lack of another radiolabeled D1 antagonist 
the interactions involved in binding of SCH23390 at the D1 receptor is ill-defined.  These 
findings support our hypothesis that the targeted residues do not play an important role in 
agonist binding.  
Test compounds did not exhibit dramatic changes in the potency or intrinsic 
activity of compounds at any of the D1 mutant receptors.  However, the decrease in 
intrinsic activity of A77636 at the D1-V159A mutant receptor suggests that this valine 
residue might be positioned in a region of the D1 receptor binding pocket important for 
receptor activation by A77636, presumably by interacting with the adamantly group 
appended to A77636.  While unexpected, the decrease in intrinsic activity of A77636 at 
the V159A mutant receptor is not surprising as receptor activation is inherently dynamic, 
confounding our ability to predict residues important for creating an active receptor state 
from an inactive receptor model.
As with the stably transfected HA-hD1 cell line used our previous study, the time 
course of internalization for the transiently expressed wild-type receptor reached steady-
state by 30 min and was constant through 2 h.  The rank order of agonist internalization 
efficacy of the HA-hD1-wild type receptor was identical at the stably and transiently 
expressed receptors.  The non-specific changes in the degree of receptor internalization 
for dopamine, A77636 and DNS at the mutant D1 receptors were unexpected given the 
predicted location of the amino acid residues targeted in this study.  This result indicates 
that these residues- indirect of agonist interaction- contribute to formation of the 
conformational state required for D1 receptor phosphorylation by GRKs or PKA and/or 
receptor interaction with β-arrestin.  
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Although previous studies suggest that receptor internalization and long-term 
trafficking might be interrelated (i.e. at the wild type receptor A77636 exhibited the 
greatest degree of receptor internalization and long-term trafficking), these mechanisms 
may in fact be distinct and dependent on different molecular interactions.  The 
conformational changes that lead to receptor internalization are largely unknown, and it is 
feasible that any residues that may be responsible for creating the conformational state 
that may be responsible for the unexpected endocytic trafficking of the A77636 bound-D1
receptor come into contact with the adamantly group of A77636 only upon D1 receptor 
internalization.  Numerous studies have demonstrated that slight changes in receptor 
conformation- due to mutation of an amino acid residue or interaction with intracellular 
signaling partners- can produce receptor conformational changes that cause dramatic 
effects on receptor function. Thus, it is feasible that binding of β-arrestin may produce 
alterations in receptor conformation, thereby creating new molecular interactions between 
the ligand and receptor. 
Preliminary experiments were performed to confirm that the results of long-term 
receptor trafficking studies in our previous study using HEK293 cells stably expressing 
the D1 receptor could be reproduced, and expanded, with the mutant receptors, using 
transiently transfected HEK cells.  Initial experiments showed that the degree of D1-wt 
receptor internalization at 48 h was roughly equivalent to that of receptor internalization 
following 1 hr incubation (data not shown).  While preliminary, these results suggest that 
the use of transiently expressed mutant receptors may not be amenable for examining the 
effects of long-term receptor trafficking, however time constraints did not permit 
definitive conclusions to be drawn.  Additional troubleshooting and assay optimization 
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will be necessary to determine the feasibility of trafficking studies using transiently 
transfected wild-type and mutant receptors.  The hypothesis of this study was that 
mutation of one or more of the targeted amino acid residues would selectively affect 
receptor internalization and/or receptor trafficking and not agonist affinity or efficacy. 
Despite the unexpected non-specific effects of the mutant receptors on agonist 
internalization, it is possible that long-term receptor trafficking is affected.  Future studies 
will explore the effects of each of these mutations on long-term receptor trafficking of 
dopamine, dinapsoline, and A77636. These studies will reveal whether these residues are 
indeed responsible for differences in receptor trafficking between A77636, DNS, and 
dopamine.
In our previous study, scanning of the D1 receptor model resulted in the 
identification of a much weaker but perhaps significant binding site for dopamine in the 
intracellular portion of TMs 3, 4, 5, and 6 (Ryman-Rasmussen et al., 2007). This led us to 
formulate an alternative hypothesis, that this secondary site serves as an allosteric binding 
site for the endogenous ligand to regulate reformation of the receptor.  Other agonists 
(such as dinapsoline and A77636) may not bind to this site, thus leading to the low 
degree of dissociation and subsequent effects on receptor trafficking.  An additional 
direction is to explore whether differential phosphorylation by PKA and GRK may be 
responsible for the differences in endocytic trafficking of dopamine, DNS, and A77636. 
A study of the β1-adrenergic receptor demonstrated that the pathway selected for receptor 
internalization is primarily dictated by the kinase that phosphorylates the receptor 
(Rapacciuolo et al., 2003).  The authors found that PKA-mediated phosphorylation 
directs internalization via the caveolae pathway, whereas GRK-mediated phosphorylation 
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occurs through clathrin-coated pits.  Studies indicate a role for both PKA- and GRK-
mediated phosphorylation in D1 receptor desensitization (Bates et al., 1991; Black et al., 
1994; Tiberi et al., 1996; Zhou and Fishman, 1991; Zhou and Fishman, 1991).
In summary, the experiments in this Chapter demonstrate that V159, W163, L291, 
and L295 have minimal effects on the affinity, potency, and intrinsic activity of 
dopamine, dinapsoline, and A77636, and appear to play a role in creating the 
conformational state required for D1 receptor internalization. These interactions, 
however, appear to be agonist independent.  These findings provide the foundation for 
important experiments that will explore the effects of these mutations on long-term 
receptor trafficking of dopamine, dinapsoline, and A77636.  Results of the trafficking 
experiments will help guide future studies to understand the basis of long-term receptor 
trafficking and the development of tolerance.  Such studies may provide evidence of a 
structural basis for functional selectivity at the D1 receptor and aid in the design of 
clinically useful D1 agonists that are less likely to lead to tolerance.
CHAPTER 7. SUMMAY, CONCLUSIONS AND FUTURE DIRECTIONS
SUMMARY OF STUDIES CONDUCTED 
Overview of original goals
Recent advances in neurobiology have demonstrated the potential utility of D1-
like dopamine receptor agonists as therapeutic compounds. Multiple disorders have been 
linked to dopaminergic dysfunction, and many of these disorders may be ameliorated 
with D1 agonists. Despite immense promise, there are no D1 receptor agonists currently 
available as therapeutic compounds. To develop such compounds, it is necessary to 
understand the structural basis for ligand-binding and activation of D1-like receptors. 
Very few studies have attempted to determine ligand-receptor interactions in the D1
receptor, and virtually none have been conducted for the D5 receptor. Consequently, the 
structural mechanisms governing ligand-binding and activation of D1-like receptors are 
poorly understood. The work described in this Dissertation investigates key molecular 
interactions underlying binding, activation, and internalization of the D1-like dopamine 
receptors. 
The data collected in these studies relied on the use of a group of structurally and 
pharmacologically diverse probe ligands [phenylbenzazepines (SKF38393, SKF82526, & 
SKF82958), an isochroman (A77636), rigid compounds (DHX & DNS), and the 
endogenous ligand (dopamine)]. The resulting data greatly extend our knowledge of the 
structural mechanisms involved in binding and activation of the D1-like receptors. 
Furthermore, these findings provide evidence of structural differences between the D1
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and D5 receptor subtypes. This work lays the foundation for future studies that will 
investigate further the molecular interactions mediating binding and activation of the D1-
like dopamine receptors. 
Improvement of cAMP assay
Chapter 2 described improvements to our method of assessing cAMP 
accumulation. The cAMP pathway is the most studied D1 receptor signaling pathway and 
was central to the work conducted for this Dissertation. Modifications of the original 
cAMP assay included coupling the primary antibody directly to magnetic beads (opposed 
to the secondary antibody) and separating the antibody-bound magnetic beads from 
unbound marker using filtration on microplates. These alterations markedly improved 
speed and costs while retaining high sensitivity. 
Analysis of TM3 threonine residue
Chapter 3 addressed the role of a TM3 threonine residue (3.37) in governing 
binding and activation of the D1-like dopamine receptors. T3.37 is highly conserved 
across aminergic GPCRs yet no published studies have examined the role of this residue 
in receptor activation. A study of the D2 dopamine receptor utilizing SCAM techniques 
indicated that T3.37 is not water-accessible in the binding site crevice (Javitch et al., 
1998), however we hypothesized that T3.37 is positioned to influence receptor interaction 
with the para-OH of D1 receptor agonists. Results from this study showed that mutation 
of T.3.37 to alanine had more dramatic effects on the affinity and functional effects of the 
rigid D1 agonists (DA, DHX, DNS, and A77636) than phenylbenzazepine compounds 
(SKF38393, SKF822526, and SKF82958). These findings closely parallel studies of the 
D1- and D5-S5.46A mutant receptors, a residue that has been shown to interact with the 
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para-OH of D1 compounds (unpublished observations), indicating that these two residues 
have similar ligand-receptor interactions. A double mutant receptor (i.e. D1- and D5-
T3.37A/S5.46A) resulted in even greater changes in binding and function, further 
supporting our hypothesis. While the exact nature of the interaction of T3.37 with D1
agonists is unclear, these findings provide strong evidence that this residue influences the 
interaction of the para-OH group of D1 agonists. 
Analysis of TM6 residues
Chapters 4 and 5 focused on three amino acid residues located in sixth 
transmembrane helix. Residues in TM6 have been shown to play a key role in the 
activation of several GPCRs (Liapakis et al., 2000; Strader et al., 1989) as several studies 
have suggested the highly conserved cluster of aromatic residues (coined the ‘rotamer 
toggle switch’) surrounding the proline-kink in TM6 serves a key role in coupling agonist 
binding to receptor activation (Kroeze et al., 2003; Shapiro et al., 2000; Shi et al., 2002; 
Bissantz et al., 2003; Kroeze et al., 2003; Shapiro et al., 2000; Shi et al., 2002). Agonist 
interaction with one or more of the residues located in the switch region is thought to 
cause a coordinated change in the rotamer configurations of these aromatic residues, 
modulating the bend angle of TM6 around the proline kink and leading to the movement 
of the cytoplasmic end of TM6 (Shi et al., 2002).
Analysis of D1- and D5-F6.51 mutant receptors
Studies have shown that the residue at position 6.51 can play a role in ligand 
binding and receptor activation (Chen et al., 2002a; Ward et al., 1999). Prior studies in 
our lab demonstrated that mutation of F6.51 to alanine affected the potency of D1
agonists according to structural class. The potency and intrinsic activity of the 
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structurally rigid full agonists (DNS, DHX, and A77636) decreased while the 
phenylbezazepines (SKF38393, SKF82958, and SKF82526) were affected minimally 
(unpublished results). To explore further the role of F6.51, I constructed non-conservative 
(Leu and Ile) and conservative (Trp and Tyr) mutations of the D1 and D5 receptors and 
characterized each mutation with the structurally and functionally diverse test compounds 
utilized in our studies of the F6.51A mutant receptor. The results support the notion that 
F6.51 plays a critical role in the activation of D1-like receptors by interacting with the 
catechol ring of D1 agonists. Similar to the F6.51A mutant receptors, the potency and 
intrinsic activity of test compounds at the D1- and D5-F6.51I/L mutant receptors was 
affected by structural class. SKF38393 exhibited striking increases in intrinsic activity at 
the F6.51I/L mutant receptors, increasing from partial agonist activity at the D1 and D5
wild-type receptors to full agonists at the mutant receptors. DHX and DNS, structurally 
similar full agonists with near identical potency at the D1 wild-type receptor, exhibited 
dramatic differences in function at the D1-F6.51Y and W mutant receptors. Additionally, 
data suggested that the D5-F6.51W mutant receptor disrupts the molecular interactions 
necessary for stabilizing an active receptor conformational state. The data in this chapter 
demonstrated that F6.51 is a key switch in the activation of the D1-like receptors, and 
provided evidence for ligand-specific receptor conformations. 
Analysis of N6.55 and W6.48 
Chapter 5 addressed the role of two TM6 residues, N6.55 and W6.48. The residue 
at position 6.55 varies across aminergic GPCRs but studies have demonstrated direct 
agonist interaction at this locus (Berthold and Bartfai, 1997; Wieland et al., 1996). At the 
β2-adrenergic receptor, a receptor that shares high homology with the D1 receptor, N6.55 
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was shown to interact directly with the β-hydroxyl in the aliphatic side chain of 
isoproterenol (Wieland et al., 1996; Zuurmond et al., 1999). W6.48 is completely 
conserved across aminergic receptors is thought to be a key residue in the ‘rotamer toggle 
switch’ region of GPCRs (Bissantz et al., 2003; Roth et al., 1997; Shi et al., 2002). The 
results of this chapter indicated that N6.55 might play a direct role in agonist-stimulated 
receptor activation of the D1 receptor, as potency and intrinsic activity of test compounds 
at the D1-N6.55A mutant receptor was affected according to structural class. Conversely, 
a class-specific trend in potency and intrinsic activity was not observed at the D5-N6.55A 
mutant receptor, indicating possible global changes in receptor conformation. 
Basal and ligand stimulated levels of cAMP accumulation were greatly reduced at 
the D1- and D5-W6.48A mutant receptors, supporting the notion of a critical role for 
W6.48 in the creating an active receptor state. As predicted by our D1 modeling studies, 
SKF82958 and SKF82526 caused a dramatic reduction in cAMP accumulation at the D1
and D5-W6.48A mutant receptors. These data support our hypothesis that agonist 
interaction with W6.48 is a critical step in the formation of an active D1-like receptor 
conformational state.
Analysis of D1 receptor internalization and long-term trafficking
The experiments in Chapter 6 were based on prior studies in our lab concerning 
the divergent endocytic trafficking patterns exhibited by structurally dissimilar full 
agonists (DNS and A77636) (Ryman-Rasmussen et al., 2007). This study found that the 
D1 receptor was retained intracellulary up to 48 h after removal of A77636, whereas DNS 
caused the receptor to recycle back to the cell surface after 48 h. We hypothesized that 
structural differences in the binding modes of A77636 and DNS were responsible for the 
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differences in long-term trafficking. Alteration of several amino acids predicted to 
interact with the adamantly group of A77636, but not DNS or dopamine, did not cause 
dramatic differences in the affinity, potency, or intrinsic activity of the test compounds. 
Receptor internalization experiments 1 h after agonist removal indicated that the targeted 
residues may play a role in stabilizing the D1 receptor for phosphorylation, indirect of 
agonist interaction. This work provides the foundation for future studies that will assess 
whether the targeted residues are responsible for the differences observed in agonist-
induced long term trafficking.
Implications of this work
The work presented in this Dissertation provides invaluable insight into the 
structural mechanisms underlying D1-like receptor binding and activation, and offers 
information that may be used in the design of novel D1-like receptor compounds. This 
work addressed the structural features of the ligand and receptor that impart 
characteristics (e.g. efficacy, bioavailability, etc.) of clinical relevance, and therefore 
have implications for D1 agonist design. The experiments in Chapters 4 and 5 provide 
insight into the structural basis of efficacy at the D1-like receptors. These data provide 
clear evidence that subtle structural changes can have profound effects on receptor 
activation, underscoring the importance of understanding the interactions involved in 
creating an active receptor state. Effective amelioration of PD symptoms requires full D1
agonism while evidence suggests that partial D1 agonists may be more effective in 
treating cognitive dysfunction. It is therefore important, for the design of effective D1
receptor drugs, to determine the structural features responsible for efficacy. Our studies
of T3.37 provide convincing evidence that this residue influences ligand-binding and 
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receptor activation by contributing to the network of hydrogen bonds involved in 
stabilizing the catechol hydroxyls of D1 agonists. These data reinforce the catechol 
requirement for D1 full agonists, a feature that contributes greatly to the low 
bioavailability associated with most D1 agonists. Lastly, this work elucidated possible 
structural differences between the D1 and D5 receptor subtypes that may aid in the design 
of the first D1 subtype selective compound. Such an advance would be tremendously 
valuable for characterizing the in vivo role of D1 and D5 receptors and may prove to have 
clinical promise as well. The findings presented in this Dissertation will not only guide 
the design of future studies but may help direct the development of novel D1 receptor 
agonists. 
RELATED STUDIES
Structural changes involved in GPCR activation
Numerous studies have focused on understanding the conformational changes that 
occur from ligand binding to receptor activation. Methods such as x-ray crystallography 
(Schertler, 2005), site-directed mutagenesis (Chen et al., 2002b; Gabilondo et al., 1996), 
molecular modeling (Bhattacharya et al., 2008b; Bhattacharya et al., 2008a), site-directed 
spin labeling (Altenbach et al., 1999; Altenbach et al., 2001b) fluorescence spectroscopy 
(Gether, 2000; Ghanouni et al., 2001b) and others have provided insight into the 
molecular interactions responsible for the conformational changes that lead to GPCR 
activation.
The crystal structure of bovine rhodopsin has served as a useful template for 
generation of homology-based GPCR models but, as discussed in the Introduction of this 
Dissertation, has significant limitations. Data from the recently crystallized β2-adrenergic 
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receptor (Cherezov et al., 2007) offers important insight that can be incorporated into 
GPCR homology models. While the x-ray structure of an inactive state of a GPCR does 
not provide insight into the conformational changes that occur during activation, resultant 
homology models, as well as ab initio models, has served to identify target residues for 
mutational studies and are equally as important in the interpretation of experimental 
results. 
An iterative approach of receptor modeling and site-directed mutagenesis has lead 
to the identification of numerous molecular interactions that contribute to ligand 
recognition and receptor activation. For the catecholamine receptors, studies have shown 
that the endogenous ligand is anchored in the receptor binding pocket by an amine group 
on TM3 and a network of hydrogen bonds formed largely by serine residues in TM5 
(Kristiansen, 2004). Studies have identified several conformational switches, common to 
all catecholamine GPCRs, important for receptor activation (Weinstein, 2006). Three of 
the most well-characterized molecular switches are: i) the DRY motif (D.349, R3.50, and 
E3.60), termed the “ionic lock”. These residues form a salt bridge between TMs 3 and 6, 
this interaction is broken during receptor activation through protonation by the amine of 
catecholamine receptor ligands, ii) the “rotamer toggle switch” in TM6. This switch is 
comprised of a cluster of highly conserved aromatic residues that surround the proline 
kink in TM6. The rotamer configurations of these residues are thought to be coupled such 
that agonist interaction with one or more of these residues causes a coordinated 
movement of residues in the switch region thereby modulating the bend angle of the 
proline kink in TM6, iii) the NPxxY motif in TM7. Studies have shown that the 
interaction of this motif with helix 8 is important in regulating the interactions of the C-
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terminal end of the GPCR with signaling partners (Kalatskaya et al., 2004; Prioleau et al., 
2002). These motifs have a significant role in stabilizing the inactive receptor state as 
well as in the creation of the molecular interactions that stabilize an active receptor state. 
The nature of agonist interaction with these motifs, dependent the structural features of 
each agonist, dictates agonist affinity and efficacy.
Recent studies utilizing biochemical and biophysical approaches such as in situ
disulfide cross-linking (Zeng et al., 1999), fluorescent spectroscopy (Gether et al., 1995; 
Swaminath et al., 2005), and FRET (Vilardaga et al., 2003) have provided direct insight 
into the conformational changes that occur upon receptor activation. Use of an in situ
disulphide cross-linking strategy, largely utilizing the M3 muscarinic receptor, has 
provided insight about the rotational movement of TM6 upon receptor activation (Ward 
et al., 2006) as well as other helical movements (Han et al., 2005a; Han et al., 2005b). A 
recent study of the M3 receptor found that agonists and inverse agonists cause opposite 
effects in the distance between the C-terminal part of TM8 and the cytoplasmic end of 
TM1 (Li et al., 2007). A series of studies by Kobilka and co-workers have greatly 
advanced our understanding of the conformational changes that occur upon GPCR 
activation (Gether et al., 1995; Gether et al., 1997b; Gether et al., 1997a; Ghanouni et al., 
2001b; Ghanouni et al., 2001a; Swaminath et al., 2004; Swaminath et al., 2005). For 
these studies they labeled a modified β2-adrenergic receptor with small cysteine-reactive 
fluorescent probes that provide information regarding intensity and lifetimes of the 
fluorophore (Gether et al., 1997b). These studies have demonstrated that receptor 
activation is not, as believed previously, a bimodal process but occurs through a series of 
intermediate conformational states (Swaminath et al., 2004; Swaminath et al., 2005). 
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Recently, Yao et al. (2006) demonstrated that full agonists could induce conformational 
changes in TM3 and TM6 whereas a partial agonist induced conformational changes in 
only TM6. These studies suggest that agonists stabilize the receptor in a full or partial 
active conformational state by interacting with different combinations of molecular 
switches. A recently developed method using a cyan variant of GFP (CFP) and yellow 
variant (YFP), inserted into the third intracellular loop and C terminus, allows direct 
measurement of receptor activation in living cells (Vilardaga et al., 2003). Using this 
approach, Nikolaev et al. (2006) showed that structurally distinct ligands induce 
kinetically distinct conformational states, confirming that ligand-induced conformations 
(Ghanouni et al., 2001b) are not a product of reconstituted systems.
These studies underscore the need to understand the structural features of ligands 
responsible for stabilizing active receptor conformational states. If agonist binding results 
in several intermediate conformational states, it is intriguing to hypothesize that these 
intermediate states may have functional significance. Distinct conformational states may 
cause activation of specific G protein heterotrimers, favoring the activation of one or 
more effector pathways over others. For example, in one intermediate conformational 
state a ligand may activate G proteins that lead to partial activation of a specific effector 
pathway while another conformational state induced by the same ligand may activate a 
different set of G proteins that elicits full activation of a different effector pathway. 
Crystal structures of GPCRs
Recent studies have produced high resolution crystal structures of the β1- (Warne 
et al., 2008) and β2-adrenergic receptors (Cherezov et al., 2007; Rasmussen et al., 2007).  
These studies provide invaluable information concerning the structural features of 
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GPCRs that, prior to these findings, was available only from bovine rhodopsin.  The 
ligand-binding site of the β1-and β2-adrenergic receptors is located in a position similar to 
that of retinal in rhodopsin, but key differences were observed from rhodopsin, 
particularly in two conserved regions thought to serve as key motifs regulating activation 
of aminergic receptors.  In constrast to the inactive rhodopsin state, the “ionic lock” 
formed by a salt bridge between D131 of the DRY motif in TM3 and E268 at the bottom 
of TM6 is open.  This indicates the ionic lock, proposed to have an essential role in 
maintaining GPCRs in an inactive state (Ballesteros et al., 2001b), is not an essential 
feature of the inactive state of β1-and β2-adrenergic receptors. The “rotamer toggle 
switch”, comprised of a  cluster of highly conserved aromatic residues in TM6, has been 
proposed to play a key role in formation of an active receptor state. The crystal structure 
of the β2-adrenergic receptor revealed extensive interaction between the bound inverse 
agonist carazolol and amino aid residues thought to comprise the toggle switch region 
(i.e. F6.51, F6.52, and W6.48) (Rasmussen et al., 2007).  Yet the switch region is closed 
in both the β1-and β2-adrenergic receptor structures, and can be overlayed with that of the 
dark (i.e., inactive) state of rhodopsin. Han et al. (2008) suggest that the molecular state 
of the β2-adrenergic receptor is ambiguous, and is likely to be in some intermediate 
signaling state.  Thus, they state that it is not surprising that some motifs are in an active-
like state whereas as others are in an inactive-like state (Han et al., 2008).  Additionally, 
it is possible that the “ionic lock” and “rotamer toggle switch” regions are not 
interdependent, that one region can assume an active-like state and the other an inactive-
like state that is dependent on the ligand bound.  Future studies that utilize a variety of 
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experimental approaches are needed to reconcile apparent contradictions between newly 
obtained data derived from structural studies and current notions of GPCR activation.
Evidence for the existence of multiple D1 effector pathways
The cAMP/PKA pathway is the most studied and therefore the best characterized 
D1 receptor effector pathway. D1 receptor-mediated stimulation of adenylate cyclase 
leads to accumulation of cAMP, activation of PKA, and a subsequent 
phosphorylation/dephosphorylation cycle of DARPP-32 (Greengard et al., 1999). 
Activated PKA can phosphorylate other receptors in the cell (e.g. L-Ca2+, NMDA) and 
also inhibit PP-1 that then dephosphorylates many substrates, including the same 
receptors phosphorylated by PKA (Snyder et al., 1998), thereby creating a feedback loop 
that enables tight control over dopaminergic signaling. The apparent dependence of the 
D1 receptor on the cAMP/PKA signaling pathway presents a challenge in identifying 
distinct effector pathways for examining functional selectivity.
Very few studies have investigated the ability of the D1-like receptors to activate 
MAP kinases, and those that have are confounded by the promiscuity of ERK1/2. 
Phospho-ERK has been shown to form a stable heterotrimeric complex with the D1
receptor and β-arrestin2 (Chen et al., 2004) suggesting that MAP kinase activation may 
be mediated by a D1 receptor- β-arrestin2 complex. Additionally, Nagai et al. (2007)
showed dose-dependent D1 receptor activation of ERK1/2 in the mouse prefrontal cortex 
that was unaffected by microinjection of a D2 antagonist and blocked by a D1 antagonist.
Several studies suggest that the D1 receptor couples to PLC activation. However, 
the mechanism of D1-mediated PLC activation remains ambiguous. Two studies using 
several phenylbenzazepine compounds in rat brain tissue lead the authors to hypothesize 
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the existence of a “D1-like” phospholipase C-coupled receptor (Friedman et al., 1997; 
Undie et al., 1994). The potency values reported for PI hydrolysis were in the 10-100 µM 
range lending some uncertainty as to whether the effect was due to off-target effects or if 
D1-mediated PLC signaling is a real phenomenon. Further evidence of a cAMP/PKA-
independent PLC signaling pathway was shown in studies of adenylate cyclase V 
deficient mice (Iwamoto et al., 2003; Lee et al., 2002). In these studies, 85-90% of 
cyclase activity was abrogated in adenylate cyclase V deficient mice yet locomotion was 
enhanced. It is not clear whether the behavioral effects are due to a cyclase-independent 
PLC pathway, but these findings suggest a dependence on other signaling pathways for 
locomotion. A recent study that examined intracellular Ca2+ release supported the idea of 
D1-Gαq-mediated PLC activation; however, this mechanism was found to be co-
dependent on a PKA-cAMP signal (Dai et al., 2008). 
Evidence for functional selectivity at the D1 dopamine receptor
D1 receptor functional selectivity has been difficult to demonstrate due to the lack 
of clear signaling pathways coupled to the receptor. As was discussed in the Introduction 
of this dissertation, the best evidence of functional selectivity at the D1 receptor was 
shown in two recent studies comparing the functional endpoints of adenylate cyclase 
activation and receptor internalization. The first study examined the relationship between 
agonist structure receptor affinity, and efficacy of adenylate cyclase activation and 
receptor internalization in response to thirteen agonists from three different structural 
classes (Ryman-Rasmussen et al., 2005). This study identified several D1 agonists that 
activate adenylate cyclase with high efficacy but fail to cause receptor internalization. A 
subsequent study investigated the effects of two clinically relevant agonists (DNS and 
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A77636) on long-term receptor trafficking (Ryman-Rasmussen et al., 2007). This study 
found that these agonists target the D1 receptor to different intracellular trafficking 
pathways. Experiments revealed a slow dissociation rate of A77636 from the D1 receptor, 
suggesting that ligand-receptor interactions distal to the binding pocket may dictate the 
ability of an agonist to cause receptor internalization and regulate long-term receptor 
trafficking. These findings served as the basis for the studies in Chapter 5. 
Characterization of additional D1 receptor signaling pathways will greatly facilitate 
further investigation of functional selectivity at the D1-like dopamine receptors. 
In vivo D1 receptor functional selectivity
The clinical promise of functionally selective compounds lies in their postulated 
ability to selectively activate specific signaling pathways leading to decreased side effects 
while retaining therapeutic efficacy. SKF83822, a high affinity D1 agonist, has been 
reported to selectively activate adenylate cyclase and not PLC (Undie et al., 1994).  
Unlike typical D1 agonists, SKF83822 does not induce intense grooming in rats 
(O’Sullivan 2004) or oral dyskinesia in non-human primates (Peacock and Gerlach, 
2001). More intensive study must be performed to confirm the functionally selective 
actions SKF83822 in other systems, but these findings imply that differential behavioral 
effects can be induced by selective activation of signaling pathways.
Excessive stimulation of peripheral D1 receptors can result in hypotension and 
tachycardia thereby precluding the use of high doses of D1 agonists to treat disorders such 
as Parkinson’s disease. Dopamine, via D1-like receptors, can modulate blood pressure by 
regulating renal sodium excretion and controlling the resistance of arteries 
(Chatziantoniou et al., 1995; Zeng et al., 2004). A clearer understanding of D1-like 
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signaling pathways in the central nervous system, kidney, and vascular tissues is an 
important step for the identification and design of functionally selective D1 compounds. 
D1-family receptors are expressed peripherally in many tissues including the adrenal 
glands, blood vessels, heart, the kidney and urinary tract, demonstrating the possible 
novel D1 signaling pathways that have yet to be elucidated. Design of a D1 agonist that is 
less efficacious at these transduction pathway(s), or others that have yet to be identified, 
could permit the use of high doses of drug in patients.
Additional work is required to elucidate the signaling pathway(s) underlying D1-
agonism induced side effects; however, the potential clinical utility of a functionally 
selective D1 agonist is clear. Design of such compounds requires greater knowledge of D1
signaling pathways as well as a better understanding of the structural characteristics 
underlying the functionally selective properties. 
FUTURE DIRECTIONS
The goal of this Dissertation was to explore the structural mechanisms underlying 
binding and activation of the D1-like dopamine receptors. The following major 
conclusions can be drawn from the data presented in this Dissertation: i) that subtle 
structural changes in the ligand-receptor interaction can have profound ramifications on 
receptor activation, ii) that agonist engagement with aromatic residues in TM6 of the D1-
like receptors is an important determinant of efficacy, iii) that structurally dissimilar- as 
well as structurally similar- D1 receptor compounds have distinct modes of interaction 
with the D1-like receptors. These conclusions suggest a variety of directions for future 
study.
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Further mutagenesis studies
The data discussed in this Dissertation provides important information into D1-
like receptor structure-based function, but there is a plethora of future studies that would 
expand the work presented herein. Our data suggest that F6.51 and W6.48 are key 
components of the rotamer toggle switch in D1-like dopamine receptor, coupling agonist 
binding to receptor activation. We propose that F6.51 serves as a “sensor” that interacts 
directly with the agonist. Agonist interaction with F6.51 may cause a change in the 
rotamer configuration of this residue that, in turn, alters the rotamer conformation of 
W6.48, leading to receptor activation. More detailed knowledge of the residues in, and 
around, the rotamer toggle switch will reveal important information concerning about the 
conformational changes that give rise to receptor activation. 
The studies in Chapter 5 suggested that W6.48 plays a key role in the transduction 
of agonist binding to receptor activation in the D1-like receptors. Shi et al. (2002) propose 
that agonist binding at the β2-adrenergic receptor causes a change of W6.48 from its 
inactive, g+ ,conformation to an active conformation, t. To explore this hypothesis in the 
D1-like receptors, W6.48 could be mutated to threonine, a residue essentially restricted to 
the g+ conformation. A Trp to Thr mutation should result in a largely inactive receptor. 
Additionally, mutation of F6.51 to threonine could provide further evidence that F6.51 
influences the rotamer configuration of W6.48. A F6.51T mutant receptor, favoring the 
g+ rotamer, should force W6.48 into the g+ rotamer, promoting an inactive receptor state.  
Studies have also suggested that C6.47 influences the rotamer configuration of W6.48. In 
the inactive state of bovine rhodopsin, C6.47 appears to from an H-bond interaction with 
W6.48 (Palczewski et al., 2000). Studies of the β2-adrenergic receptor indicate that C6.47 
is strongly correlated with the rotamer of W6.48 (Bhattacharya et al., 2008a). 
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Additionally, studies of the histamine H1 receptor and β2-adrenergic receptor suggest that 
the residue at position 7.45 interacts with W6.48, and possibly C6.47. In histamine H1 
receptor, N7.45 restrains C6.47 and W6.48 in rotamer configurations, t and g+ 
respectively, that favor an inactive receptor state (Jongejan and Leurs, 2005). There is 
evidence that suggests N7.45 may hydrogen bond with C6.47 in β2-adrenergic receptor 
(Bhattacharya et al., 2008a). These studies indicate N7.45 could be an important link 
between ligand-binding and GPCR activation. Mutation to cysteine, glutamine, or leucine 
would provide insight into the role of this residue in the D1-like receptors. 
In rhodopsin, W6.48 is bounded above by Y6.51 and below by F6.44 (Palczewski 
et al., 2000; Palczewski, 2006). Similarly, in the α1B- and β2-adrenergic receptors W6.48 
is bounded by F6.52 and F6.51 above and F6.44 below (Chen et al., 2002b; Chen et al., 
2002a; Han et al., 1996). If this is true for the D1-like receptors, F6.44 may influence the 
conformational freedom of W6.48 because the aromaticity of F6.44 stabilized the 
inactive state conformation of TM6 (Chen et al., 2002b; Han et al., 1996). Mutation of 
F6.44 to Leu, which should promote an active receptor conformation, may provide 
insight into the role of this residue in the D1-like receptors.
The experiments in Chapter 3 provided evidence that T3.37 contributes to ligand-
binding and activation by influencing receptor interaction with the para-OH of D1
compounds. The nature of this interaction is unclear. T3.37 may interact directly with the 
para-OH of D1 agonists or could hydrogen bond with the backbone carbonyl of S5.46. A 
reciprocal double mutant of S5.46 and T3.37 to threonine and serine respectively may 
help determine whether T3.37 and S5.46 H-bond. Substitution of the polar T3.37 with 
glutamine (more flexible and also polar side chain) and serine (shorter and less polar) 
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may provide additional insight into the role of T3.37. Bhattacharya et al. (2008b) suggest 
that T3.37 H-bonds with T4.56 and S5.46 in the inactive receptor state, forming a 
network of H-bonds involving TMs 3, 4, and 5. The role of T4.56 in the D1-like receptors 
represents another intriguing direction to pursue.  Additionally, our D1 model suggests 
that T3.37 may hydrogen bond with S5.42, not S5.46.  Future studies could explore this 
possibility by constructing a double mutant receptor (i.e. T3.37A/S5.42A).
Determination of multiple D1-like signaling pathways
As was previously mentioned, several studies have indicated D1-like receptors 
may be capable of activating other signaling pathways. However, the mechanism(s) by 
which D1 receptors activate these pathways is unclear and requires additional study. For 
example, studies indicate that D1 might be coupled to the activation of PLC (Friedman et 
al., 1997; Undie et al., 1994) but there is some uncertainty as to whether the effect was 
due to off-target effects, and the mechanism is poorly understood. Several studies have 
revealed the ability of the D1 dopamine receptor to mediate the phosphorylation of each 
MAP kinase subfamily (Brami-Cherrier et al., 2002; Gerfen et al., 2002) but the 
mechanism by which D1 receptors activate ERK1/2 has yet to be determined. More 
detailed knowledge of D1-mediated signaling pathways will be useful for future studies 
relevant to the work in this Dissertation. Studies using receptor mutagenesis and 
structurally dissimilar agonists could be used to identify a structural basis for the 
selective activation of effector pathways.
D1 receptor functional selectivity
Studies in our lab, using the endpoints of adenylate cyclase and long-term 
trafficking, have demonstrated functional selectivity at the D1 dopamine receptor. The 
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mechanistic basis of this finding is unclear, but we hypothesize that structural differences 
in binding modes of the agonists are largely responsible. Future studies that examine 
whether mutation of V159, L291, L295, and W163 affects the long-term trafficking of 
A77636 or DNS will test our hypothesis. The data in this Dissertation demonstrate that 
structurally different- and even structurally similar- D1 agonists interact with the receptor 
in a unique way. There is evidence that suggests the distinct conformational states 
induced by an agonist may have functional consequences (Swaminath et al., 2004; 
Swaminath et al., 2005; Yao et al., 2006). This underscores the importance of identifying 
and characterizing additional D1-like receptor signaling pathways that can be used to 
explore a structural basis for functional selectivity. 
Long-term trafficking of the D1 receptor
Chapter 6 provides the foundation for future studies to examine the mechanism of 
long-term receptor trafficking. These studies will test our hypothesis that ligand-receptor 
interactions distal to the binding pocket are responsible for the prolonged interaction of 
A77636 with the D1 receptor, leading to differences in long-term receptor trafficking. 
However, it is important to consider alternative hypotheses. A recent study of the β1-
adrenergic receptor demonstrated that the pathway selected for receptor internalization is 
primarily dictated by the kinase that phosphorylates the receptor (Rapacciuolo et al., 
2003). The authors found that PKA-mediated phosphorylation directs internalization via 
the caveolae pathway, whereas GRK-mediated phosphorylation is through clathrin-
coated pits. Studies indicate a role for both PKA- and GRK-mediated phosphorylation in 
D1 receptor desensitization (Bates et al., 1991; Black et al., 1994; Tiberi et al., 1996; 
Zhou and Fishman, 1991; Zhou and Fishman, 1991). Agonists could stabilize a 
156
conformational state, or activate a specific G protein heterotrimer, that favors one form of 
receptor phosphorylation over another thus leading to differences in receptor trafficking.  
It is clear that β-arrestin plays an essential role in the desensitization and 
endocytosis of GPCRs, however, recent studies have shown that β-arrestin can also 
function as a signaling intermediate in GPCR signal transduction to MAP kinase 
pathways independent of G proteins (Lefkowitz and Shenoy, 2005; Shenoy and 
Lefkowitz, 2003). An interesting future direction is to explore whether the D1 receptor 
activates MAP-kinase signaling pathways via β-arrestin scaffolding. It is intriguing to 
hypothesize that upon endocytosis A77636-occupied D1 receptors might activate MAP-
kinase pathways. 
APPENDIX: 
SUMMARY OF BIOLOGICAL METHODS USED IN THIS WORK.
CELL CULTURE AND TRANSFECTION
HEK293 cells were grown in 5% CO2 at 37°C in Dulbecco’s modified Eagle’s 
medium, supplemented with 10% fetal bovine serum. For transient expression, HEK293 
cells were transfected according to the Lipofectamine protocol (GibcoBRL -Life 
Technologies) using 0.5 μg (hD1) or 0.75 μg (hD5) pcDNA3.1 constructs per 100mm 
culture dish containing HEK cells at approximately 80% confluency. The transfected 
cells were incubated with DNA/liposomes in serum free media for ~6 hours at which 
time Fetal Bovine Serum was added to 20%. The cells were incubated for an additional 
12 hours followed by aspiration of the transfection media and addition of fresh DMEM-H 
containing 10% FBS. Cells were harvested 24-36 hours later for use in binding and 
functional assays.
MEMBRANE PREPARATION
Plates of HEK293 cells transfected with D1-like receptor DNA were harvested 
~48 hours post transfection. Each 100mm dish of HEK293 cells was washed 1X with 4 
mL of ice cold PBS. Cells were then lysed at 4oC for 10 minutes using 3 mL of hypo-
osmotic buffer (10mM Hepes, pH 7.4 with KOH). Cells were scraped, transferred to a 
centrifuge tube and spun at 28,000 x g for 20 minutes. The pellet was transferred to a 
Wheaton Glass/Teflon homogenizer in 10mM Hepes buffer and homogenized 4-5 times. 
The homogenate was then spun at 28,000 x g for 20 minutes. This process was repeated 
for a total of 3 times. After the third spin membranes were homogenized in storage buffer 
(20mM Hepes, 250mM sucrose, pH 7.4 with KOH), aliquoted at 1 mL per 
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microcentrifuge tube and flash frozen in 100% ethanol-dry ice mixture. Membranes were 
stored at -80oC until use in binding and functional assays.
GENERATION OF MUTANT RECEPTORS
The human D1 and D5 receptor were cloned from a human cDNA library. The 
primers were complementary to the 5’ and 3’ ends and also contained an EcoRI (5’) and 
XhoI (3’) site for ligation into the expression vector pcDNA3 containing a HA tag. PCR 
amplification was performed in a volume of 100 L containing 0.16 ng DNA, 0.3 M of 
each primer, 0.2 mM dNTPs, 10 L 10x reaction buffer, and 1 L of Pfu Turbo enzyme. 
The PCR construct was digested with EcoRI and XhoI, gel-purified and ligated into HA-
pcDNA3. The sequences of the human D1 and D5 receptors were verified and large 
quantities were generated by growth in LB overnight. This cDNA was then used as the 
template for the generation of the mutants. The various mutants were generated using the 
Quickchange kit from Stratagene (La Jolla, CA). Primers were designed according to the 
kit’s specifications and purchased from Invitrogen (Carlsbad, CA). PCR was performed 
according to the manufacturer’s instructions. Following PCR, the mutated receptor 
cDNAs were transformed in XL-1 Blue cells (Stratagene, La Jolla, CA). The mutant 
receptors were sequenced to verify the particular mutation and then large cultures of the 
mutated receptors were grown in LB broth overnight. Larger quantities of mutant cDNA 
were purified using the Sigma GenElute Maxiprep Kit (Sigma). 
SATURATION ASSAYS USING [3H]SCH23390
Saturation binding experiments were performed to determine receptor expression 
level and KD of SCH23390 for wild-type and mutant receptors. Membrane homogenates 
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from HA-hD1 HEK cells were prepared as previously described (Lewis et al., 1999). For 
saturation binding experiments, HEK293 cell membranes were incubated for 15 minutes 
at 37 °C with 8-10 concentrations of [3H]SCH23390 (Wyrick and Mailman, 1985) in 
binding buffer (50mM HEPES, 4mM MgCl2, pH 7.4 with KOH). Nonspecific binding 
was determined using 1 µM cold SCH23390. Protein concentrations were determined 
using the Bradford protein assay kit.
COMPETITION ASSAYS USING [3H]SCH23390
Competition binding experiments were conducted to assess the affinity (K0.5) of 
each test compound at wild-type and mutant receptors. HEK293 cell membranes 
expressing wild-type or mutant receptors were incubated with a single concentration of 
[3H]SCH23390 and 7-12 concentrations of test ligand in buffer (50mM HEPES, 4 mM 
MgCl2, 0.01% ascorbic acid, pH 7.4 with KOH). Total binding was defined as the 
amount of [3H]SCH23390 bound in the absence of a competing ligand. Non-specific 
binding was determined by binding in the presence of 1uM cold SCH23390. 
Saturation and competition binding experiments were performed in triplicate for 
each assay condition in 96 well plates. Reactions were terminated by filtration using a 
Packard 96 Filtermate Harvester (Packard BioScience Company; Meridian, Connecticut). 
The filter plates were allowed to dry, 35 L of Packard MicroScint 20 scintillation 
cocktail was added to each well, and radioactivity was counted using a Packard 
TopCount NXT Microplate scintillation counter (Packard, Downers Grove, IL).
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ASSESSMENT OF CELL SURFACE RECEPTOR EXPRESSION
HEK 293 cells were seeded at ca. 50,000 cells/ well in 24-well cell culture plates. 
48 hr later, cells were fixed with 4% PFA (30 min), rinsed with HBSS, and treated with 
blocking solution (50mM Hepes, 10%FBS, DMEM-H) for 30 min. Cells were then 
incubated for 1 hr with an anti-HA primary antibody (BabCO HA.11) diluted at 1:1000 
(in blocking solution). Cells were washed with HBSS and subsequently incubated for 2 hr 
with a [125I]-rabbit-anti-mouse (New England Nuclear) secondary antibody diluted at 
1:500 (in blocking solution). Cells were washed with HBSS, solubilized overnight with 
1M NaOH, transferred to 12x75 glass tubes and counted.
ANALYSIS OF BINDING AND FUNCTIONAL DATA
Saturation binding data were analyzed by nonlinear regression using a one-site 
binding rectangular hyperbola model using Prism Ver. 4 (GraphPad, Inc, San Diego 
CA.). Competition binding data and cAMP accumulation data were analyzed by 
nonlinear regression using either a variable slope or fixed slope (nH=1) dose-response fit 
using Prism for the best fit of points. Functional data were expressed relative to the 
percentage of the stimulation produced by 1 mM dopamine at each receptor type unless 
otherwise noted. Affinity data were fit first to a sigmoidal model of variable slope. An 
ANOVA with a post-hoc Tukey test was used to compare means for all internalization 
and recovery experiments. Significance was set at p<0.05. All statistical testing was done 
using Prism 4.0. 
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